[{"id":"acta-oncologica","kind":"journal","name":"Acta oncologica","aka":["Acta Oncologica","Acta Oncol"],"tldr":"Acta Oncologica is a Nordic clinical oncology journal, now fully open access, read by medical and radiation oncologists and cancer epidemiologists, especially in Scandinavia.","summary":"Acta Oncologica is published in Uppsala, Sweden, by Medical Journals Sweden AB. Its about page describes a broad remit across cancer epidemiology, prevention, translational oncology, cancer immunology, diagnostics, medical oncology, precision medicine, radiotherapy, radiophysics, psychosocial oncology, rehabilitation and palliative care, and lists original articles, review articles, short reports, editorials, letters and commentaries as article types. The journal traces its history to 1963 and has carried the present title since 1987, the start year in the NLM catalogue. Since moving to Medical Journals Sweden in 2024 it has been fully open access under a CC BY 4.0 licence with an article processing charge and anonymous peer review, and it is listed in DOAJ. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://medicaljournalssweden.se/actaoncologica"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8709065"},{"label":"DOAJ record","url":"https://doaj.org/toc/1651-226X"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Medical Journals Sweden AB (MJS Publishing)","url":"https://medicaljournalssweden.se/actaoncologica","issn":"0284-186X","scope":"clinical oncology","access":"open-access","founded":1987,"matchNames":["Acta Oncol","Acta oncologica","Acta Oncologica"]},{"id":"advances-in-cancer-research","kind":"journal","name":"Advances in cancer research","aka":["Advances in Cancer Research","Adv Cancer Res"],"tldr":"Advances in Cancer Research is a long-running review series of invited, in-depth chapters on cancer biology, read by laboratory scientists and trainees who want an authoritative overview of a topic.","summary":"Advances in Cancer Research is a serial review publication catalogued by the NLM from 1953, published from Amsterdam by Elsevier under its Academic Press imprint and hosted on ScienceDirect as a book series. As a review serial rather than a primary research journal, its volumes are made up of extended review chapters on themes in cancer research. The NLM record lists it as a United States publication that is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/bookseries/advances-in-cancer-research"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/370416"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier (Academic Press)","url":"https://www.sciencedirect.com/bookseries/advances-in-cancer-research","issn":"0065-230X","scope":"cancer biology","founded":1953,"matchNames":["Adv Cancer Res","Advances in cancer research","Advances in Cancer Research"]},{"id":"american-journal-of-clinical-oncology","kind":"journal","name":"American journal of clinical oncology","aka":["American Journal of Clinical Oncology","Am J Clin Oncol","AJCO"],"tldr":"The American Journal of Clinical Oncology is a general clinical cancer journal from Wolters Kluwer covering medical and radiation oncology, read by practising oncologists.","summary":"The American Journal of Clinical Oncology has been published since 1982 from Hagerstown, Maryland, by Lippincott Williams & Wilkins, part of Wolters Kluwer; Crossref lists the publisher as Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins. Its current issue pages carry original clinical studies, reviews and analyses across medical oncology and radiation oncology, for example retrospective cohort studies of radiotherapy fractionation and reviews of molecular markers in lung cancer and lymphoma, and the site notes that licensing terms apply to its open access content. It is indexed in MEDLINE. The journal is not listed in DOAJ, and the publisher does not state a single access model on the pages that could be read, so none is recorded here.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/amjclinicaloncology/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8207754"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://journals.lww.com/amjclinicaloncology/pages/default.aspx","issn":"0277-3732","scope":"clinical oncology","founded":1982,"matchNames":["Am J Clin Oncol","American journal of clinical oncology","American Journal of Clinical Oncology"]},{"id":"asco-educational-book","kind":"journal","name":"American Society of Clinical Oncology educational book","aka":["American Society of Clinical Oncology Educational Book","ASCO Educational Book","Am Soc Clin Oncol Educ Book"],"tldr":"The ASCO Educational Book is the American Society of Clinical Oncology's annual educational publication tied to its Annual Meeting, giving clinicians readable summaries of each year's main topics.","summary":"The American Society of Clinical Oncology Educational Book is published from Alexandria, Virginia, by the American Society of Clinical Oncology, which Crossref also lists as its publisher. As its title states, it is the society's own educational book, the annual collection of educational articles that accompanies the ASCO Annual Meeting and spans the breadth of clinical oncology. It is indexed in MEDLINE and is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://ascopubs.org/journal/edbk"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101233985"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/edbk","issn":"1548-8748","scope":"clinical oncology education","matchNames":["Am Soc Clin Oncol Educ Book","American Society of Clinical Oncology educational book","American Society of Clinical Oncology Educational Book","ASCO Educational Book"],"society":"American Society of Clinical Oncology"},{"id":"analytical-cellular-pathology","kind":"journal","name":"Analytical cellular pathology (Amsterdam)","aka":["Analytical Cellular Pathology","Anal Cell Pathol (Amst)","Anal Cell Pathol"],"tldr":"Analytical Cellular Pathology is an open access pathology journal on cytology, biomarkers and diagnostic and immunopathology, read by pathologists and laboratory researchers.","summary":"Analytical Cellular Pathology has been published since 2010 and is now issued by John Wiley and Sons after Hindawi, its previous publisher (still named in Crossref), became part of Wiley. The journal profile describes it as a forum for pathologists and medical practitioners working in cellular pathology, with topics including cytology, carcinogenesis, cell receptors, biomarkers, diagnostic pathology and immunopathology. It is fully open access, listed in DOAJ under a CC BY licence with an article processing charge and anonymous peer review, and open access content dates from 2010. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/2641"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101541993"},{"label":"DOAJ record","url":"https://doaj.org/toc/2210-7177"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley (formerly Hindawi)","url":"https://onlinelibrary.wiley.com/journal/2641","issn":"2210-7177","scope":"cellular pathology and cancer diagnostics","access":"open-access","founded":2010,"matchNames":["Anal Cell Pathol (Amst)","Anal Cell Pathol","Analytical cellular pathology (Amsterdam)","Analytical Cellular Pathology"]},{"id":"annals-internal-medicine","kind":"journal","name":"Annals of Internal Medicine","aka":["Ann Intern Med"],"tldr":"Annals of Internal Medicine is the American College of Physicians' journal. In cancer it carries the US Preventive Services Task Force evidence reviews and modelling studies that set screening ages and intervals, so primary care doctors read it for screening guidance rather than treatment trials.","summary":"Publishes the ACP guidance statements, US Preventive Services Task Force evidence reviews and decision-analytic modelling that underpin cancer screening ages and intervals, alongside cohort studies on cancer risk factors. Hybrid access with a strong methods focus (it hosts the PRISMA and other reporting-guideline statements).","asOf":"2026-09-09","links":[{"label":"Oncology topic","url":"https://www.acpjournals.org/topic/category/oncology"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American College of Physicians","url":"https://www.acpjournals.org/journal/aim","issn":"0003-4819","scope":"general medicine","access":"hybrid","founded":1927,"matchNames":["Annals of Internal Medicine","Ann Intern Med"],"society":"American College of Physicians"},{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","aka":["Ann Oncol","src-annals-oncology"],"tldr":"Annals of Oncology is ESMO's flagship journal, publishing European phase 3 trials, the ESMO Clinical Practice Guidelines and the abstract books for the ESMO Congress.","summary":"Annals of Oncology appears monthly and publishes the ESMO Clinical Practice Guidelines (free to read), ESMO-MCBS benefit scores, trial results often presented at ESMO Congress, translational biomarker studies and the ESMO congress abstract supplements. Published by Elsevier since 2019 (previously Oxford University Press). Hybrid access.","asOf":"2026-09-09","links":[{"label":"ESMO Guidelines","url":"https://www.esmo.org/guidelines"}],"tags":[],"related":["src-esmo-congress","esmo-guidelines"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: ESMO journal: trials, ESMO guidelines, ESMO-MCBS scorecards and congress abstracts. Access: Paywalled; guidelines and abstracts free."],"publisher":"Elsevier","url":"https://www.annalsofoncology.org","issn":"0923-7534","scope":"clinical oncology","access":"hybrid","founded":1990,"impactFactor":{"value":56.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Annals of Oncology","Ann Oncol"],"society":"European Society for Medical Oncology"},{"id":"annals-of-surgical-oncology","kind":"journal","name":"Annals of surgical oncology","aka":["Annals of Surgical Oncology","Ann Surg Oncol"],"tldr":"Annals of Surgical Oncology is the main journal of the Society of Surgical Oncology and the leading venue for surgical cancer research, read by surgical oncologists worldwide.","summary":"Annals of Surgical Oncology was launched in 1994 and has been published from New York by Springer since 2005; Crossref records the publisher as Springer - Society of Surgical Oncology, reflecting its role as the society's journal. As its title indicates, it is devoted to surgical oncology, the surgical management of cancer, and it is the venue for the society's clinical research and meeting content. The NLM record lists it as a United States serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10434"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9420840"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10434","issn":"1068-9265","scope":"surgical oncology","founded":1994,"matchNames":["Ann Surg Oncol","Annals of surgical oncology","Annals of Surgical Oncology"],"society":"Society of Surgical Oncology"},{"id":"anticancer-research","kind":"journal","name":"Anticancer research","aka":["Anticancer Research","Anticancer Res"],"tldr":"Anticancer Research is a monthly journal from the International Institute of Anticancer Research in Greece that has published experimental and clinical cancer papers with fast turnaround since 1981. It is indexed in MEDLINE, but its access model is mixed and it is not listed in DOAJ, so check individual articles.","summary":"Anticancer Research is published from Kapandriti, Attica, Greece, by the International Institute of Anticancer Research (IIAR), which describes it as an international print and online monthly journal designed to rapidly publish peer-reviewed original works and reviews on all aspects of experimental and clinical cancer research, established in 1981. It is one of four IIAR journals alongside In Vivo, Cancer Genomics & Proteomics and Cancer Diagnosis & Prognosis. The current issue lists individual articles labelled Open Access alongside others, and the journal is not listed in DOAJ, so no single access model is recorded here. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://ar.iiarjournals.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8102988"}],"tags":[],"related":["pubmed-europepmc","in-vivo","cancer-genomics-and-proteomics"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"International Institute of Anticancer Research","url":"https://ar.iiarjournals.org/","issn":"0250-7005","scope":"experimental and clinical cancer research","founded":1981,"matchNames":["Anticancer Res","Anticancer research","Anticancer Research"]},{"id":"asia-pacific-journal-of-clinical-oncology","kind":"journal","name":"Asia-Pacific journal of clinical oncology","aka":["Asia-Pacific Journal of Clinical Oncology","Asia Pac J Clin Oncol"],"tldr":"The Asia-Pacific Journal of Clinical Oncology is a Wiley clinical oncology journal focused on cancer treatment and care across the Asia-Pacific region, read by oncologists, surgeons, radiation oncologists and nurses there.","summary":"Asia-Pacific Journal of Clinical Oncology began in 2005 with Blackwell Publishing Asia in Carlton South, Victoria, and is published by Wiley. Its overview describes a multidisciplinary oncology journal that acts as a forum for collaboration and information exchange on cancer treatment and care in the countries of the Asia-Pacific region, welcoming pre-clinical, translational, clinical trial and epidemiological studies, and particularly prospectively designed clinical trials, along with reviews, editorials, letters and short communications; case reports are generally not considered. The journal states that it is endorsed by the Chinese Society of Clinical Oncology, the Clinical Oncology Society of Australia, the Korean Association for Clinical Oncology, the Medical Oncology Group of Australia and the Singapore Society of Oncology. Indexed in MEDLINE; not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/17437563"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101241430"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley (Blackwell Publishing Asia)","url":"https://onlinelibrary.wiley.com/journal/17437563","issn":"1743-7555","scope":"clinical oncology","founded":2005,"matchNames":["Asia Pac J Clin Oncol","Asia-Pacific journal of clinical oncology","Asia-Pacific Journal of Clinical Oncology"]},{"id":"asian-pacific-journal-of-cancer-prevention","kind":"journal","name":"Asian Pacific journal of cancer prevention","aka":["Asian Pacific journal of cancer prevention : APJCP","Asian Pacific Journal of Cancer Prevention","APJCP","Asian Pac J Cancer Prev"],"tldr":"APJCP is a monthly open access journal on cancer prevention and epidemiology in Asia and the Pacific, read by public health researchers and clinicians across the region.","summary":"The Asian Pacific Journal of Cancer Prevention describes itself as a monthly electronic journal that publishes papers across a wide spectrum of cancer sciences. It was launched in 2000 as the official publication of the Asian Pacific Organization for Cancer Prevention (APOCP), a non-profit scientific association founded the same year to promote cancer prevention and collaborative research in the region; the NLM record gives Bangkok, Thailand, as the place of publication and the journal is now hosted by the West Asia Organization for Cancer Prevention. It is open access, with all articles free on publication under a Creative Commons Attribution licence, listed in DOAJ with an article processing charge and anonymous peer review, and its full text has been preserved in PubMed Central since 2017. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journal.waocp.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101130625"},{"label":"DOAJ record","url":"https://doaj.org/toc/1513-7368"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Asian Pacific Organization for Cancer Prevention (APOCP), hosted by the West Asia Organization for Cancer Prevention","url":"https://journal.waocp.org/","issn":"1513-7368","scope":"cancer epidemiology and prevention","access":"open-access","founded":2000,"matchNames":["Asian Pac J Cancer Prev","Asian Pacific journal of cancer prevention","Asian Pacific Journal of Cancer Prevention","APJCP"],"society":"Asian Pacific Organization for Cancer Prevention"},{"id":"bba-reviews-on-cancer","kind":"journal","name":"Biochimica et biophysica acta. Reviews on cancer","aka":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","BBA Reviews on Cancer","Biochim Biophys Acta Rev Cancer"],"tldr":"BBA Reviews on Cancer is the cancer review section of the Biochimica et Biophysica Acta family, publishing in-depth reviews on the molecular and cellular biology of cancer for laboratory scientists.","summary":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer is published from Amsterdam by Elsevier, which Crossref confirms as the publisher, and is hosted on ScienceDirect. As its title indicates, it is the section of the Biochimica et Biophysica Acta family that publishes reviews on cancer, so its content is review articles on the biochemical and molecular biology of cancer rather than primary research papers. The print ISSN 0304-419X belongs to the long-running BBA Reviews on Cancer series, while the NLM catalogue record used here dates the current title form from 2017.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/biochimica-et-biophysica-acta-bba-reviews-on-cancer"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9806362"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/biochimica-et-biophysica-acta-bba-reviews-on-cancer","issn":"1879-2561","scope":"cancer biology","founded":2017,"matchNames":["Biochim Biophys Acta Rev Cancer","Biochimica et biophysica acta. Reviews on cancer","Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","BBA Reviews on Cancer"]},{"id":"biorxiv","kind":"journal","name":"bioRxiv","aka":["bioRxiv","src-biorxiv"],"tldr":"bioRxiv is the preprint server for biology. Most cancer genomics, immunology and computational papers now appear here before the journal version.","summary":"Free, non-profit preprint server run by Cold Spring Harbor Laboratory since 2013. Manuscripts are screened for scope and plagiarism but not peer reviewed; a large share of cancer biology, methods and AI papers are posted here first, with the peer-reviewed version linked later. Indexed by Europe PMC; supports direct transfer to many journals.","asOf":"2026-09-09","links":[{"label":"About bioRxiv","url":"https://www.biorxiv.org/about-biorxiv"},{"label":"bioRxiv cancer biology collection","url":"https://www.biorxiv.org/collection/cancer-biology"}],"tags":[],"related":["pubmed-europepmc","medrxiv"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Biology preprints; the cancer biology collection. Access: Open (author-chosen CC licences)."],"publisher":"Cold Spring Harbor Laboratory","url":"https://www.biorxiv.org","scope":"preprints","access":"open-access","founded":2013,"matchNames":["bioRxiv"]},{"id":"blood","kind":"journal","name":"Blood","aka":["Blood (ASH)","src-blood"],"tldr":"Blood is the American Society of Hematology's flagship journal, covering leukaemia, lymphoma, myeloma and transplant biology and trials, plus the ASH annual meeting abstracts.","summary":"Blood appears weekly and publishes the science and phase 2 trials of blood cancers (venetoclax, CAR-T, bispecifics, MRD methods), the ASH abstract supplement each November, and 'How I Treat' expert reviews that shape practice. Hybrid access; articles free after 12 months. Sister titles are Blood Advances (open access) and Blood Neoplasia.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Blood_(journal)","links":[{"label":"ASH annual meeting","url":"https://www.hematology.org/meetings/annual-meeting"}],"tags":[],"related":["src-ash-annual"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Flagship of haematology: leukaemia, lymphoma and myeloma trials and biology; ASH abstracts. Access: Paywalled; abstracts free."],"publisher":"American Society of Hematology","url":"https://ashpublications.org/blood","issn":"0006-4971","scope":"haematology","access":"hybrid","founded":1946,"impactFactor":{"value":21,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Blood"],"society":"American Society of Hematology"},{"id":"blood-advances","kind":"journal","name":"Blood Advances","aka":["Blood Adv"],"tldr":"ASH's fully open-access journal for haematology, including real-world outcomes, phase 1 and 2 trials and the ASH clinical practice guidelines.","summary":"Blood Advances (Blood Adv) is the fully open-access haematology journal of the American Society of Hematology (ASH), launched in 2016 as the open-access companion to Blood and published by the society itself, with CC BY licences available. It publishes real-world outcomes, phase 1 and 2 trials, registry analyses and translational studies in blood cancers, and it carries the ASH clinical practice guidelines, for example on venous thromboembolism in cancer. Its readers are haematologists and haematology-oncology trialists who want early-phase and real-world evidence without a paywall. Within OnCo it is linked from the Eunice Wang biography, and it is the place to look for ASH guidelines and early-phase blood cancer trials.","asOf":"2026-09-09","links":[{"label":"ASH guidelines","url":"https://www.hematology.org/education/clinicians/guidelines-and-quality-care"}],"tags":[],"related":["blood"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ash"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society of Hematology","url":"https://ashpublications.org/bloodadvances","issn":"2473-9529","scope":"haematology","access":"open-access","founded":2016,"matchNames":["Blood Advances","Blood Adv"],"society":"American Society of Hematology"},{"id":"blood-cancer-discovery","kind":"journal","name":"Blood cancer discovery","aka":["Blood Cancer Discovery","Blood Cancer Discov"],"tldr":"Blood Cancer Discovery is the American Association for Cancer Research's journal, launched in 2020, for basic, translational and clinical research in leukaemia, lymphoma and myeloma. Authors pay publication charges and can pay extra to make articles open access; haematologists and cancer biologists working on blood cancers read it.","summary":"Blood Cancer Discovery was launched in 2020 by the American Association for Cancer Research (AACR) in Philadelphia. The AACR describes it as publishing high-quality Research Articles and Briefs representing major advances in basic, translational and clinical research of leukaemia, lymphoma, myeloma and associated diseases. Authors pay publication charges, and the AACR site refers separately to an Open Access fee, so articles can be made open access on payment; the journal is not listed in DOAJ. Members of the AACR's working group on blood cancers receive a discount on publication charges. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://aacrjournals.org/bloodcancerdiscov"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101764786"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/bloodcancerdiscov","issn":"2643-3249","scope":"haematological oncology","access":"hybrid","founded":2020,"matchNames":["Blood Cancer Discov","Blood cancer discovery","Blood Cancer Discovery"],"society":"American Association for Cancer Research"},{"id":"blood-cancer-journal","kind":"journal","name":"Blood cancer journal","aka":["Blood Cancer Journal","Blood Cancer J"],"tldr":"Blood Cancer Journal is a fully open access Nature Portfolio journal on leukaemia, lymphoma, myeloma and related disorders, read by clinical and laboratory haematologists.","summary":"Blood Cancer Journal has been published since 2011 by Nature Publishing Group, now part of Springer Nature, from New York. Its homepage describes a peer-reviewed, fully open access journal dedicated to articles of the highest quality on haematological malignancies and related disorders, considering original research, reviews, guidelines and letters, and it runs a Current Treatment Algorithms article type that gives concise treatment pathways for blood cancers. It is listed in DOAJ with CC BY and CC BY-NC-ND licences, an article processing charge and anonymous peer review. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.nature.com/bcj/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101568469"},{"label":"DOAJ record","url":"https://doaj.org/toc/2044-5385"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (Nature Portfolio)","url":"https://www.nature.com/bcj/","issn":"2044-5385","scope":"haematological oncology","access":"open-access","founded":2011,"matchNames":["Blood Cancer J","Blood cancer journal","Blood Cancer Journal"]},{"id":"bmc-cancer","kind":"journal","name":"BMC cancer","aka":["BMC Cancer"],"tldr":"BMC Cancer is a large open access journal that takes sound research on any aspect of cancer, including study protocols, and is read by clinicians and researchers worldwide.","summary":"BMC Cancer was launched in 2001 by BioMed Central in London and is published by BMC, part of Springer Nature. Its aims and scope describe an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers, and welcomes work in molecular and cellular biology, genetics, epidemiology and clinical trials; it also publishes study protocols. The journal uses single anonymised peer review and publishes review reports with articles. It is listed in DOAJ with CC BY and CC BY-NC-ND licences and an article processing charge. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://bmccancer.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100967800"},{"label":"DOAJ record","url":"https://doaj.org/toc/1471-2407"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://bmccancer.biomedcentral.com/","issn":"1471-2407","scope":"clinical oncology and cancer research","access":"open-access","founded":2001,"matchNames":["BMC Cancer","BMC cancer"]},{"id":"bmj","kind":"journal","name":"BMJ","aka":["The BMJ","British Medical Journal","Br Med J"],"tldr":"The BMJ is the British Medical Association's journal. It published Doll and Hill's 1950 smoking and lung cancer study and remains a leading critic of weak cancer-drug evidence and a champion of open data.","summary":"Weekly general-medicine journal with a long record in cancer epidemiology (Doll and Hill 1950; Doll and Peto's 50-year doctors study 2004) and in screening and health-services research such as HPV self-sampling. Research articles are free to read; the journal requires data-sharing statements and has campaigned for clinical trial transparency (AllTrials) and against surrogate-endpoint-driven approvals. Strong investigations desk covering the pharmaceutical industry and regulators.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_BMJ","links":[{"label":"BMJ cancer collection","url":"https://www.bmj.com/specialties/oncology"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMJ Group","url":"https://www.bmj.com","issn":"0959-8138","scope":"general medicine","access":"hybrid","founded":1840,"impactFactor":{"value":93.6,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["BMJ","The BMJ","British Medical Journal"],"society":"British Medical Association"},{"id":"brain-tumor-pathology","kind":"journal","name":"Brain tumor pathology","aka":["Brain Tumor Pathology","Brain Tumor Pathol"],"tldr":"A Japanese neuropathology journal covering the diagnosis, classification and biology of brain and spinal cord tumours, read by neuropathologists and neuro-oncologists.","summary":"This journal has been published in Tokyo since 1997 by Springer-Verlag Tokyo, now part of Springer, which Crossref confirms as the publisher. As its title indicates, it is devoted to the pathology of brain and other central nervous system tumours, the specialist field of neuropathologists and neuro-oncologists. The NLM record lists it as a Japanese serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10014"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9716507"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["glioblastoma","medulloblastoma","ependymoma","dipg-dmg","paediatric-low-grade-glioma","primary-cns-lymphoma","atrt","craniopharyngioma","pituitary-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (Springer-Verlag Tokyo)","url":"https://link.springer.com/journal/10014","issn":"1433-7398","scope":"neuro-oncology and neuropathology","founded":1997,"matchNames":["Brain Tumor Pathol","Brain tumor pathology","Brain Tumor Pathology"]},{"id":"breast-cancer-jbcs","kind":"journal","name":"Breast cancer","aka":["Breast cancer : the journal of the Japanese Breast Cancer Society","Breast Cancer (Tokyo)","Breast Cancer"],"tldr":"Breast Cancer is the official journal of the Japanese Breast Cancer Society, publishing clinical and translational breast cancer research for surgeons, oncologists and pathologists.","summary":"Breast Cancer, subtitled the journal of the Japanese Breast Cancer Society, has been published in Tokyo since 1994, originally by Maruzen and now by Springer, which Crossref lists as the publisher. Its NLM title names it as the journal of the Japanese Breast Cancer Society, and as such it is the society's venue for breast cancer research and clinical practice in Japan and internationally. The NLM record lists it as a Japanese serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/12282"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100888201"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/12282","issn":"1340-6868","scope":"breast cancer","founded":1994,"matchNames":["Breast Cancer","Breast cancer","Breast Cancer (Tokyo)","Breast cancer : the journal of the Japanese Breast Cancer Society"],"society":"Japanese Breast Cancer Society"},{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","aka":["Breast cancer research : BCR","Breast Cancer Research","BCR","Breast Cancer Res"],"tldr":"Breast Cancer Research is an open access journal for laboratory, translational and clinical breast cancer science, read by breast cancer researchers and specialist clinicians.","summary":"Breast Cancer Research was launched in 1999 by BioMed Central in London and is published by BMC, part of Springer Nature. As its title indicates, it is devoted to research on breast cancer, from laboratory science to clinical studies, and its DOAJ and NLM records list it as an English journal published from London. It is fully open access and listed in DOAJ with CC BY and CC BY-NC-ND licences, an article processing charge and anonymous peer review, with open access content from 2000. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://breast-cancer-research.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100927353"},{"label":"DOAJ record","url":"https://doaj.org/toc/1465-5411"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://breast-cancer-research.biomedcentral.com/","issn":"1465-5411","scope":"breast cancer","access":"open-access","founded":1999,"matchNames":["Breast Cancer Res","Breast cancer research","Breast Cancer Research"]},{"id":"breast-cancer-research-and-treatment","kind":"journal","name":"Breast cancer research and treatment","aka":["Breast Cancer Research and Treatment","Breast Cancer Res Treat"],"tldr":"Breast Cancer Research and Treatment is a long-established Springer journal spanning breast cancer biology, epidemiology and clinical management, read by breast oncologists and researchers.","summary":"Breast Cancer Research and Treatment has been published since 1981, first by Kluwer Academic in Dordrecht, the Netherlands, and now by Springer, which Crossref lists as the publisher. As its title indicates, it spans both breast cancer research and treatment, and it is one of the longest-running journals devoted to the disease. The NLM record lists it as a Netherlands serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10549"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8111104"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10549","issn":"0167-6806","scope":"breast cancer","founded":1981,"matchNames":["Breast Cancer Res Treat","Breast cancer research and treatment","Breast Cancer Research and Treatment"]},{"id":"british-journal-of-cancer","kind":"journal","name":"British Journal of Cancer","aka":["Br J Cancer","BJC"],"tldr":"The British Journal of Cancer is Cancer Research UK's journal, published by Springer Nature, covering translational and clinical research and the UK registry epidemiology on risk factors, attributable fractions and deprivation gaps. Its Cancer Research UK epidemiology reports are usually free to read.","summary":"Owned by Cancer Research UK and published by Springer Nature. Covers molecular, translational, clinical and epidemiological research, with a strong UK cohort and registry tradition (attributable fractions, early-diagnosis routes, deprivation gaps). Hybrid access; the Cancer Research UK-linked epidemiology reports are usually open.","asOf":"2026-09-09","links":[{"label":"Cancer Research UK","url":"https://www.cancerresearchuk.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":["preclinical","risk-factor"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/bjc/","issn":"0007-0920","scope":"clinical oncology","access":"hybrid","founded":1947,"matchNames":["British Journal of Cancer","Br J Cancer","BJC"],"society":"Cancer Research UK"},{"id":"bulletin-du-cancer","kind":"journal","name":"Bulletin du cancer","aka":["Bulletin du Cancer","Bull Cancer"],"tldr":"Bulletin du Cancer is the French-language journal of the Société Française du Cancer, publishing original and review articles across oncology for French-speaking clinicians and researchers.","summary":"Bulletin du Cancer is published in Paris by Elsevier (Elsevier Masson), which Crossref confirms as the publisher, and has been catalogued by the NLM from 1966. The Société Française du Cancer describes it as its official organ and as the reference French-language publication in oncology, covering the available information in cancer research and care in the form of original articles and review syntheses across disciplines, including fundamental research; members receive print or digital subscriptions through the society. It is indexed in MEDLINE and is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/bulletin-du-cancer"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/72416"},{"label":"Société Française du Cancer page","url":"https://sfc.asso.fr/informer/le-bulletin-du-cancer/"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier Masson","url":"https://www.sciencedirect.com/journal/bulletin-du-cancer","issn":"0007-4551","scope":"clinical oncology","founded":1966,"matchNames":["Bull Cancer","Bulletin du cancer","Bulletin du Cancer"],"society":"Société Française du Cancer"},{"id":"ca-cancer-journal","kind":"journal","name":"CA: A Cancer Journal for Clinicians","aka":["CA Cancer J Clin","CA"],"tldr":"CA: A Cancer Journal for Clinicians has the highest impact factor of any journal, because it publishes the annual US and global cancer statistics that almost every cancer paper cites.","summary":"Bimonthly review journal of the American Cancer Society. Publishes 'Cancer Statistics' (US) and 'Global Cancer Statistics' each year, the ACS screening guidelines, and long-form reviews on treatment and survivorship written for practising clinicians. Articles are free to read online. Its extreme impact factor reflects a small number of extremely cited statistical reports rather than a broad research programme.","asOf":"2026-09-09","links":[{"label":"Cancer Facts & Figures","url":"https://www.cancer.org/research/cancer-facts-statistics.html"}],"tags":[],"related":["american-cancer-society","globocan","seer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://acsjournals.onlinelibrary.wiley.com/journal/15424863","issn":"0007-9235","scope":"cancer statistics and reviews","founded":1950,"impactFactor":{"value":503.1,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["CA: A Cancer Journal for Clinicians","CA: a Cancer Journal for Clinicians","CA Cancer J Clin"],"society":"American Cancer Society"},{"id":"cancer-wiley","kind":"journal","name":"Cancer","aka":["Cancer (ACS journal)"],"tldr":"Cancer is the American Cancer Society's peer-reviewed clinical journal, publishing across all cancers since 1948 with a focus on epidemiology, survivorship and outcomes.","summary":"Twice-monthly interdisciplinary journal covering clinical research, epidemiology, health services, survivorship and psychosocial oncology. Publishes many cooperative-group secondary analyses, SEER-based outcome studies and quality-of-life work. Hybrid access via Wiley; sister to CA: A Cancer Journal for Clinicians and Cancer Cytopathology.","asOf":"2026-09-09","links":[{"label":"American Cancer Society journals","url":"https://acsjournals.onlinelibrary.wiley.com"}],"tags":[],"related":["american-cancer-society","seer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://acsjournals.onlinelibrary.wiley.com/journal/10970142","issn":"0008-543X","scope":"clinical oncology","access":"hybrid","founded":1948,"matchNames":["Cancer"],"society":"American Cancer Society"},{"id":"cancer-biology-and-medicine","kind":"journal","name":"Cancer biology & medicine","aka":["Cancer Biology & Medicine","Cancer Biology and Medicine","Cancer Biol Med","CBM"],"tldr":"Cancer Biology & Medicine is a monthly open access journal from the China Anti-Cancer Association covering cancer biology through clinical research, read by Chinese and international oncology researchers.","summary":"Cancer Biology & Medicine has been published in Tianjin since 2012 and is sponsored by the China Anti-Cancer Association (CACA) and Tianjin Medical University Cancer Institute and Hospital. The journal describes itself as a peer-reviewed open access monthly providing innovative and significant information on the biological basis of cancer, the cancer microenvironment, translational cancer research and all aspects of clinical cancer research, including cancer genetics, immunology, prevention, biomarkers, radiation oncology, drug resistance, targeted therapy and personalised medicine, with all full texts freely available. It follows ICMJE and COPE guidance and is listed in DOAJ under a CC BY-NC licence with an article processing charge. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.cancerbiomed.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101588850"},{"label":"DOAJ record","url":"https://doaj.org/toc/2095-3941"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["caca","tmucih"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"China Anti-Cancer Association and Tianjin Medical University Cancer Institute and Hospital","url":"https://www.cancerbiomed.org/","issn":"2095-3941","scope":"cancer biology and clinical oncology","access":"open-access","founded":2012,"matchNames":["Cancer Biol Med","Cancer biology & medicine","Cancer Biology & Medicine","Cancer Biology and Medicine"],"society":"China Anti-Cancer Association"},{"id":"cancer-biology-and-therapy","kind":"journal","name":"Cancer biology & therapy","aka":["Cancer Biology & Therapy","Cancer Biology and Therapy","Cancer Biol Ther"],"tldr":"Cancer Biology & Therapy is an open access journal on the molecular basis of cancer and its translation into diagnosis and treatment, read by translational cancer researchers.","summary":"Cancer Biology & Therapy began in 2002 with Landes Bioscience, which Crossref still names, and has been published by Taylor & Francis from Philadelphia since 2015. Its aims and scope describe an international journal examining all aspects of the molecular basis of cancer with translational relevance to diagnosis and therapy, covering new technologies, mechanisms of action of novel agents, combination chemotherapy, pharmacogenomics and pharmacokinetics, and chemotherapeutic, biological, immunomodulatory, cell and gene therapies. It publishes original research, reviews, meeting reports, bedside-to-bench reports, letters and journal club articles under single-blind peer review, converted to full open access from volume 23 in 2022 and is now online only. Listed in DOAJ with CC BY and CC BY-NC licences and an article processing charge. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/kcbt"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101137842"},{"label":"DOAJ record","url":"https://doaj.org/toc/1538-4047"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pharmacokinetics","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis (formerly Landes Bioscience)","url":"https://www.tandfonline.com/journals/kcbt","issn":"1538-4047","scope":"cancer biology and therapeutics","access":"open-access","founded":2002,"matchNames":["Cancer Biol Ther","Cancer biology & therapy","Cancer Biology & Therapy","Cancer Biology and Therapy"]},{"id":"cancer-biomarkers","kind":"journal","name":"Cancer biomarkers","aka":["Cancer biomarkers : section A of Disease markers","Cancer Biomarkers","Cancer Biomark"],"tldr":"Cancer Biomarkers publishes research on molecular markers for cancer detection, prognosis and treatment response, read by laboratory medicine and translational oncology researchers.","summary":"Cancer Biomarkers, subtitled section A of Disease Markers, has been published since 2005 and moved to SAGE Publications in Thousand Oaks, California, in 2024 after IOS Press, its founding publisher, became part of SAGE; Crossref lists SAGE Publications as the publisher. As its title indicates, its subject is biomarkers of cancer, the molecular and cellular markers used in cancer diagnosis, prognosis and treatment monitoring. The NLM record lists it as a United States serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/cbm"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101256509"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publications (formerly IOS Press)","url":"https://journals.sagepub.com/home/cbm","issn":"1574-0153","scope":"cancer biomarkers and diagnostics","founded":2005,"matchNames":["Cancer Biomark","Cancer biomarkers","Cancer Biomarkers"]},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","aka":["Cancer Biotherapy & Radiopharmaceuticals","Cancer Biotherapy and Radiopharmaceuticals","Cancer Biother Radiopharm"],"tldr":"Cancer Biotherapy and Radiopharmaceuticals covers immunotherapy, targeted biological agents and radiolabelled drugs for cancer imaging and treatment, read by nuclear medicine and biotherapy researchers.","summary":"Cancer Biotherapy & Radiopharmaceuticals has been published since 1996 and, according to the NLM catalogue, is issued from 2026 by SAGE Publications in Thousand Oaks, California, following its long run with Mary Ann Liebert; Crossref lists SAGE Publications as the publisher. As its title indicates, its two subjects are cancer biotherapy, meaning biological agents used to treat cancer, and radiopharmaceuticals, meaning radiolabelled compounds used to image and treat it. The NLM record lists it as a United States serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/cbr"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9605408"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publications (formerly Mary Ann Liebert)","url":"https://journals.sagepub.com/home/cbr","issn":"1084-9785","scope":"cancer biotherapy and radiopharmaceuticals","founded":1996,"matchNames":["Cancer Biother Radiopharm","Cancer biotherapy & radiopharmaceuticals","Cancer Biotherapy & Radiopharmaceuticals","Cancer Biotherapy and Radiopharmaceuticals"]},{"id":"cancer-causes-and-control","kind":"journal","name":"Cancer causes & control","aka":["Cancer causes & control : CCC","Cancer Causes & Control","Cancer Causes and Control","Cancer Causes Control"],"tldr":"Cancer Causes & Control is a Springer journal of cancer epidemiology, publishing studies of cancer risk factors, screening and prevention for epidemiologists and public health researchers.","summary":"Cancer Causes & Control has been published since 1990, originally by Kluwer Academic Publishers in Dordrecht, the Netherlands, and now by Springer, which Crossref lists as the publisher. As its title indicates, its subject is cancer epidemiology and cancer control: the causes of cancer in populations and the measures used to prevent and control it. The NLM record lists it as a Netherlands serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10552"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9100846"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10552","issn":"0957-5243","scope":"cancer epidemiology and prevention","founded":1990,"matchNames":["Cancer Causes Control","Cancer causes & control","Cancer Causes & Control","Cancer Causes and Control"]},{"id":"cancer-cell","kind":"journal","name":"Cancer Cell","aka":["Cancer Cell","src-cancer-cell"],"tldr":"Cancer Cell is Cell Press's dedicated cancer journal, publishing mechanism-rich papers on tumour biology, the microenvironment, resistance and biomarkers, plus the CPTAC proteogenomic atlases.","summary":"Cancer Cell is Cell Press's dedicated cancer journal, founded in 2002, appearing monthly and published by Cell Press (Elsevier) on a hybrid model. It publishes mechanism-rich papers on tumour biology, the microenvironment, drug resistance and biomarkers, including multi-omic studies such as the CPTAC proteogenomic atlases and TCGA subtype papers and translational biomarker work that often accompanies clinical trials. Its readers are cancer biologists and translational researchers. Within OnCo it is related to the CPTAC consortium and the Cancer Cell source feed and is linked from the biographies of Rui-Hua Xu, Ross Levine, Aaron Schimmer, Frank McCormick, Lajos Pusztai and Michael Taylor, and it is where a reader would look for the mechanistic paper behind a resistance story.","asOf":"2026-09-09","links":[{"label":"Cell Press","url":"https://www.cell.com"}],"tags":[],"related":["cptac"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Mechanistic cancer biology, multi-omic atlases and translational studies. Access: Paywalled."],"publisher":"Cell Press (Elsevier)","url":"https://www.cell.com/cancer-cell/home","issn":"1535-6108","scope":"basic cancer biology","access":"hybrid","founded":2002,"impactFactor":{"value":48.8,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Cancer Cell"]},{"id":"cancer-chemotherapy-and-pharmacology","kind":"journal","name":"Cancer chemotherapy and pharmacology","aka":["Cancer Chemotherapy and Pharmacology","Cancer Chemother Pharmacol"],"tldr":"Cancer Chemotherapy and Pharmacology publishes the pharmacokinetics, pharmacodynamics, dosing and early clinical evaluation of anticancer drugs, read by clinical pharmacologists and medical oncologists.","summary":"Cancer Chemotherapy and Pharmacology has been published in Berlin by Springer since 1978; Crossref lists Springer as the publisher. As its title indicates, its subject is the pharmacology of cancer chemotherapy: how anticancer drugs behave in the body and how they are dosed and evaluated. The NLM record lists it as a German serial that is indexed in MEDLINE; it is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10280"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7806519"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10280","issn":"0344-5704","scope":"cancer pharmacology and therapeutics","founded":1978,"matchNames":["Cancer Chemother Pharmacol","Cancer chemotherapy and pharmacology","Cancer Chemotherapy and Pharmacology"]},{"id":"cancer-communications","kind":"journal","name":"Cancer communications","aka":["Cancer Commun (Lond)","Cancer Communications","Chinese Journal of Cancer"],"tldr":"Cancer Communications is the open-access English-language journal of the Chinese Anti-Cancer Association, covering basic, translational and clinical cancer research. Read by oncologists and cancer researchers, particularly those following work from China.","summary":"Cancer Communications is the official journal of the Chinese Anti-Cancer Association and the US Chinese Anti-Cancer Association. It continued the Chinese Journal of Cancer under its present title in 2018 and is an open-access, peer-reviewed online journal spanning basic, clinical and translational cancer research, including clinical trials, epidemiology, molecular and cellular biology and genetics. Recent articles are registered with Crossref under the American Association for the Advancement of Science as a Science Partner Journal (DOI prefix 10.34133), after an earlier period with Wiley, which is the publisher named on the DOAJ record. DOAJ lists CC BY and CC BY-NC-ND licences, an article processing charge with waivers, and anonymous peer review. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://spj.science.org/journal/cancomm"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101723675"},{"label":"DOAJ record","url":"https://doaj.org/toc/2523-3548"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for the Advancement of Science (Science Partner Journals)","url":"https://spj.science.org/journal/cancomm","issn":"2523-3548","scope":"clinical oncology","access":"open-access","founded":2018,"matchNames":["Cancer Commun (Lond)","Cancer communications","Cancer Communications","Cancer Commun"],"society":"Chinese Anti-Cancer Association"},{"id":"cancer-control","kind":"journal","name":"Cancer control","aka":["Cancer control : journal of the Moffitt Cancer Center","Cancer Control"],"tldr":"Cancer Control is the open-access journal of the Moffitt Cancer Center in Florida, covering cancer prevention, detection, treatment, survivorship and palliative care. Read by clinicians and cancer-control researchers.","summary":"Cancer Control began in 1994 as the journal of the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and is now published by SAGE Publishing with Moffitt Cancer Center as its affiliated institution. DOAJ records it as fully open access since 2018 under CC BY and CC BY-NC licences, with an article processing charge (waivers available) and double anonymous peer review. Its stated subject coverage on DOAJ spans cancer prevention, detection, diagnosis, treatment, survivorship and palliative care. NLM notes that print issues ceased around 2014 and that from 2021 articles are published as they are accepted and compiled into an annual volume. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/ccx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9438457"},{"label":"DOAJ record","url":"https://doaj.org/toc/1073-2748"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["moffitt"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publishing","url":"https://journals.sagepub.com/home/ccx","issn":"1073-2748","scope":"clinical oncology","access":"open-access","founded":1994,"matchNames":["Cancer Control","Cancer control","Cancer Control: Journal of the Moffitt Cancer Center"]},{"id":"cancer-cytopathology","kind":"journal","name":"Cancer cytopathology","aka":["Cancer Cytopathol","Cancer Cytopathology"],"tldr":"Cancer Cytopathology is the American Cancer Society's journal for cytopathology, the diagnosis of cancer from cells rather than tissue blocks. Read by cytopathologists, cytotechnologists and pathologists.","summary":"Cancer Cytopathology is a journal of the American Cancer Society, published by Wiley alongside Cancer and CA: A Cancer Journal for Clinicians. It publishes research of interest to cytopathology, cytology and pathology professionals on the causes of cancer, its diagnosis and its prevention, and describes itself as international in scope. NLM records that from 1997 to 2009 it appeared as every third volume of the journal Cancer and that from volume 118 in 2010 it has been issued independently, bimonthly. The journal site offers open access publishing options for authors; the default access model is not stated on the pages consulted. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://acsjournals.onlinelibrary.wiley.com/journal/19346638"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101499453"}],"tags":[],"related":["pubmed-europepmc","cancer-wiley","ca-cancer-journal"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://acsjournals.onlinelibrary.wiley.com/journal/19346638","issn":"1934-662X","scope":"cytopathology","founded":2010,"matchNames":["Cancer Cytopathol","Cancer cytopathology","Cancer Cytopathology"],"society":"American Cancer Society"},{"id":"cancer-discovery","kind":"journal","name":"Cancer Discovery","aka":["Cancer Discov","src-cancer-discovery"],"tldr":"AACR's high-profile journal bridging discovery and the clinic: first-in-human targeted-therapy data, resistance mechanisms and translational biology.","summary":"Cancer Discovery has appeared monthly since 2011 and publishes early clinical results with deep correlative science (KRAS, menin, and other targeted agents' first reports), mechanisms of acquired resistance, and the AACR Cancer Progress Report coverage. Hybrid access; AACR annual meeting plenary papers frequently appear here.","asOf":"2026-09-09","links":[{"label":"AACR","url":"https://www.aacr.org"}],"tags":[],"related":["src-aacr-annual","blood-cancer-discovery"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: High-impact translational and early-clinical science, plus In the Spotlight pieces and news digests of the field. Access: Paywalled; news free."],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cancerdiscovery","issn":"2159-8274","scope":"basic cancer biology","access":"hybrid","founded":2011,"impactFactor":{"value":29.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Cancer Discovery","Cancer Discov"],"society":"American Association for Cancer Research"},{"id":"cancer-epidemiology","kind":"journal","name":"Cancer epidemiology","aka":["Cancer Epidemiol","Cancer Epidemiology","Cancer Detection and Prevention"],"tldr":"Cancer Epidemiology is an Elsevier journal about what causes cancer, how it can be prevented and how outcomes vary across populations. Read by epidemiologists, public-health researchers and cancer registries.","summary":"Cancer Epidemiology, subtitled on its journal page as covering cancer determinants, prevention, prognosis and outcomes, publishes original research that adds new information about cancer causes, prevention and control: risk factors for initiation, development and prognosis, early detection and screening, survivorship, descriptive patterns and trends, and methodology. It accepts original articles, systematic and critical reviews, meta-analyses, invited editorials, commentaries and letters. Published by Elsevier six times a year, it continued Cancer Detection and Prevention under the present title in 2009. The ScienceDirect page states that the journal supports open access with an article publishing charge for authors who choose it, alongside subscription content. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/cancer-epidemiology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101508793"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/cancer-epidemiology","issn":"1877-7821","scope":"cancer epidemiology and prevention","access":"hybrid","founded":2009,"matchNames":["Cancer Epidemiol","Cancer epidemiology","Cancer Epidemiology"]},{"id":"cancer-epidemiology-biomarkers-prevention","kind":"journal","name":"Cancer Epidemiology, Biomarkers & Prevention","aka":["Cancer Epidemiol Biomarkers Prev","CEBP"],"tldr":"AACR's epidemiology and prevention journal: risk factors, screening, early-detection biomarkers and cancer disparities.","summary":"Cancer Epidemiology, Biomarkers & Prevention (CEBP) is the epidemiology and prevention journal of the American Association for Cancer Research (AACR), founded in 1991, appearing monthly and published by the society on a hybrid access model. It covers risk factors, screening, early-detection biomarkers and cancer disparities, publishing cohort and case-control studies of cancer risk, biomarker validation for early detection, screening uptake and disparities research, and coverage of the AACR Cancer Disparities Progress Report. Its readers are epidemiologists, prevention researchers and public health specialists. A reader of OnCo would use it for the population evidence on cancer risk, screening and early-detection biomarkers that sits upstream of treatment.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cebp","issn":"1055-9965","scope":"cancer epidemiology","access":"hybrid","founded":1991,"matchNames":["Cancer Epidemiology, Biomarkers & Prevention","Cancer Epidemiol Biomarkers Prev","CEBP"],"society":"American Association for Cancer Research"},{"id":"cancer-gene-therapy","kind":"journal","name":"Cancer gene therapy","aka":["Cancer Gene Ther","Cancer Gene Therapy"],"tldr":"Cancer Gene Therapy covers gene and cell therapies for cancer, from CAR-T cells to oncolytic viruses and gene editing. Read by translational researchers and clinicians developing these treatments.","summary":"Cancer Gene Therapy, published by Springer Nature on nature.com, describes itself as the essential gene and cellular therapy resource for cancer researchers and clinicians. It publishes research articles, reviews and analysis, brief communications and news and comment on gene therapy, cellular therapy including CAR-T cells, cancer biology, drug discovery, genetics, immunology, molecular biology and biomarkers. It is a hybrid journal: subscription content with an open access option and open access funding guidance for authors. The journal began in 1994 and has appeared twelve times a year since 2000. Its editorial checks include cover letters on institutional letterhead and author contribution statements. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.nature.com/cgt/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9432230"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/cgt/","issn":"0929-1903","scope":"cancer gene and cell therapy","access":"hybrid","founded":1994,"matchNames":["Cancer Gene Ther","Cancer gene therapy","Cancer Gene Therapy"]},{"id":"cancer-genetics","kind":"journal","name":"Cancer genetics","aka":["Cancer Genet","Cancer Genetics","Cancer Genetics and Cytogenetics"],"tldr":"Cancer Genetics is an Elsevier journal on the genetic and genomic changes that drive cancer, in both tumours and inherited predisposition. Read by cancer geneticists, cytogeneticists and molecular pathologists.","summary":"Cancer Genetics is published by Elsevier and is registered with Crossref under that publisher. NLM records that it continued Cancer Genetics and Cytogenetics under the present title in 2011, is published from New York, and is currently indexed for MEDLINE. It covers the genetics and genomics of cancer, including chromosomal and molecular alterations in tumours.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/cancer-genetics"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101539150"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/cancer-genetics","issn":"2210-7762","scope":"cancer genetics","founded":2011,"matchNames":["Cancer Genet","Cancer genetics","Cancer Genetics"]},{"id":"cancer-genomics-and-proteomics","kind":"journal","name":"Cancer genomics & proteomics","aka":["Cancer Genomics Proteomics","Cancer Genomics & Proteomics","CGP"],"tldr":"Cancer Genomics & Proteomics is a Greek-published journal on the genes, transcripts and proteins that mark and drive cancers. Read by molecular oncology researchers, especially those working on prognostic markers.","summary":"Cancer Genomics & Proteomics is published bimonthly by the International Institute of Anticancer Research (IIAR) in Kapandriti, Attiki, Greece, the publisher of Anticancer Research and In Vivo. It began in 2004; NLM notes that print issues ceased with volume 9 in 2012 and the journal is now online only. It publishes research articles and reviews on cancer genomics, proteomics, molecular markers and immunotherapy targets across tumour types, with recent issues covering glioma, cervical, lung and colon cancers and Ewing sarcoma. Articles in current issues are labelled open access on the journal site, although the journal is not listed in DOAJ. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://cgp.iiarjournals.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101188791"}],"tags":[],"related":["pubmed-europepmc","anticancer-research","in-vivo"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"International Institute of Anticancer Research","url":"https://cgp.iiarjournals.org/","issn":"1109-6535","scope":"cancer genomics and proteomics","founded":2004,"matchNames":["Cancer Genomics Proteomics","Cancer genomics & proteomics","Cancer Genomics & Proteomics","Cancer Genomics and Proteomics"]},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","aka":["Cancer imaging : the official publication of the International Cancer Imaging Society","Cancer Imaging"],"tldr":"Cancer Imaging is the open-access journal of the International Cancer Imaging Society, covering CT, MRI, PET and other imaging of cancer. Read by radiologists and nuclear medicine specialists working in oncology.","summary":"Cancer Imaging is the official publication of the International Cancer Imaging Society (ICIS), published by BMC, part of Springer Nature. It is an open access, peer-reviewed journal publishing original articles, reviews and editorials by radiologists specialising in oncology, covering CT, MR, PET, ultrasound, radionuclide and multimodal imaging across tumour sites, including breast, chest, gastrointestinal, hepatobiliary and pancreatic, neuro-oncology, paediatric oncology and theranostics. DOAJ records CC BY and CC0 licences, an article processing charge with waivers, and that authors retain copyright. The journal began in 2000 (originally published by e-med), with the first issue of each early volume carrying the annual ICIS conference; it has been fully open access with BMC since 2014. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://cancerimagingjournal.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101172931"},{"label":"DOAJ record","url":"https://doaj.org/toc/1470-7330"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://cancerimagingjournal.biomedcentral.com/","issn":"1470-7330","scope":"cancer imaging","access":"open-access","founded":2000,"matchNames":["Cancer Imaging","Cancer imaging"],"society":"International Cancer Imaging Society"},{"id":"cancer-immunology-research","kind":"journal","name":"Cancer Immunology Research","aka":["Cancer Immunol Res"],"tldr":"AACR's tumour immunology journal: mechanisms of immune response and escape, checkpoint and cell-therapy biology and immune biomarkers.","summary":"Cancer Immunology Research (Cancer Immunol Res) is the tumour immunology journal of the American Association for Cancer Research (AACR), appearing monthly since 2013 and published by the society on a hybrid access model. It publishes basic and translational tumour immunology: mechanisms of immune response and escape, T-cell and myeloid biology in the microenvironment, checkpoint and cell-therapy biology, neoantigen and vaccine research and correlative studies from immunotherapy trials. Its readers are tumour immunologists and immunotherapy trialists, and its scope maps to OnCo's Immunotherapy area. It is linked from the biographies of Elizabeth Jaffee, Kellie Smith, Pawel Kalinski, Hatem Soliman and Elizabeth Mittendorf, and a reader would use it for immune biomarkers and mechanisms.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cancerimmunolres","issn":"2326-6066","scope":"immunotherapy","access":"hybrid","founded":2013,"matchNames":["Cancer Immunology Research","Cancer Immunol Res"],"society":"American Association for Cancer Research"},{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","aka":["Cancer immunology, immunotherapy : CII","Cancer Immunol Immunother","CII","Cancer Immunology, Immunotherapy"],"tldr":"Cancer Immunology, Immunotherapy (CII) is a long-running Springer journal on how the immune system recognises cancer and how that can be turned into treatment. Read by tumour immunologists and immunotherapy clinicians.","summary":"Cancer Immunology, Immunotherapy (CII) is published by Springer and is affiliated with six cancer immunotherapy organisations: the Association for Cancer Immunotherapy (CIMT), the Canadian Cancer Immunotherapy Consortium, the Japanese Association for Cancer Immunology, the Network Italiano per la Bioterapia dei Tumori, the Spanish SEI-GEIT group and Cancer Immunotherapy and Immunomonitoring (CITIM). Its aims page states that since its inception in 1976 it has reported advances in tumour immunology, publishing broad-ranging ideas and reviews, results that extend or challenge established paradigms, and negative studies, across basic, translational and clinical research. NLM dates the present title to 1982, when it continued Cancer Immunology and Immunotherapy; it appears twelve times a year. DOAJ records it as fully open access since 2024 under CC BY and CC BY-NC-ND licences with an article processing charge, and anonymous peer review. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/262"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8605732"},{"label":"DOAJ record","url":"https://doaj.org/toc/0340-7004"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/262","issn":"0340-7004","scope":"cancer immunology","access":"open-access","founded":1982,"matchNames":["Cancer Immunol Immunother","Cancer immunology, immunotherapy","Cancer Immunology, Immunotherapy","Cancer Immunology Immunotherapy","CII"]},{"id":"cancer-investigation","kind":"journal","name":"Cancer investigation","aka":["Cancer Invest","Cancer Investigation"],"tldr":"Cancer Investigation is a Taylor & Francis journal of translational and clinical oncology with fast publication. Read by medical oncologists and clinical researchers.","summary":"Cancer Investigation, published by Taylor & Francis (Informa UK), publishes original papers, essays, reports on new technologies and reviews in translational and clinical oncology, and offers accelerated publication. It is an Open Select journal, meaning a subscription journal in which authors may choose to publish open access. NLM records it as the official journal of the Chemotherapy Foundation and the Inter-American Society for Chemotherapy (IASC), founded in 1983 (originally with Marcel Dekker), appearing eight times a year since 2005, with print issues ceasing after volume 32 in 2014. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/icnv20"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8307154"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["chemotherapy-term","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/icnv20","issn":"0735-7907","scope":"clinical oncology","access":"hybrid","founded":1983,"matchNames":["Cancer Invest","Cancer investigation","Cancer Investigation"],"society":"Chemotherapy Foundation and Inter-American Society for Chemotherapy"},{"id":"cancer-letters","kind":"journal","name":"Cancer letters","aka":["Cancer Lett","Cancer Letters"],"tldr":"Cancer Letters is a high-volume Elsevier journal for basic and translational cancer biology, with an emphasis on experimental targeted therapies. Read by laboratory cancer researchers.","summary":"Cancer Letters is an international journal that considers full-length articles and Mini Reviews in the broad area of basic and translational oncology, with Special Issues on topical areas of cancer research. Areas of interest listed on its aims page include the molecular genetics and cell biology of cancer, radiation biology, molecular pathology, hormones and cancer, viral oncology, metastasis and chemoprevention, with emphasis on experimental therapeutics and targeted therapies for personalised cancer medicine. Published by Elsevier since 1975 (originally Elsevier/North-Holland), it appears twenty-six times a year. The ScienceDirect page states that the journal supports open access, so it runs a hybrid model with subscription content and an open access option. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/cancer-letters"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7600053"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["metastasis","targeted-therapy-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/cancer-letters","issn":"0304-3835","scope":"cancer biology","access":"hybrid","founded":1975,"matchNames":["Cancer Lett","Cancer letters","Cancer Letters"]},{"id":"cancer-medicine","kind":"journal","name":"Cancer medicine","aka":["Cancer Med","Cancer Medicine"],"tldr":"Cancer Medicine is a large open-access Wiley journal, launched in 2012, that takes research from every part of oncology, from laboratory biology to clinical trials and prevention, and also accepts papers referred from other Wiley journals. All articles are CC BY, with an article processing charge.","summary":"Cancer Medicine is a peer-reviewed, open access, interdisciplinary Wiley journal providing rapid publication of research across the cancer sciences. It considers submissions from all oncology specialties in four broad sections: clinical cancer research (trials, chemotherapy, radiation and surgical therapy, guidelines), cancer biology (molecular and cellular biology, genomics, immunology, epigenetics, carcinogenesis, drug discovery), cancer prevention (behavioural and psychosocial studies, screening, nutrition, epidemiology) and bioinformatics. Article types are original research, systematic reviews, meta-analyses, methods papers, brief communications and invited editorials and commentaries, and it also takes papers referred from other Wiley journals. All articles are published under the Creative Commons Attribution (CC BY) licence with authors retaining copyright; DOAJ records an article processing charge with waivers and anonymous peer review. Launched in 2012. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/20457634"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101595310"},{"label":"DOAJ record","url":"https://doaj.org/toc/2045-7634"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/20457634","issn":"2045-7634","scope":"clinical oncology","access":"open-access","founded":2012,"matchNames":["Cancer Med","Cancer medicine","Cancer Medicine"]},{"id":"cancer-metastasis-reviews","kind":"journal","name":"Cancer metastasis reviews","aka":["Cancer Metastasis Rev","Cancer and Metastasis Reviews","Cancer Metastasis Reviews"],"tldr":"Cancer and Metastasis Reviews is a Springer review journal on how cancers grow, spread and resist treatment, and on the biology behind new therapies. Read by researchers who want authoritative overviews rather than primary data.","summary":"Cancer and Metastasis Reviews (catalogued by NLM as Cancer Metastasis Reviews) is a quarterly Springer review journal founded in 1982, originally with Martinus Nijhoff; its founding editors are listed as Isaiah J. Fidler, Garth L. Nicolson and George Poste. It aims to highlight recent significant advances in basic, translational and clinical cancer research, emphasising studies with high impact for the control of cancer. Topics named on its aims page include oncogenes and tumour suppressors, cell death regulation, DNA repair, immune defects, the microbiome, cell metabolism, genetic and epigenetic alterations, the tumour microenvironment, targeted therapies and immunotherapies, biomarkers, early detection technologies and cancer disparities. It is a hybrid journal with open access funding options. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10555"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8605731"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10555","issn":"0167-7659","scope":"cancer biology and metastasis","access":"hybrid","founded":1982,"matchNames":["Cancer Metastasis Rev","Cancer metastasis reviews","Cancer Metastasis Reviews","Cancer and Metastasis Reviews"]},{"id":"cancer-nursing","kind":"journal","name":"Cancer nursing","aka":["Cancer Nurs","Cancer Nursing"],"tldr":"Cancer Nursing is the international journal for research on nursing care of people with cancer, from symptom management to survivorship and end-of-life care. Read by oncology nurses, nurse researchers and educators.","summary":"Cancer Nursing is published six times a year by Wolters Kluwer under the Lippincott Williams & Wilkins imprint (Crossref lists Ovid Technologies, Wolters Kluwer). NLM records it as the official publication of the International Society of Nurses in Cancer Care and, from 1985, the European Oncology Nursing Society; the journal site carries an About the Society page and publishes the oral abstracts of the ICCN congress as supplements. It began in 1978 with Masson Publishing USA. Content on the current site includes research articles, literature reviews, editorials, Insights pieces and plain language summaries, with an Open Access Collection alongside subscription content. Recent issues cover topics such as survivorship care systems, end-of-life care in surgical departments and financial hardship after cancer. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/cancernursingonline/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7805358"}],"tags":[],"related":["pubmed-europepmc","european-journal-of-oncology-nursing","clinical-journal-of-oncology-nursing"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wolters Kluwer (Lippincott Williams & Wilkins)","url":"https://journals.lww.com/cancernursingonline/pages/default.aspx","issn":"0162-220X","scope":"oncology nursing","founded":1978,"matchNames":["Cancer Nurs","Cancer nursing","Cancer Nursing"],"society":"International Society of Nurses in Cancer Care"},{"id":"cancer-prevention-research","kind":"journal","name":"Cancer prevention research","aka":["Cancer Prev Res (Phila)","Cancer Prevention Research"],"tldr":"Cancer Prevention Research is the AACR's journal for stopping cancer before it starts or catching it early: chemoprevention, risk factors, screening and interception. Read by prevention scientists, epidemiologists and clinicians running early-detection studies.","summary":"Cancer Prevention Research is published by the American Association for Cancer Research. It publishes original studies, reviews and commentaries in cancer prevention, early detection and interception, spanning preclinical, clinical, translational and implementation research with an emphasis on molecular discoveries and on bridging basic, clinical and population sciences. Areas of interest on its About page include early detection technologies and biomarkers such as liquid biopsy, risk assessment and screening, the biology of susceptibility and premalignancy, risk factors from the microbiome and viruses to obesity, inflammation and environmental carcinogens, and preventive interventions including their implementation in underserved populations. Launched in 2008, it has appeared twenty-four times a year since 2009; NLM notes print ceased with volume 13 in December 2020. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://aacrjournals.org/cancerpreventionresearch"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101479409"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cancerpreventionresearch","issn":"1940-6207","scope":"cancer prevention and early detection","founded":2008,"matchNames":["Cancer Prev Res (Phila)","Cancer Prev Res","Cancer prevention research","Cancer Prevention Research"],"society":"American Association for Cancer Research"},{"id":"cancer-radiotherapie","kind":"journal","name":"Cancer radiothérapie","aka":["Cancer radiothérapie : journal de la Société française de radiothérapie oncologique","Cancer Radiother","Cancer/Radiothérapie","Bulletin du cancer. Radiothérapie"],"tldr":"Cancer/Radiothérapie is the journal of the French society of radiation oncologists, published mostly in French with English abstracts. Read by radiation oncologists and medical physicists in France and francophone countries.","summary":"Cancer/Radiothérapie is the journal of the Société française de radiothérapie oncologique (SFRO), published by Elsevier Masson in Paris, with copyright held by the society. Its presentation page records a first publication in 1997 (it continued Bulletin du cancer. Radiothérapie), eight issues a year, and publication in French and English; NLM notes that articles are in French with summaries and contents in English and French. It covers clinical and technical radiation oncology and publishes thematic issues alongside regular numbers. The journal is indexed in MEDLINE, Embase, Science Citation Index Expanded, Scopus and LiSSa according to the publisher page. The access model is not stated on the pages consulted.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.em-consulte.com/revue/CANRAD/presentation/cancer-radiotherapie"},{"label":"ScienceDirect","url":"https://www.sciencedirect.com/journal/cancer-radiotherapie"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9711272"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier Masson","url":"https://www.em-consulte.com/revue/CANRAD/presentation/cancer-radiotherapie","issn":"1278-3218","scope":"radiation oncology","founded":1997,"matchNames":["Cancer Radiother","Cancer radiothérapie","Cancer/Radiothérapie","Cancer Radiothérapie","Cancer Radiotherapie"],"society":"Société française de radiothérapie oncologique"},{"id":"cancer-reports","kind":"journal","name":"Cancer reports","aka":["Cancer Rep (Hoboken)","Cancer Reports"],"tldr":"Cancer Reports is a broad open-access Wiley journal for basic, translational and clinical cancer research, including sound studies that are not headline results. Read by researchers across oncology.","summary":"Cancer Reports is a peer-reviewed, international, open access Wiley journal covering basic, translational, clinical and interdisciplinary cancer research; DOAJ lists its keywords as cancer biology, clinical oncology, bioinformatics, psycho-oncology, cancer immunology and anticancer agents. It began in 2018 and joined Wiley's open access portfolio in January 2021, with all articles from August 2020 published under the Creative Commons Attribution (CC BY) licence and subject to an article processing charge (waivers available); DOAJ records anonymous peer review and that authors retain copyright. Six issues a year. The journal also offers a Registered Reports format. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/25738348"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101747728"},{"label":"DOAJ record","url":"https://doaj.org/toc/2573-8348"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/25738348","issn":"2573-8348","scope":"clinical oncology","access":"open-access","founded":2018,"matchNames":["Cancer Rep (Hoboken)","Cancer Rep","Cancer reports","Cancer Reports"]},{"id":"cancer-research","kind":"journal","name":"Cancer Research","aka":["Cancer Res","src-cancer-research"],"tldr":"Cancer Research is AACR's original journal, publishing since 1941: broad basic and preclinical cancer biology, tumour immunology and the AACR annual meeting abstracts.","summary":"Cancer Research (Cancer Res) is the original journal of the American Association for Cancer Research (AACR), publishing since 1941, appearing twice a month and available on a hybrid model with articles free a year after publication. It covers broad basic and preclinical cancer biology, including the tumour microenvironment, tumour immunology, preclinical therapeutics and computational cancer biology, and it publishes the AACR annual meeting abstract supplement. Its readers are laboratory cancer biologists and preclinical researchers. Within OnCo it has its own Cancer Research source feed, is tied to the AACR institution entry and is linked from the Shari Pilon-Thomas and Evanthia Galanis biographies, and a reader would use it for preclinical biology and the AACR meeting abstracts.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":["cancer-research-communications"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Oldest AACR journal: preclinical and mechanistic cancer science. Access: Paywalled."],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cancerres","issn":"0008-5472","scope":"basic cancer biology","access":"hybrid","founded":1941,"impactFactor":{"value":12.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Cancer Research","Cancer Res"],"society":"American Association for Cancer Research"},{"id":"cancer-research-and-treatment","kind":"journal","name":"Cancer research and treatment","aka":["Cancer Res Treat","Cancer Research and Treatment","CRT","Taehan Am Hakhoe chi"],"tldr":"Cancer Research and Treatment is the open-access journal of the Korean Cancer Association, publishing experimental and clinical cancer research. Read by oncologists in Korea and internationally, and it is a common home for Korean clinical trial reports.","summary":"Cancer Research and Treatment is a peer-reviewed open access publication of the Korean Cancer Association, the Korean Society of Medical Oncology and the Korean Association for Lung Cancer, published quarterly from Seoul. It accepts manuscripts on experimental and clinical cancer research, including carcinogenesis, tumour biology, molecular oncology, cancer genetics, tumour immunology, epidemiology, predictive markers and prevention, pathology, diagnosis, screening and therapies (chemotherapy, surgery, radiation therapy, immunotherapy, gene therapy, multimodality treatment and palliative care). NLM dates the present title to 2000, continuing the Korean-language Taehan Am Hakhoe chi, and records content in English and Korean. Indexed in MEDLINE, PubMed Central, KoreaMed, Scopus and SCI according to its aims page.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.e-crt.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101155137"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["chemotherapy-term","radiotherapy","immunotherapy-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Korean Cancer Association","url":"https://www.e-crt.org/","issn":"1598-2998","scope":"clinical oncology","access":"open-access","founded":2000,"matchNames":["Cancer Res Treat","Cancer research and treatment","Cancer Research and Treatment"],"society":"Korean Cancer Association"},{"id":"cancer-research-communications","kind":"journal","name":"Cancer research communications","aka":["Cancer Res Commun","Cancer Research Communications"],"tldr":"Cancer Research Communications is the AACR's fully open-access journal for rapid publication across all of cancer research, including confirmatory and null results. Read by researchers who want AACR peer review without a paywall.","summary":"Cancer Research Communications is an open access, peer-reviewed journal of the American Association for Cancer Research launched in October 2021 and published monthly since 2022. It covers the full spectrum of cancer research, aiming to accelerate discovery by rapidly publishing hypotheses, methods, results, data resources and new knowledge; articles may report novel findings, support previously published results or present thought-provoking null results. Its sections span molecular and cellular biology, tumour biology, immuno-oncology, emerging technologies and data science, therapeutic development, precision medicine and biomarkers, clinical research and trials, epidemiology and prevention, and health disparities. All content is free to read under the Budapest Open Access Initiative definition; DOAJ records the CC BY licence, an article processing charge with discounts, anonymous peer review and author retention of copyright. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://aacrjournals.org/cancerrescommun"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/489454"},{"label":"DOAJ record","url":"https://doaj.org/toc/2767-9764"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/cancerrescommun","issn":"2767-9764","scope":"cancer research","access":"open-access","founded":2021,"matchNames":["Cancer Res Commun","Cancer research communications","Cancer Research Communications"],"society":"American Association for Cancer Research"},{"id":"cancer-science","kind":"journal","name":"Cancer science","aka":["Cancer Sci","Cancer Science","Japanese Journal of Cancer Research"],"tldr":"Cancer Science is the open-access journal of the Japanese Cancer Association, publishing basic, translational and clinical cancer research. Read by oncologists and cancer biologists, and a principal outlet for Japanese cancer research.","summary":"Cancer Science, formerly the Japanese Journal of Cancer Research, is the monthly journal of the Japanese Cancer Association, published by Wiley. Its overview page traces the journal to 1907; NLM dates the present title to 2003, with print ceasing after volume 102 in 2011. It publishes original articles, editorials, letters, review articles and reports in basic, translational and clinical cancer research, in categories including immunology, carcinogenesis, cell and stem cell biology, clinical research, drug discovery, epidemiology and prevention, genetics and genomics, inflammation and virology, and pathology, and aims for findings with significant clinical impact. Since 2017 it does not accept work funded by the tobacco industry. DOAJ records it as fully open access since 2014 under CC BY, CC BY-NC and CC BY-NC-ND licences with an article processing charge and anonymous peer review. Indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/13497006"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101168776"},{"label":"DOAJ record","url":"https://doaj.org/toc/1349-7006"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/13497006","issn":"1347-9032","scope":"cancer research","access":"open-access","founded":2003,"matchNames":["Cancer Sci","Cancer science","Cancer Science"],"society":"Japanese Cancer Association"},{"id":"cancer-treatment-and-research","kind":"journal","name":"Cancer treatment and research","aka":["Cancer Treat Res","Cancer Treatment and Research"],"tldr":"Cancer Treatment and Research is a Springer book series, not a conventional journal, in which each volume reviews current treatment of one cancer or one area of oncology, from basic science to safety and efficacy. Its chapters are indexed in MEDLINE, which is why it appears among journals.","summary":"Cancer Treatment and Research is a book series published by Springer Nature (series editor Steven T. Rosen) that NLM catalogues as a serial and indexes in MEDLINE. Each volume addresses the state of the art in the treatment of a form of cancer or an area of oncology, ranging from basic science advances to new treatment tools and evaluations of safety and efficacy, for an interdisciplinary readership of clinicians and researchers. The series began in 1981 with Martinus Nijhoff and appears irregularly; volumes are issued in hardcover, softcover and eBook editions. Crossref holds no journal-level record for its ISSN, consistent with it being a book series.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/bookseries/5808"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8008541"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/bookseries/5808","issn":"0927-3042","scope":"clinical oncology (book series)","founded":1981,"matchNames":["Cancer Treat Res","Cancer treatment and research","Cancer Treatment and Research"]},{"id":"cancer-treatment-and-research-communications","kind":"journal","name":"Cancer treatment and research communications","aka":["Cancer Treat Res Commun","Cancer Treatment and Research Communications","Cancer Treatment Communications"],"tldr":"Cancer Treatment and Research Communications is an open-access Elsevier journal for clinical and translational oncology papers, including smaller studies and case series. Read by practising oncologists and clinical researchers.","summary":"Cancer Treatment and Research Communications is an online-only Elsevier journal that continued Cancer Treatment Communications under the present title in 2016. DOAJ lists it as fully open access since 2020 under CC BY, CC BY-NC and CC BY-NC-ND licences, with an article processing charge (waivers available) and anonymous peer review, and gives its subject coverage as cancer research, oncology, cancer diagnosis and treatment, molecular oncology, clinical trials in oncology and cancer prevention. Published from London. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/cancer-treatment-and-research-communications"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101694651"},{"label":"DOAJ record","url":"https://doaj.org/toc/2468-2942"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/cancer-treatment-and-research-communications","issn":"2468-2942","scope":"clinical oncology","access":"open-access","founded":2016,"matchNames":["Cancer Treat Res Commun","Cancer treatment and research communications","Cancer Treatment and Research Communications"]},{"id":"cancer-treatment-reviews","kind":"journal","name":"Cancer treatment reviews","aka":["Cancer Treat Rev","Cancer Treatment Reviews"],"tldr":"Cancer Treatment Reviews is an Elsevier review journal, published six times a year since 1974, that gives oncologists overviews of drugs, combinations and treatment strategies across systemic therapy, radiotherapy, surgery and supportive care. It is read by clinicians rather than laboratory scientists.","summary":"Cancer Treatment Reviews is a review journal published by Elsevier six times a year and registered with Crossref under that publisher. NLM records that it began in 1974 with Academic Press in London and New York, with K. Hellmann and S. K. Carter as founding editors, and that it is currently indexed for MEDLINE. It publishes reviews on the treatment of cancer, spanning systemic therapy, radiotherapy, surgery and supportive care.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/cancer-treatment-reviews"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7502030"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["palliative-treatment","radiotherapy","systemic-vs-local-therapy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/cancer-treatment-reviews","issn":"0305-7372","scope":"clinical oncology reviews","founded":1974,"matchNames":["Cancer Treat Rev","Cancer treatment reviews","Cancer Treatment Reviews"]},{"id":"cancers-mdpi","kind":"journal","name":"Cancers","aka":["Cancers (Basel)"],"tldr":"A high-volume open-access oncology journal from MDPI publishing thousands of papers a year across basic, translational and clinical cancer research.","summary":"Fully open access with article processing charges and rapid turnaround, publishing thousands of original articles and reviews a year, often in special issues. Widely indexed and read, though MDPI's volume and speed have drawn scrutiny; treat individual findings with the usual care and check for replication.","asOf":"2026-09-09","links":[{"label":"MDPI","url":"https://www.mdpi.com"}],"tags":[],"related":["current-oncology-mdpi","pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"MDPI","url":"https://www.mdpi.com/journal/cancers","issn":"2072-6694","scope":"clinical oncology","access":"open-access","founded":2009,"matchNames":["Cancers","Cancers (Basel)"]},{"id":"carcinogenesis","kind":"journal","name":"Carcinogenesis","aka":["Carcinogenesis"],"tldr":"Carcinogenesis is an Oxford University Press journal on how cancers arise: chemical and environmental carcinogens, DNA damage, genetics and epigenetics, inflammation and prevention. Read by cancer biologists, toxicologists and molecular epidemiologists.","summary":"Carcinogenesis is a monthly journal published by Oxford University Press (originally by IRL Press, from 1980). It describes itself as a multidisciplinary journal bringing together the varied aspects of research that will ultimately lead to the prevention and effective treatment of human cancer. Its About page groups content into four areas: cancer prevention, epidemiology and molecular epidemiology; inflammation, the tumour microenvironment and cancer immunology; carcinogenesis, genetics and epigenetics; and translational cancer research. It is a hybrid journal, with subscription access and an open access publishing option with associated charges. Indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/carcin"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8008055"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["inflammation","risk-factor"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/carcin","issn":"0143-3334","scope":"cancer biology and carcinogenesis","access":"hybrid","founded":1980,"matchNames":["Carcinogenesis"]},{"id":"cell","kind":"journal","name":"Cell","aka":["Cell (Cell Press)"],"tldr":"Cell is the leading molecular and cell biology journal. It published the Hallmarks of Cancer and much of the mechanistic biology behind today's cancer drugs.","summary":"Cell appears every two weeks. Hanahan and Weinberg's Hallmarks of Cancer (2000, 2011) appeared here, as did many TCGA Pan-Cancer Atlas papers, single-cell tumour microenvironment atlases, CRISPR screening resources and the mechanistic work on oncogene signalling. Elsevier hybrid model; STAR Methods and data-availability requirements are strict.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Cell_(journal)","links":[{"label":"Cell Press","url":"https://www.cell.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Cell Press (Elsevier)","url":"https://www.cell.com/cell/home","issn":"0092-8674","scope":"basic cancer biology","access":"hybrid","founded":1974,"impactFactor":{"value":45.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Cell"]},{"id":"cell-stem-cell","kind":"journal","name":"Cell Stem Cell","aka":["Cell Stem Cell"],"tldr":"Cell Stem Cell is Cell Press's stem-cell journal. Cancer readers go to it for leukaemia stem cell and clonal haematopoiesis biology, patient-derived organoid biobanks used for drug testing, and induced pluripotent stem cell-derived immune cells for off-the-shelf cell therapies; access is hybrid.","summary":"Cell Stem Cell is Cell Press's stem-cell journal, founded in 2007, appearing monthly and published by Cell Press (Elsevier) on a hybrid model. It publishes haematopoietic and cancer stem cell biology, patient-derived organoid biobanks used for drug testing, and induced-pluripotent-stem-cell-derived immune cells for allogeneic cell therapy. For cancer readers its relevance lies in leukaemia stem cells, clonal haematopoiesis, organoid models and off-the-shelf cell therapies. Within OnCo it is linked from the Patient-derived organoids technology entry and the Michael Teitell biography, and it is where a reader would look for organoid biobank and cell-therapy engineering papers.","asOf":"2026-09-09","links":[{"label":"Cell Press","url":"https://www.cell.com"}],"tags":[],"related":["cell"],"cancers":[],"sections":[],"technologies":["organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Cell Press (Elsevier)","url":"https://www.cell.com/cell-stem-cell/home","issn":"1934-5909","scope":"stem cell biology","access":"hybrid","founded":2007,"matchNames":["Cell Stem Cell"]},{"id":"cellular-oncology","kind":"journal","name":"Cellular oncology","aka":["Cell Oncol (Dordr)","Cellular Oncology"],"tldr":"Cellular Oncology is an online-only, open access Springer journal for basic and translational cancer research at the level of the cell and the tissue. Its readers are molecular biologists, geneticists, pathologists and oncologists working on how cell biology translates into the clinic.","summary":"Cellular Oncology publishes research from biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, and describes itself as a platform for molecular biologists and geneticists, technical developers, pathologists, medical oncologists and other clinicians managing cancer patients, with a focus on converting cell biology into clinical applications. The homepage lists an open access publishing model and recent article types include research papers and reviews, with topical collections on the tumour microenvironment, immunotherapy signalling and cell death mechanisms. NLM records it as a bimonthly title that began in 2011 as the continuation in part of Analytical Cellular Pathology, published in Dordrecht by Springer, indexed in MEDLINE and PubMed with content in PMC. The journal is online only and its print ISSN has ceased. Crossref lists IOS Press as the publisher of record for the ISSN, reflecting its earlier publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/13402"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101552938"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["apoptosis","histology"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/13402","issn":"2211-3428","scope":"cancer biology","access":"open-access","founded":2011,"matchNames":["Cell Oncol (Dordr)","Cell Oncol","Cellular oncology","Cellular Oncology"]},{"id":"chinese-clinical-oncology","kind":"journal","name":"Chinese clinical oncology","aka":["Chin Clin Oncol","CCO","Chinese Clinical Oncology"],"tldr":"Chinese Clinical Oncology is an open access, peer-reviewed bimonthly journal from AME Publishing in Hong Kong, the official journal of the Society for Translational Medicine, publishing diagnosis, prevention and treatment studies with a large share of authors from China and Asia. It is indexed in MEDLINE but not listed in DOAJ.","summary":"Chinese Clinical Oncology describes itself as an open access, peer-reviewed bimonthly journal (quarterly from September 2012 to December 2015) that publishes original articles, editorials, case reports and reviews. Its stated focus is new findings in oncology and practical information on diagnosis, prevention and clinical investigation of cancer, with areas of interest including multimodality therapy, markers, imaging, tumour biology, pathology, chemoprevention and technical advances. The journal is the official journal of the Society for Translational Medicine and is published by AME Publishing Company with support from Wolters Kluwer, whose Lippincott and Ovid platforms carry the content. It is a member of COPE and follows ICMJE recommendations, and charges an article processing fee. NLM records the title as beginning in 2012, published in Hong Kong, and indexed in MEDLINE and PubMed (the journal says since 2014). It is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://cco.amegroups.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101608375"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["systemic-vs-local-therapy","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"AME Publishing Company","url":"https://cco.amegroups.org/","issn":"2304-3873","scope":"clinical oncology","access":"open-access","founded":2012,"matchNames":["Chin Clin Oncol","Chinese clinical oncology","Chinese Clinical Oncology"],"society":"Society for Translational Medicine"},{"id":"clinical-and-experimental-metastasis","kind":"journal","name":"Clinical & experimental metastasis","aka":["Clin Exp Metastasis","Clinical and Experimental Metastasis","Clinical & Experimental Metastasis"],"tldr":"Clinical & Experimental Metastasis is the official journal of the Metastasis Research Society and the main specialist venue for laboratory and clinical research on how cancer spreads. It is read by metastasis biologists and by clinicians who treat advanced disease.","summary":"Clinical & Experimental Metastasis is an international, multidisciplinary Springer journal devoted to the rapid publication of fundamental advances in basic and applied metastasis research, and is the official journal of the Metastasis Research Society. It publishes original articles, reviews, short communications, commentaries and letters to the editor across molecular biology, pharmacology, tumour biology and clinical treatment (surgery, chemotherapy, radiotherapy, pathology and epidemiology) insofar as they concern metastasis formation, prevention and treatment. Case studies are accepted only exceptionally, correlative clinical studies with small patient numbers must include experimental validation, and laboratory work is expected to provide mechanistic insight with validation in animal models. The homepage lists a hybrid publishing model. NLM records the title from 1983 (originally Taylor & Francis, later Kluwer Academic), published ten times a year since 1999 and indexed in MEDLINE. The journal is now online only and its print ISSN has ceased.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10585"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8409970"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10585","issn":"0262-0898","scope":"cancer biology","access":"hybrid","founded":1983,"matchNames":["Clin Exp Metastasis","Clinical & experimental metastasis","Clinical & Experimental Metastasis","Clinical and Experimental Metastasis"],"society":"Metastasis Research Society"},{"id":"clinical-and-translational-oncology","kind":"journal","name":"Clinical & translational oncology","aka":["Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico","Clin Transl Oncol","Clinical and Translational Oncology"],"tldr":"Clinical and Translational Oncology is the official journal of the Federation of Spanish Oncology Societies, bridging laboratory cancer biology and clinical practice. It is read by Spanish and international medical oncologists and translational researchers.","summary":"Clinical and Translational Oncology is an international Springer journal devoted to fostering interaction between experimental and clinical oncology and is the official journal of the Federation of Spanish Oncology Societies (FESEO); NLM's title statement also names the National Cancer Institute of Mexico. Its scope runs from cell and molecular biology of tumour cells to clinical assays of conventional and new drugs, and it publishes full research articles on the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, diagnosis, prognosis and treatment, together with educational series intended to close the gap between molecular and clinical oncologists. The homepage lists a hybrid publishing model. NLM records the title from 2005 as the successor to Revista de Oncologia (Barcelona), first published by Doyma and from 2010 by Springer Italia in Milan, eleven issues a year, with print issues ceasing in 2015; it is indexed in MEDLINE and PubMed.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/12094"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101247119"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/12094","issn":"1699-048X","scope":"clinical oncology","access":"hybrid","founded":2005,"matchNames":["Clin Transl Oncol","Clinical & translational oncology","Clinical & Translational Oncology","Clinical and Translational Oncology"],"society":"Federation of Spanish Oncology Societies (FESEO)"},{"id":"clinical-advances-in-hematology-and-oncology","kind":"journal","name":"Clinical advances in hematology & oncology","aka":["Clinical advances in hematology & oncology : H&O","Clin Adv Hematol Oncol","H&O","CAH&O"],"tldr":"Clinical Advances in Hematology & Oncology is a monthly US clinical review magazine that reaches practising haematologists and oncologists with expert interviews, review articles and case commentary rather than original trials.","summary":"Clinical Advances in Hematology & Oncology (CAH&O) describes itself as a monthly peer-reviewed journal reaching more than 27,000 haematology and oncology clinicians. Its content covers oncology and haematology separately and together: feature-length review articles, monthly columns of interviews with experts on solid tumour oncology, haematological malignancies, benign haematological disorders and drug development, and clinical case studies with expert commentary. The journal also publishes industry-supported meeting highlights, clinical roundtable monographs and clinical review supplements, and states that the journal and its supplements are indexed in PubMed/MEDLINE and EMBASE. Section editors cover melanoma, prostate, colorectal, ovarian, lung and breast cancer, haematology and drug development. NLM records the title from 2003, published monthly in New York by Millennium Medical Publishing and indexed in MEDLINE. The access model is not stated on the site and the title is not in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.hematologyandoncology.net/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101167661"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["leukaemia-type"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Millennium Medical Publishing","url":"https://www.hematologyandoncology.net/","issn":"1543-0790","scope":"clinical oncology and haematology","founded":2003,"matchNames":["Clin Adv Hematol Oncol","Clinical advances in hematology & oncology","Clinical Advances in Hematology & Oncology","Clinical Advances in Hematology and Oncology"]},{"id":"clinical-breast-cancer","kind":"journal","name":"Clinical breast cancer","aka":["Clin Breast Cancer","Clinical Breast Cancer"],"tldr":"Clinical Breast Cancer is an Elsevier specialty journal for clinical and translational breast cancer research, from detection and prevention to treatment. Breast oncologists, surgeons and translational researchers read it.","summary":"Clinical Breast Cancer is a peer-reviewed journal that publishes original articles on clinical and translational research in breast cancer, with eight issues a year. Its aims and scope statement says it is devoted to detection, diagnosis, prevention and treatment of breast cancer, with emphasis on recent scientific developments, and lists clinical research reports across therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumour genomics, biomarkers and chemoprevention strategies as areas of interest. The journal site includes an open access section for authors but does not state its overall access model in the text consulted, so no access model is recorded here. NLM records the title from 2000, first published in Dallas by the Cancer Information Group and since 2011 by Elsevier in New York, bimonthly from 2010 with supplements accompanying some volumes, and indexed in MEDLINE and PubMed.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinical-breast-cancer.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100898731"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinical-breast-cancer.com/","issn":"1526-8209","scope":"breast cancer","founded":2000,"matchNames":["Clin Breast Cancer","Clinical breast cancer","Clinical Breast Cancer"]},{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","aka":["Clin Cancer Res","CCR","src-clinical-cancer-research"],"tldr":"AACR's clinical journal: phase 1 dose-escalation trials, biomarker studies, pharmacodynamics and the FDA approval summaries written by agency reviewers.","summary":"Clinical Cancer Research appears twice a month and is the main venue for phase 1 trials of new oncology drugs, translational biomarker and pharmacokinetic analyses, and the FDA Oncology Center of Excellence approval summaries that explain the evidence behind each new indication. Hybrid access; free after 12 months.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":["fda-approvals"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Phase 1 and 2 trials, biomarker studies and CCR Translations commentaries. Access: Paywalled."],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/clincancerres","issn":"1078-0432","scope":"clinical oncology","access":"hybrid","founded":1995,"impactFactor":{"value":10,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Clinical Cancer Research","Clin Cancer Res","CCR"],"society":"American Association for Cancer Research"},{"id":"clinical-colorectal-cancer","kind":"journal","name":"Clinical colorectal cancer","aka":["Clin Colorectal Cancer","Clinical Colorectal Cancer"],"tldr":"Clinical Colorectal Cancer is an Elsevier journal for clinical and translational research in colorectal and other gastrointestinal cancers. Gastrointestinal oncologists and trialists read it for original reports tied to clinical practice.","summary":"Clinical Colorectal Cancer is devoted to manuscripts on early detection and screening, diagnosis, prevention and treatment of colorectal cancer and other gastrointestinal cancers, including pancreatic, liver, gastric and gastro-oesophageal, biliary and other GI tumours. Its aims and scope emphasise original peer-reviewed reports of clinical research and of translational correlative science directly related to clinical trials, across all multidisciplinary therapeutic fields, plus research on drug sensitivity and resistance to cytotoxic, targeted and immune therapies, pathology, validated predictive markers and prognostic indicators, chemoprevention and integration of therapeutic approaches. Meta-analyses, pooled analyses and real-world analyses receive lower priority unless clearly applicable to practice, and unsolicited reviews are discouraged without prior discussion with the editor. ScienceDirect lists the journal as supporting open access, offering authors a choice of open access or subscription publication. NLM records the title from 2001, first published in Dallas by the Cancer Information Group and from 2011 by Elsevier, quarterly, indexed in MEDLINE and PubMed.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinical-colorectal-cancer.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101120693"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["colorectal","anal","pancreatic","gastric","esophageal","hcc","cholangiocarcinoma","gallbladder"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinical-colorectal-cancer.com/","issn":"1533-0028","scope":"gastrointestinal oncology","access":"hybrid","founded":2001,"matchNames":["Clin Colorectal Cancer","Clinical colorectal cancer","Clinical Colorectal Cancer"]},{"id":"clinical-genitourinary-cancer","kind":"journal","name":"Clinical genitourinary cancer","aka":["Clin Genitourin Cancer","Clinical Genitourinary Cancer","Clinical prostate cancer"],"tldr":"Clinical Genitourinary Cancer is an Elsevier journal for clinical and translational research in prostate, kidney, bladder and other genitourinary cancers. Urologic oncologists and medical oncologists treating these tumours read it.","summary":"Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles on clinical and translational research in genitourinary cancers, devoted to detection, diagnosis, prevention and treatment of genitourinary malignancies with emphasis on recent scientific developments. Its stated areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention strategies, multimodality therapy and integration of approaches. The access model is not stated in the pages consulted and is therefore not recorded here. NLM records the title from 2005 as the successor to Clinical Prostate Cancer, with the note 'Prostate, kidney, & bladder', first published in Dallas by the Cancer Information Group and from 2009 by Elsevier, quarterly, with print issues ceasing in January 2009; it is indexed in MEDLINE and PubMed.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinical-genitourinary-cancer.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101260955"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["prostate","rcc","urothelial","testicular","penile"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinical-genitourinary-cancer.com/","issn":"1558-7673","scope":"genitourinary oncology","founded":2005,"matchNames":["Clin Genitourin Cancer","Clinical genitourinary cancer","Clinical Genitourinary Cancer"]},{"id":"clinical-journal-of-oncology-nursing","kind":"journal","name":"Clinical journal of oncology nursing","aka":["Clin J Oncol Nurs","CJON","Clinical Journal of Oncology Nursing"],"tldr":"The Clinical Journal of Oncology Nursing is the Oncology Nursing Society's practice-focused journal, giving cancer nurses evidence-based articles, case reports and continuing education on day-to-day patient care.","summary":"The Clinical Journal of Oncology Nursing (CJON) is published by the Oncology Nursing Society and describes itself as publishing clinically relevant, evidence-based articles to advance excellence in oncology nursing and quality cancer care. Recent content covers topics such as infection prevention and management in multiple myeloma, palliative care perspectives, nursing advocacy and cell and gene therapy, including a dedicated supplement on cellular therapy, and article types include research and review articles, case reports, online exclusives and continuing education articles that carry nursing continuing professional development credit. Access is included with ONS membership, with organisational subscriptions and individual article purchase also offered. NLM records the title from 1997, issued by the Oncology Nursing Society (originally Oncology Nursing Press, Pittsburgh), bimonthly from 2000, with print issues ceasing after 2024; it is indexed in MEDLINE and PubMed, with content in PMC. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ons.org/publications-research/cjon"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9705336"}],"tags":[],"related":["pubmed-europepmc","cancer-nursing","european-journal-of-oncology-nursing"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oncology Nursing Society","url":"https://www.ons.org/publications-research/cjon","issn":"1092-1095","scope":"oncology nursing","founded":1997,"matchNames":["Clin J Oncol Nurs","Clinical journal of oncology nursing","Clinical Journal of Oncology Nursing","CJON"],"society":"Oncology Nursing Society"},{"id":"clinical-lung-cancer","kind":"journal","name":"Clinical lung cancer","aka":["Clin Lung Cancer","Clinical Lung Cancer"],"tldr":"Clinical Lung Cancer is an Elsevier journal for clinical and translational lung cancer research, from screening and diagnosis to drug resistance and multimodality treatment. Thoracic oncologists and lung cancer researchers read it.","summary":"Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles on clinical and translational research in lung cancer, devoted to detection, diagnosis, prevention and treatment with emphasis on recent scientific developments. Its stated areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention strategies, multimodality therapy and integration of approaches. ScienceDirect lists the journal as supporting open access, meaning authors may choose open access or subscription publication. NLM records the title from 1999, first published in Dallas by the Cancer Information Group and from 2011 by Elsevier in New York, bimonthly since July 2002, indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinical-lung-cancer.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100893225"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinical-lung-cancer.com/","issn":"1525-7304","scope":"thoracic oncology","access":"hybrid","founded":1999,"matchNames":["Clin Lung Cancer","Clinical lung cancer","Clinical Lung Cancer"]},{"id":"clinical-lymphoma-myeloma-and-leukemia","kind":"journal","name":"Clinical lymphoma, myeloma & leukemia","aka":["Clin Lymphoma Myeloma Leuk","Clinical Lymphoma, Myeloma & Leukemia","Clinical Lymphoma Myeloma and Leukemia","Clinical lymphoma and myeloma"],"tldr":"This Elsevier journal covers clinical and translational research in lymphoma, myeloma, leukaemia and related plasma cell disorders. Haematologist-oncologists read it for treatment, biomarker and resistance studies.","summary":"The journal describes itself as a peer-reviewed monthly journal publishing original articles on clinical and translational research in lymphoma, myeloma and leukaemia, devoted to detection, diagnosis, prevention and treatment of these diseases and related disorders including macroglobulinaemia, amyloidosis and plasma cell dyscrasias. Stated areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention, multimodality therapy and integration of approaches. ScienceDirect describes it as a Transformative Journal that offers authors a choice of open access or subscription publication and is committed to transitioning to fully open access. NLM records the title from 2010 as the successor to Clinical Lymphoma and Myeloma, first published in Dallas by the Cancer Media Group and from 2011 by Elsevier, bimonthly in the NLM record, indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinical-lymphoma-myeloma-leukemia.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101525386"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["multiple-myeloma","waldenstrom","dlbcl","follicular-lymphoma","hodgkin-lymphoma","mantle-cell-lymphoma","cll","cml","aml","all-leukemia","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinical-lymphoma-myeloma-leukemia.com/","issn":"2152-2650","scope":"haematological oncology","access":"hybrid","founded":2010,"matchNames":["Clin Lymphoma Myeloma Leuk","Clinical lymphoma, myeloma & leukemia","Clinical Lymphoma, Myeloma & Leukemia","Clinical Lymphoma, Myeloma and Leukemia","Clinical Lymphoma Myeloma and Leukemia"]},{"id":"clinical-oncology-rcr","kind":"journal","name":"Clinical oncology","aka":["Clinical oncology : a journal of the Royal College of Radiologists","Clin Oncol (R Coll Radiol)","Clinical Oncology (Royal College of Radiologists)"],"tldr":"Clinical Oncology is the Royal College of Radiologists' journal, with a strong radiotherapy and multidisciplinary cancer management focus. UK and international clinical oncologists read it for original research, editorials and reviews.","summary":"Clinical Oncology is a journal of The Royal College of Radiologists, published by Elsevier, and describes itself as essential reading for all those with an active interest in the treatment of cancer. Each issue combines original research, editorials and state-of-the-art reviews covering all aspects of the clinical management of cancer patients, with papers on all types of malignant disease including pathology, diagnosis and therapy, including radiotherapy and systemic treatment, from authors at leading international centres. The College lists it as one of its three journals alongside Clinical Radiology and RCR Open. ScienceDirect lists the journal as supporting open access, so authors may choose open access or subscription publication. NLM records the title from 1989, first published by Springer International in London and from 2003 by W.B. Saunders, ten issues a year since 2006, indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.clinicaloncologyonline.net/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9002902"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.clinicaloncologyonline.net/","issn":"0936-6555","scope":"radiation oncology","access":"hybrid","founded":1989,"matchNames":["Clin Oncol (R Coll Radiol)","Clinical oncology","Clinical Oncology","Clinical Oncology (Royal College of Radiologists)","Clin Oncol"],"society":"The Royal College of Radiologists"},{"id":"clinical-pharmacology-and-therapeutics","kind":"journal","name":"Clinical Pharmacology & Therapeutics","aka":["Clin Pharmacol Ther","CPT"],"tldr":"Clinical Pharmacology & Therapeutics is the ASCPT journal for dose optimisation, pharmacokinetics, drug interactions and pharmacogenomics, increasingly central to how oncology doses are chosen after FDA's Project Optimus.","summary":"Clinical Pharmacology & Therapeutics (Clin Pharmacol Ther, CPT) is the journal of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), founded in 1960, appearing monthly and published by Wiley on a hybrid access model. It publishes clinical pharmacology of anticancer drugs, exposure-response and model-informed dosing, pharmacokinetics, drug-interaction and pharmacogenomic (CPIC) guidelines, and regulatory science commentary from FDA and EMA scientists. Its readers are clinical pharmacologists, trialists and regulators, and it has become increasingly central to how oncology doses are chosen after the FDA's Project Optimus. A reader of OnCo would use it for dose optimisation, drug-interaction and pharmacogenomic guidance relevant to cancer therapy.","asOf":"2026-09-09","links":[{"label":"ASCPT","url":"https://www.ascpt.org"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pharmacokinetics","dose","mtd","project-optimus"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://ascpt.onlinelibrary.wiley.com/journal/15326535","issn":"0009-9236","scope":"pharmacology","access":"hybrid","founded":1960,"matchNames":["Clinical Pharmacology and Therapeutics","Clinical Pharmacology & Therapeutics","Clin Pharmacol Ther"],"society":"American Society for Clinical Pharmacology and Therapeutics"},{"id":"cns-oncology","kind":"journal","name":"CNS oncology","aka":["CNS Oncol","CNS Oncology"],"tldr":"CNS Oncology is a fully open access neuro-oncology journal, now published by Taylor & Francis, covering diagnosis, staging and treatment of brain and spinal tumours in practice-oriented formats for oncologists and other clinicians.","summary":"CNS Oncology addresses diagnosis, staging and treatment of central nervous system tumours by publishing patient-centred clinical research both as direct clinical findings and in practice-oriented formats, with the stated aim of giving oncologists and other health professionals the latest findings and opinions on reducing the burden of the disease. It considers papers on diagnosis and imaging, staging, epidemiology, case reports and series, patient perspectives, pharmacoeconomics and outcomes research, pathology, palliative care, radiotherapy, chemotherapy, surgical approaches, systemic and adjuvant therapies, biomarkers, clinical trial protocols and updates, comparative effectiveness, molecular biology and diagnostics, and risk and prevention, welcoming original research, narrative and systematic reviews and opinion pieces. DOAJ lists it as open access since 2018 under a CC BY-NC licence with an article processing charge and double anonymous peer review. NLM records it from 2012, launched by Future Medicine in London and published by Taylor & Francis from 2024, with print issues ceasing in 2017 and articles now compiled into annual volumes; indexed in MEDLINE and PubMed with content in PMC.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/icns20"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101594668"},{"label":"DOAJ record","url":"https://doaj.org/toc/2045-0907"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["glioblastoma","medulloblastoma","ependymoma","primary-cns-lymphoma","dipg-dmg","paediatric-low-grade-glioma","craniopharyngioma","pituitary-tumours","atrt"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/icns20","issn":"2045-0907","scope":"neuro-oncology","access":"open-access","founded":2012,"matchNames":["CNS Oncol","CNS oncology","CNS Oncology"]},{"id":"critical-reviews-in-oncogenesis","kind":"journal","name":"Critical reviews in oncogenesis","aka":["Crit Rev Oncog","CRO","Critical Reviews in Oncogenesis"],"tldr":"Critical Reviews in Oncogenesis is a quarterly review journal from Begell House covering the mechanisms by which cancers arise. Cancer biologists read it for thematic review issues rather than original data.","summary":"Critical Reviews in Oncogenesis is a review journal on the mechanisms of cancer development. NLM records the title from 1989, first published by CRC Press in Boca Raton and later by Begell House in New York, issued four times a year since 1997, and notes that publication was suspended after volume 11 (2000) and resumed with volume 12 in July 2006, with issues from 2006 also carrying the title CRO. Crossref lists Begell House Inc. as the publisher for both the print and electronic ISSNs. The journal is indexed in MEDLINE and PubMed and is not listed in DOAJ. The access model is not stated in the sources consulted and is therefore left unrecorded.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.begellhouse.com/journals/critical-reviews-in-oncogenesis.html"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8914610"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Begell House","url":"https://www.begellhouse.com/journals/critical-reviews-in-oncogenesis.html","issn":"0893-9675","scope":"cancer biology","founded":1989,"matchNames":["Crit Rev Oncog","Critical reviews in oncogenesis","Critical Reviews in Oncogenesis"]},{"id":"critical-reviews-in-oncology-hematology","kind":"journal","name":"Critical reviews in oncology/hematology","aka":["Crit Rev Oncol Hematol","Critical Reviews in Oncology/Hematology"],"tldr":"This Elsevier journal publishes expert critical reviews across all of oncology and haematology and is the official journal of the European School of Oncology. Clinicians and trainees read it for structured overviews of a field.","summary":"Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and haematology written by experts from around the world, and is the official journal of the European School of Oncology (ESO) and of the International Society of Liquid Biopsy. Its sections include basic experimental oncology, career development and education, clinical research, global oncology, haematology, immunotherapy, molecular pathology, genomics and liquid biopsy, palliative and supportive care, paediatric oncology, radiotherapy, regulatory, ethics and health policy, solid tumours, statistics, meta-analysis and clinical trial design, and surgery. All review articles, whether invited or submitted spontaneously, undergo peer review before acceptance. The access model is not stated in the pages consulted and is not recorded here. NLM records the title from 1983, first published by CRC Press in Boca Raton and from 2005 by Elsevier in Amsterdam, twelve issues a year, indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8916049"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/critical-reviews-in-oncology-hematology","issn":"1040-8428","scope":"clinical oncology and haematology","founded":1983,"matchNames":["Crit Rev Oncol Hematol","Critical reviews in oncology/hematology","Critical Reviews in Oncology/Hematology","Critical Reviews in Oncology Hematology"],"society":"European School of Oncology (ESO)"},{"id":"current-cancer-drug-targets","kind":"journal","name":"Current cancer drug targets","aka":["Curr Cancer Drug Targets","Current Cancer Drug Targets"],"tldr":"Current Cancer Drug Targets is a Bentham Science journal on molecular targets for cancer drugs and the agents aimed at them. Pharmacologists and translational cancer researchers read it for reviews and research on targeted therapy.","summary":"Current Cancer Drug Targets is published by Bentham Science Publishers and, according to its publisher pages, supports open access alongside subscription publication, issues thematic issues alongside general articles, and is indexed in Scopus, Science Citation Index Expanded and MEDLINE/PubMed. The publisher notes that from September 2024 submissions are handled through a new submission system. NLM records the title from 2001, published by Bentham Science Publishers in Hilversum, the Netherlands, and Boca Raton, Florida, eleven issues a year since 2019, and indexed in MEDLINE and PubMed. Crossref lists Bentham Science Publishers Ltd. for both ISSNs. The journal is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.eurekaselect.com/journal/7"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101094211"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Bentham Science Publishers","url":"https://www.eurekaselect.com/journal/7","issn":"1568-0096","scope":"cancer pharmacology and drug targets","access":"hybrid","founded":2001,"matchNames":["Curr Cancer Drug Targets","Current cancer drug targets","Current Cancer Drug Targets"]},{"id":"current-hematologic-malignancy-reports","kind":"journal","name":"Current hematologic malignancy reports","aka":["Curr Hematol Malig Rep","Current Hematologic Malignancy Reports"],"tldr":"Current Hematologic Malignancy Reports is a Springer review journal in which invited experts summarise recent papers on leukaemias, lymphomas, myeloma and related blood cancers, with annotated reference lists. Haematologist-oncologists and trainees use it to keep up; it is online only with hybrid access.","summary":"Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on recent developments in the field, presenting clear, balanced reviews that emphasise recently published papers that change practice or understanding, to elucidate current and emerging approaches to the diagnosis, treatment, management and prevention of conditions associated with haematological malignancy. The homepage lists a hybrid publishing model, and recent content includes reviews on acute lymphoblastic leukaemia immunotherapies, acute myeloid leukaemia variants, allogeneic transplantation and myelodysplastic syndromes, with topical collections on molecular testing and on chronic myelomonocytic leukaemia. The journal is online only and its print ISSN has ceased. NLM records the title from 2006, published quarterly in Philadelphia by Current Science, with print issues ceasing in October 2008, and indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/11899"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101262565"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["aml","all-leukemia","cll","cml","cmml","mds","myeloproliferative-neoplasms","multiple-myeloma","dlbcl","hodgkin-lymphoma","follicular-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/11899","issn":"1558-8211","scope":"haematological oncology","access":"hybrid","founded":2006,"matchNames":["Curr Hematol Malig Rep","Current hematologic malignancy reports","Current Hematologic Malignancy Reports"]},{"id":"current-oncology-mdpi","kind":"journal","name":"Current oncology","aka":["Curr Oncol","Current Oncology"],"tldr":"Current Oncology is a Canadian-rooted, open access clinical oncology journal now published by MDPI, with several Canadian oncology associations affiliated. Clinical oncologists read it for original research, reviews and practice guidance.","summary":"Current Oncology describes itself as an international, peer-reviewed, open access journal published online by MDPI from volume 28 (2021). Established in 1994, it is a multidisciplinary medium for clinical oncologists to report and review progress in the management of cancer. The Canadian Association of Medical Oncologists, the Canadian Association of Psychosocial Oncology, the Canadian Association of General Practitioners in Oncology, Cell Therapy Transplant Canada, the Canadian Leukemia Study Group and others are affiliated with the journal and their members receive a discount on article processing charges. Articles are free for readers with an APC paid by authors or their institutions. DOAJ lists it as open access since 2006 under a CC BY licence with an APC and anonymous peer review. NLM records the title from 1994, published in Toronto by Multimed and from 2021 by MDPI in Basel, with print issues ceasing in 2020; it is indexed in MEDLINE and PubMed with content in PMC.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.mdpi.com/journal/curroncol"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9502503"},{"label":"DOAJ record","url":"https://doaj.org/toc/1198-0052"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"MDPI","url":"https://www.mdpi.com/journal/curroncol","issn":"1198-0052","scope":"clinical oncology","access":"open-access","founded":1994,"matchNames":["Curr Oncol","Current oncology","Current Oncology"]},{"id":"current-oncology-reports","kind":"journal","name":"Current oncology reports","aka":["Curr Oncol Rep","Current Oncology Reports"],"tldr":"Current Oncology Reports is a Springer review journal in which section editors commission experts to review recent clinical findings across oncology, with annotated reference lists that mark which papers change practice. Busy clinicians read it for summaries rather than primary data.","summary":"Current Oncology Reports aims to review recently published clinical findings in oncology that change practice or understanding, through clear, balanced contributions by international experts, serving all those involved in the care of people affected by cancer. International authorities act as section editors in key areas such as cancer prevention, leukaemia, melanoma, neuro-oncology and palliative medicine, and select topics for which leading experts write comprehensive reviews emphasising new developments and recently published papers of major importance, highlighted by annotated reference lists; an international editorial board reviews the annual table of contents, and commentaries from well-known figures are also published. The homepage lists a hybrid publishing model. NLM records the title from 1999, published bimonthly in Philadelphia by Current Science, with print issues ceasing in March 2008, and indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/11912"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100888967"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["curative-intent","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/11912","issn":"1523-3790","scope":"clinical oncology","access":"hybrid","founded":1999,"matchNames":["Curr Oncol Rep","Current oncology reports","Current Oncology Reports"]},{"id":"current-opinion-in-oncology","kind":"journal","name":"Current opinion in oncology","aka":["Curr Opin Oncol","Current Opinion in Oncology"],"tldr":"Current Opinion in Oncology is a bimonthly Wolters Kluwer review journal whose structured reviews (purpose of review, recent findings, summary) survey each area of oncology in turn. Clinicians read it to catch up on a topic quickly.","summary":"Current Opinion in Oncology is published by Lippincott Williams & Wilkins, part of Wolters Kluwer, and its journal page lists six issues a year with Jean Klastersky as editor-in-chief. The reviews follow a structured format with sections headed purpose of review, recent findings and summary, and recent issues cover topics such as artificial intelligence in gynaecological cancer treatment selection and surgery and paraneoplastic neurological syndromes. NLM records the title from 1989, first published in Philadelphia by Current Science and later by Lippincott Williams & Wilkins, bimonthly, and notes that it includes a section called Bibliography of the current world literature; it is indexed in MEDLINE and PubMed. Crossref lists Ovid Technologies (Wolters Kluwer) Lippincott Williams & Wilkins as publisher for both ISSNs. The access model is not stated on the pages consulted and the title is not in DOAJ, so no access model is recorded.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/co-oncology/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9007265"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://journals.lww.com/co-oncology/pages/default.aspx","issn":"1040-8746","scope":"clinical oncology","founded":1989,"matchNames":["Curr Opin Oncol","Current opinion in oncology","Current Opinion in Oncology"]},{"id":"current-problems-in-cancer","kind":"journal","name":"Current problems in cancer","aka":["Curr Probl Cancer","CPCa","Current Problems in Cancer"],"tldr":"Current Problems in Cancer is an Elsevier journal for patient-oriented cancer research that changes or challenges practice, with occasional curated topic overviews. Clinical oncologists and trialists read it.","summary":"Current Problems in Cancer seeks to promote and disseminate innovative, transformative and impactful data on patient-oriented cancer research and clinical care, focusing on well-designed studies that influence or alter practice or identify new directions in translational and clinical cancer research, including new therapeutic approaches, new strategies for early diagnosis, clinical trials and supportive care. Pre-clinical and purely laboratory studies are discouraged. The format occasionally allows a multi-faceted overview of a single topic through a curated selection of review articles, and case reports are directed to its open access companion title, Current Problems in Cancer: Case Reports. ScienceDirect lists the journal as supporting open access, so authors may choose open access or subscription publication. NLM records the title from 1976, first published in Chicago by Year Book Medical Publishers and later by Mosby in St. Louis, bimonthly, indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/current-problems-in-cancer"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7702986"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","early-detection-term","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/current-problems-in-cancer","issn":"0147-0272","scope":"clinical oncology","access":"hybrid","founded":1976,"matchNames":["Curr Probl Cancer","Current problems in cancer","Current Problems in Cancer"]},{"id":"current-treatment-options-in-oncology","kind":"journal","name":"Current treatment options in oncology","aka":["Curr Treat Options Oncol","Current Treatment Options in Oncology"],"tldr":"Current Treatment Options in Oncology is a Springer review journal in which experts set out current and emerging approaches to treating each cancer. Practising oncologists read it for treatment-focused overviews.","summary":"Current Treatment Options in Oncology offers in-depth review articles contributed by international experts on recent developments in the field; by providing clear, balanced reviews that emphasise recently published papers that change treatment, it aims to elucidate current and emerging approaches to the treatment of cancer. The homepage lists a hybrid publishing model, and topical collections cover upper gastrointestinal cancers, neuroendocrine cancers, breast cancer and palliative and supportive care, with recent reviews on PARP inhibitor resistance in ovarian cancer and dermatological side effects of cancer therapies. NLM records the title from 2000, published bimonthly in Philadelphia by Current Science, with print issues ceasing in 2010, and indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/11864"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100900946"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["curative-intent","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/11864","issn":"1527-2729","scope":"clinical oncology","access":"hybrid","founded":2000,"matchNames":["Curr Treat Options Oncol","Current treatment options in oncology","Current Treatment Options in Oncology"]},{"id":"elife","kind":"journal","name":"eLife","aka":["eLife"],"tldr":"A non-profit open-access life-science journal backed by HHMI, Wellcome and the Max Planck Society, known for its reviewed-preprint publishing model.","summary":"Fully open access. Since 2023 eLife publishes 'Reviewed Preprints' with public peer reviews and an editorial assessment instead of accept/reject decisions, a model that has been both praised and contested. Publishes cancer biology, evolution and computational studies, including reproducibility work on high-profile cancer papers.","asOf":"2026-09-09","links":[{"label":"eLife publishing model","url":"https://elifesciences.org/about/peer-review"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hhmi"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"eLife Sciences Publications","url":"https://elifesciences.org","issn":"2050-084X","scope":"basic cancer biology","access":"open-access","founded":2012,"matchNames":["eLife"]},{"id":"endocrine-related-cancer","kind":"journal","name":"Endocrine-related cancer","aka":["Endocr Relat Cancer","ERC","Endocrine-Related Cancer"],"tldr":"Endocrine-Related Cancer is the Society for Endocrinology's cancer journal, covering endocrine tumours and hormone-dependent cancers such as breast, prostate, thyroid and neuroendocrine tumours. Endocrinologists and cancer biologists read it.","summary":"Endocrine-Related Cancer provides an international forum for original articles describing basic laboratory, translational and clinical investigations of human health and disease focusing on endocrine neoplasias and hormone-dependent cancers, together with authoritative review articles on these topics. The journal has continuous online publication in monthly issues. It is published by Bioscientifica, the publishing arm of the Society for Endocrinology, and NLM records that it was published for the Society for Endocrinology by the Journal of Endocrinology Ltd from 1994 and by Bioscientifica in Bristol from January 2011, as the successor to Reviews on Endocrine-Related Cancer, and is also known as ERC. NLM lists it as quarterly in its record and indexed in MEDLINE and PubMed. The journal site has an open access policy and publication charges page, but the overall access model was not readable from the pages consulted, so none is recorded. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.bioscientifica.com/erc"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9436481"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["thyroid","adrenocortical","pituitary-tumours","neuroendocrine","breast-hr-positive","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Bioscientifica","url":"https://journals.bioscientifica.com/erc","issn":"1351-0088","scope":"endocrine oncology","founded":1994,"matchNames":["Endocr Relat Cancer","Endocrine-related cancer","Endocrine-Related Cancer"],"society":"Society for Endocrinology"},{"id":"esmo-open","kind":"journal","name":"ESMO Open","aka":["ESMO Open","src-esmo-open"],"tldr":"ESMO's fully open-access journal: trials, real-world studies, ESMO position papers and the Living Guidelines updates, all free to read.","summary":"Gold open access under Creative Commons licences. Publishes phase 2 trials and secondary analyses, real-world evidence, health-economics and access studies, and ESMO's own consensus and position statements. Increasingly the venue for the ESMO Living Guidelines and the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) updates.","asOf":"2026-09-09","links":[{"label":"ESMO","url":"https://www.esmo.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: ESMO open-access journal for trials, real-world data and guidelines. Access: Open access (CC BY / CC BY-NC-ND)."],"publisher":"Elsevier","url":"https://www.esmoopen.com","issn":"2059-7029","scope":"clinical oncology","access":"open-access","founded":2016,"matchNames":["ESMO Open"],"society":"European Society for Medical Oncology"},{"id":"esophagus-journal","kind":"journal","name":"Esophagus","aka":["Esophagus : official journal of the Japan Esophageal Society","Esophagus (Tokyo)"],"tldr":"Esophagus is the official journal of the Japan Esophageal Society, publishing studies of benign and malignant oesophageal disease. Oesophageal surgeons, gastroenterologists and oncologists read it, especially for squamous cell carcinoma research from Japan and Asia.","summary":"Esophagus is a Springer journal and the official journal of the Japan Esophageal Society, described as a comprehensive journal offering studies in benign and malignant diseases of the oesophagus. It welcomes original articles, review articles and 'How I Do It' papers, encourages letters to the editor, and carries special articles on oesophageal diseases from the editorial board, with peer review by that board. The homepage lists a hybrid publishing model with a subset of open access articles, and recent content includes studies of preoperative chemoradiotherapy plus pembrolizumab for oesophageal squamous cell carcinoma, post-oesophagectomy hiatal hernias and anastomotic stricture rates. NLM records the title from 2003, published four times a year in Tokyo by Springer, indexed in MEDLINE and PubMed. Not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10388"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101206627"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10388","issn":"1612-9059","scope":"oesophageal disease and oncology","access":"hybrid","founded":2003,"matchNames":["Esophagus","Esophagus (Tokyo)"],"society":"Japan Esophageal Society"},{"id":"european-journal-of-cancer","kind":"journal","name":"European Journal of Cancer","aka":["Eur J Cancer","EJC"],"tldr":"The European Journal of Cancer is the Elsevier journal affiliated with the European Organisation for Research and Treatment of Cancer, publishing phase 2 and 3 trials, EORTC quality-of-life questionnaire work, European guidelines on melanoma and skin cancers, and EUROCARE registry epidemiology. It is the place to look for European trial reports and consensus statements.","summary":"The European Journal of Cancer (Eur J Cancer, EJC) is the European journal for clinical and translational cancer research affiliated with the European Organisation for Research and Treatment of Cancer (EORTC), founded in 1965 and published by Elsevier on a hybrid access model. It publishes phase 2 and 3 trials, EORTC quality-of-life questionnaire development and validation, European interdisciplinary guidelines (for example on melanoma and skin cancers), and registry-based epidemiology from EUROCARE. Its readers are clinical and translational oncologists, and it is notable for melanoma, sarcoma, quality-of-life and European guideline work. Within OnCo it is cited from the Desmoid tumour entry, and it is the place to look for European trial reports and guideline consensus.","asOf":"2026-09-09","links":[{"label":"EORTC","url":"https://www.eortc.org"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["qol-pro","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.ejcancer.com","issn":"0959-8049","scope":"clinical oncology","access":"hybrid","founded":1965,"matchNames":["European Journal of Cancer","Eur J Cancer","EJC"],"society":"European Organisation for Research and Treatment of Cancer"},{"id":"european-journal-of-cancer-prevention","kind":"journal","name":"European journal of cancer prevention","aka":["European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","Eur J Cancer Prev"],"tldr":"The official journal of the European Cancer Prevention Organisation, publishing epidemiology, screening and risk-factor research. Read by epidemiologists, public-health specialists and clinicians working on cancer prevention.","summary":"European Journal of Cancer Prevention is the official journal of the European Cancer Prevention Organisation (ECP) and is published by Lippincott Williams & Wilkins (Wolters Kluwer) in six issues a year, with Prof. Giovanni Corso as Editor-in-Chief. The NLM Catalog records that it began in 1991 with Rapid Communications of Oxford and is indexed in MEDLINE. Recent issues carry population-based analyses of early mortality, scoping reviews of screening in high-risk groups and other observational studies on cancer risk, screening and prevention. The publisher page does not state an access model.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/eurjcancerprev/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9300837"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://journals.lww.com/eurjcancerprev/pages/default.aspx","issn":"0959-8278","scope":"cancer epidemiology and prevention","founded":1991,"matchNames":["Eur J Cancer Prev","European journal of cancer prevention","European Journal of Cancer Prevention"],"society":"European Cancer Prevention Organisation (ECP)"},{"id":"european-journal-of-oncology-nursing","kind":"journal","name":"European journal of oncology nursing","aka":["European journal of oncology nursing : the official journal of European Oncology Nursing Society","Eur J Oncol Nurs","EJON"],"tldr":"The official journal of the European Oncology Nursing Society. It publishes nursing research on patient care, education, management and policy, and is read mainly by cancer nurses and allied health researchers.","summary":"European Journal of Oncology Nursing (EJON) is described by Elsevier as an international journal publishing research of direct relevance to patient care, nurse education, management and policy development, and it is the official journal of the European Oncology Nursing Society. It publishes original research articles and review articles in six issues a year. The NLM Catalog records that it began in 1998 with Churchill Livingstone in Edinburgh, moved from quarterly to six issues a year in 2013, and is indexed in MEDLINE. The publisher listing does not state an access model.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ejoncologynursing.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100885136"}],"tags":[],"related":["pubmed-europepmc","cancer-nursing","clinical-journal-of-oncology-nursing"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.ejoncologynursing.com/","issn":"1462-3889","scope":"oncology nursing","founded":1998,"matchNames":["Eur J Oncol Nurs","European journal of oncology nursing","European Journal of Oncology Nursing"],"society":"European Oncology Nursing Society (EONS)"},{"id":"european-journal-of-surgical-oncology","kind":"journal","name":"European journal of surgical oncology","aka":["European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology","Eur J Surg Oncol","EJSO"],"tldr":"EJSO is the journal of the European Society of Surgical Oncology and of BASO. It publishes clinical and translational research on cancer surgery and is read by surgical oncologists across Europe and beyond.","summary":"European Journal of Surgical Oncology (EJSO) is the official journal of the European Society of Surgical Oncology and BASO, the Association for Cancer Surgery, published monthly by Elsevier. Elsevier describes its aim as advancing surgical oncology research and practice through original research articles, review articles, editorials, debates and correspondence, welcoming clinical research and all other aspects of surgical oncology including surgical quality control, epidemiology, prevention and translational research relevant to surgical practice. The NLM Catalog records that it began in 1985 with Academic Press as the continuation of Clinical Oncology, has been published by Elsevier since 2004 and is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ejso.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8504356"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.ejso.com/","issn":"0748-7983","scope":"surgical oncology","founded":1985,"matchNames":["Eur J Surg Oncol","European journal of surgical oncology","European Journal of Surgical Oncology","EJSO"],"society":"European Society of Surgical Oncology (ESSO) and BASO, the Association for Cancer Surgery"},{"id":"european-thyroid-journal","kind":"journal","name":"European thyroid journal","aka":["Eur Thyroid J","ETJ"],"tldr":"The European Thyroid Association's open-access journal covering all thyroid disorders, including thyroid cancer. Read by endocrinologists, thyroid surgeons and nuclear medicine specialists.","summary":"European Thyroid Journal is published by Bioscientifica for the European Thyroid Association, which DOAJ lists as the journal's society. DOAJ records it as fully open access since 2022 under CC BY, CC BY-NC or CC BY-NC-ND licences, with an article processing charge, a waiver policy and anonymous peer review; its subject keywords are thyroid diseases, thyroid cancer and thyroidology. The NLM Catalog records that it began in 2012 with S. Karger in Basel, moved to Bioscientifica in 2022, ceased print with volume 10 (2021), appears bimonthly since 2017 and is indexed in MEDLINE and PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://etj.bioscientifica.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101604579"},{"label":"DOAJ record","url":"https://doaj.org/toc/2235-0802"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Bioscientifica","url":"https://etj.bioscientifica.com/","issn":"2235-0640","scope":"thyroid disease and thyroid cancer","access":"open-access","founded":2012,"matchNames":["Eur Thyroid J","European thyroid journal","European Thyroid Journal"],"society":"European Thyroid Association"},{"id":"european-urology","kind":"journal","name":"European Urology","aka":["Eur Urol"],"tldr":"European Urology is the European Association of Urology's journal and the most cited urology title, publishing prostate, bladder and kidney cancer trials, the EAU guidelines and PSMA imaging studies.","summary":"Publishes the EAU guidelines, prostate-cancer screening and active-surveillance cohorts, PSMA PET and radioligand studies, and secondary analyses of the large phase 3 trials in bladder and kidney cancer. Hybrid access via Elsevier; sister titles include European Urology Oncology and European Urology Open Science.","asOf":"2026-09-09","links":[{"label":"EAU Guidelines","url":"https://uroweb.org/guidelines"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.europeanurology.com","issn":"0302-2838","scope":"urology","access":"hybrid","founded":1975,"impactFactor":{"value":25.2,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["European Urology","Eur Urol"],"society":"European Association of Urology"},{"id":"european-urology-oncology","kind":"journal","name":"European Urology Oncology","aka":["Eur Urol Oncol"],"tldr":"European Urology Oncology is the European Association of Urology's dedicated cancer journal for prostate, bladder, kidney and testicular cancer research.","summary":"European Urology Oncology (Eur Urol Oncol) is the European Association of Urology's dedicated cancer journal, launched in 2018 as the oncology-focused sister of European Urology and published by Elsevier on a hybrid access model. It covers prostate, bladder, kidney and testicular cancer, publishing trials and translational studies in genitourinary cancers, systematic reviews and treatment-sequencing analyses. Its readers are urologists and uro-oncologists deciding how to order therapies in genitourinary disease. Within OnCo it is linked from the Rahul Aggarwal biography, and it is a source for genitourinary trial reports and sequencing analyses.","asOf":"2026-09-09","links":[{"label":"European Urology family","url":"https://www.europeanurology.com"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["prostate","urothelial","rcc","testicular"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://euoncology.europeanurology.com","issn":"2588-9311","scope":"urology","access":"hybrid","founded":2018,"matchNames":["European Urology Oncology","Eur Urol Oncol"],"society":"European Association of Urology"},{"id":"experimental-oncology","kind":"journal","name":"Experimental oncology","aka":["Exp Oncol"],"tldr":"A Ukrainian English-language quarterly of experimental and clinical cancer research, published for the National Academy of Sciences of Ukraine and the Kavetsky Institute. Read by laboratory cancer researchers, particularly in Eastern Europe.","summary":"Experimental Oncology describes itself as an English-language, peer-reviewed quarterly publishing review articles, original research, brief communications, clinical case reports and technical achievements on theoretical and practical questions of experimental and clinical oncology. Its founders are the National Academy of Sciences of Ukraine and the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology; the journal states that it was founded in 1979 and has been published by Akademperiodyka (Kyiv) since 2023. Site content is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0. The NLM Catalog record for the current title starts in 2004 (published by Morion, Kyiv), notes English articles with English and Russian abstracts, and lists MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://exp-oncology.com.ua/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101230541"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kavetsky-institute-kyiv"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Akademperiodyka (National Academy of Sciences of Ukraine)","url":"https://exp-oncology.com.ua/","issn":"1812-9269","scope":"experimental and clinical oncology","founded":2004,"matchNames":["Exp Oncol","Experimental oncology","Experimental Oncology"]},{"id":"expert-review-of-anticancer-therapy","kind":"journal","name":"Expert review of anticancer therapy","aka":["Expert Rev Anticancer Ther"],"tldr":"A monthly review journal on cancer treatment, part of the Expert Review series. It is read by oncologists and pharmacologists wanting commissioned overviews of drugs, regimens and treatment strategies.","summary":"Expert Review of Anticancer Therapy is published by Taylor & Francis (Informa UK) and belongs to the Expert Review family of review journals. The NLM Catalog records that it began in 2001 in London with Future Drugs Ltd, was quarterly in its first year, has appeared monthly since 2006, moved to Taylor & Francis in Abingdon in 2015 and is indexed in MEDLINE; Crossref lists Informa UK (Taylor & Francis) as the current publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/iery"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101123358"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/iery","issn":"1473-7140","scope":"clinical oncology reviews","founded":2001,"matchNames":["Expert Rev Anticancer Ther","Expert review of anticancer therapy","Expert Review of Anticancer Therapy"]},{"id":"familial-cancer","kind":"journal","name":"Familial cancer","aka":["Fam Cancer"],"tldr":"A Springer journal devoted to inherited cancer risk: hereditary cancer syndromes, genetic testing, counselling and prevention. Read by clinical geneticists, genetic counsellors and oncologists running family cancer clinics.","summary":"Familial Cancer, published by Springer under a hybrid publishing model, is a forum for clinical cancer genetics, which its aims describe as a multidisciplinary field where clinical and molecular geneticists work with oncologists and psychosocial workers. The journal covers the epidemiology of familial cancer, molecular analysis and diagnosis, clinical expression, treatment and prevention, counselling and the health economics of familial cancer, and publishes Original Articles, Reviews, Short Communications, Book Reviews and Letters to the Editor. The NLM Catalog records a start in 2000 with Kluwer Academic Publishers in Dordrecht, quarterly publication and MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10689"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100898211"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/10689","issn":"1389-9600","scope":"clinical cancer genetics","access":"hybrid","founded":2000,"matchNames":["Fam Cancer","Familial cancer","Familial Cancer"]},{"id":"future-oncology","kind":"journal","name":"Future oncology","aka":["Future Oncol"],"tldr":"A high-frequency clinical oncology journal formerly from Future Medicine and now published by Taylor & Francis. It carries trial protocols, reviews and original research and is read by clinical oncologists and industry researchers.","summary":"Future Oncology is published by Taylor & Francis (Informa UK). The NLM Catalog records that it began in 2005 in London with Future Medicine Ltd, moved to Taylor & Francis in 2024, increased from thirty-six issues a year (2019 to 2021) to forty issues a year from 2022, and is indexed in MEDLINE with content deposited in PubMed Central. Crossref lists Informa UK (Taylor & Francis) as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/ifon"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101256629"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/ifon","issn":"1479-6694","scope":"clinical oncology","founded":2005,"matchNames":["Future Oncol","Future oncology","Future Oncology"]},{"id":"gan-to-kagaku-ryoho","kind":"journal","name":"Gan to kagaku ryoho. Cancer & chemotherapy","aka":["Gan To Kagaku Ryoho","Japanese Journal of Cancer and Chemotherapy"],"tldr":"Gan to Kagaku Ryoho is a Japanese-language journal of cancer treatment and chemotherapy, published sixteen times a year with English summaries and indexed in MEDLINE since 1982. Japanese oncologists and surgeons read it, and it carries a large share of case reports and proceedings of Japanese meetings.","summary":"Gan to kagaku ryoho (Cancer & chemotherapy), also carrying the English title Japanese Journal of Cancer and Chemotherapy on some volumes, is published in Tokyo by Gan To Kagaku Ryohosha. According to the NLM Catalog it began in 1974, was monthly until 1990 and has appeared sixteen times a year since 1993, with articles in Japanese and summaries in English and Japanese; supplements accompany some volumes. It has been indexed for MEDLINE since volume 9 (1982) and NLM points to the Pier Online platform as the online location.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.pieronline.jp/content/serial/0385-0684"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7810034"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Gan To Kagaku Ryohosha","url":"https://www.pieronline.jp/content/serial/0385-0684","issn":"0385-0684","scope":"cancer chemotherapy","founded":1974,"matchNames":["Gan To Kagaku Ryoho","Gan to kagaku ryoho. Cancer & chemotherapy","Gan to kagaku ryoho","Japanese Journal of Cancer and Chemotherapy"]},{"id":"gastric-cancer","kind":"journal","name":"Gastric cancer","aka":["Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","Gastric Cancer"],"tldr":"The joint official journal of the International and Japanese Gastric Cancer Associations, devoted to stomach cancer. Read by gastrointestinal surgeons, oncologists and pathologists, particularly in East Asia where the disease is common.","summary":"Gastric Cancer is the joint official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, published by Springer under a hybrid publishing model. Its aims state that it publishes significant studies related to stomach neoplasms and welcomes original articles, case reports, short communications and technical notes peer-reviewed by the editorial board, plus Letters to the Editor; review articles are in principle solicited by the Editor and meeting reports summarise symposia or consensus from the associations' congresses. The NLM Catalog records a start in 1998 with Springer-Verlag Tokyo and MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10120"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100886238"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (Springer Japan)","url":"https://link.springer.com/journal/10120","issn":"1436-3291","scope":"gastric cancer","access":"hybrid","founded":1998,"matchNames":["Gastric Cancer","Gastric cancer"],"society":"International Gastric Cancer Association and Japanese Gastric Cancer Association"},{"id":"gastroenterology","kind":"journal","name":"Gastroenterology","aka":["Gastroenterology (AGA)","src-gastroenterology"],"tldr":"Gastroenterology is the American Gastroenterological Association's journal, where much of the pancreatic cancer early-detection literature appears: the new-onset diabetes cohorts and the ENDPAC score, the CAPS surveillance series, CA 19-9 lead-time work and the targeted profiling of thousands of tumours.","summary":"Gastroenterology appears monthly and carries the American Gastroenterological Association's clinical practice updates together with the pancreatic cancer papers the pancreatic record leans on: Chari's Rochester cohort on diabetes and pancreatic cancer (2005), Pannala's profile of cancer-associated diabetes (2008), the ENDPAC model (2018), Canto's 16-year CAPS surveillance series (2018), Fahrmann's CA 19-9 lead-time trajectory (2021), Singhi's 3,594-tumour profiling study (2019), Puleo's tumour and microenvironment subtypes (2018), the PRECEDE consortium's early-detection recommendations (2021) and the DRA-MBO stent trial (2023). Hybrid access. Added to the corpus by the pancreatic cancer review of 24 September 2026 because fourteen of the pancreatic key papers are published in it.","asOf":"2026-09-09","links":[{"label":"Gastroenterology (AGA), Elsevier","url":"https://www.gastrojournal.org"},{"label":"American Gastroenterological Association","url":"https://gastro.org"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal","gastric","hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: AGA clinical practice updates, pancreatic early-detection and surveillance cohorts, gastrointestinal cancer biology and endoscopy trials. Access: paywalled."],"publisher":"Elsevier","url":"https://www.gastrojournal.org","issn":"0016-5085","scope":"gastroenterology and hepatology","access":"hybrid","founded":1943,"matchNames":["Gastroenterology"],"society":"American Gastroenterological Association"},{"id":"genes-and-development","kind":"journal","name":"Genes & Development","aka":["Genes Dev","Genes and Development"],"tldr":"A Cold Spring Harbor molecular biology journal where much of the foundational work on oncogenes, tumour suppressors, senescence and cancer gene regulation was published.","summary":"Genes & Development (Genes Dev) is a molecular biology journal from Cold Spring Harbor Laboratory Press, founded in 1987, appearing twice a month and available on a hybrid model with articles free after six months. It covers molecular genetics, chromatin and transcription, cell cycle and development, with a strong cancer biology strand spanning p53, Myc, Ras signalling, senescence and epigenetic regulators, and much of the foundational work on oncogenes, tumour suppressors, senescence and cancer gene regulation was published here. Its readers are molecular and cell biologists. Within OnCo it is linked from the biographies of Leif Ellisen, Adrian Krainer and Justin Lathia, and a reader would use it for the foundational mechanism papers on oncogenes, tumour suppressors and senescence.","asOf":"2026-09-09","links":[{"label":"Cold Spring Harbor Laboratory Press","url":"https://www.cshlpress.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Cold Spring Harbor Laboratory Press","url":"https://genesdev.cshlp.org","issn":"0890-9369","scope":"basic cancer biology","access":"hybrid","founded":1987,"matchNames":["Genes & Development","Genes and Development","Genes Dev"]},{"id":"genes-chromosomes-and-cancer","kind":"journal","name":"Genes, chromosomes & cancer","aka":["Genes Chromosomes Cancer","Genes, Chromosomes and Cancer"],"tldr":"A Wiley journal on the genetic and chromosomal changes that drive cancer, from cytogenetics to genomic profiling. Read by cancer geneticists, molecular pathologists and cytogeneticists.","summary":"Genes, Chromosomes & Cancer is published by Wiley (John Wiley & Sons), which Crossref lists as the publisher under the title Genes Chromosomes and Cancer. The NLM Catalog records that it began in 1989 in New York with A.R. Liss, later Wiley-Liss, was quarterly in 1989 to 1990 and now appears twelve times a year, ceased print issues with volume 59 (2020) and is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10982264"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9007329"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10982264","issn":"1045-2257","scope":"cancer genetics and cytogenetics","founded":1989,"matchNames":["Genes Chromosomes Cancer","Genes, chromosomes & cancer","Genes, Chromosomes & Cancer","Genes, Chromosomes and Cancer"]},{"id":"gut","kind":"journal","name":"Gut","aka":["Gut (BMJ)","src-gut"],"tldr":"Gut is the British Society of Gastroenterology's journal: pancreatic and gastrointestinal cancer surveillance guidelines, cohort and registry studies and the microbiome papers that the pancreatic and colorectal records cite.","summary":"Gut appears monthly and publishes the British Society of Gastroenterology's guidelines alongside international consensus statements such as the CAPS consortium's 2020 recommendations for surveillance of people at inherited risk of pancreatic cancer, population studies of pancreatic cysts (the SHIP MRCP cohort), the Dutch high-risk surveillance yield, and the colorectal screening and Barrett's surveillance literature. Hybrid access; guidelines are free to read. Added to the corpus by the pancreatic cancer review of 24 September 2026 because four of the pancreatic key papers are published in it.","asOf":"2026-09-09","links":[{"label":"Gut, BMJ Group","url":"https://gut.bmj.com"},{"label":"British Society of Gastroenterology guidelines","url":"https://www.bsg.org.uk/clinical-resource"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: gastroenterology society guidelines, surveillance and screening cohorts, pancreatic precursor and cyst studies. Access: paywalled; guidelines free."],"publisher":"BMJ Group","url":"https://gut.bmj.com","issn":"0017-5749","scope":"gastroenterology and hepatology","access":"hybrid","founded":1960,"matchNames":["Gut"],"society":"British Society of Gastroenterology"},{"id":"gynecologic-oncology","kind":"journal","name":"Gynecologic Oncology","aka":["Gynecol Oncol"],"tldr":"Gynecologic Oncology is the Society of Gynecologic Oncology's journal for ovarian, endometrial, cervical and vulvar cancer research, surgery and PARP-inhibitor and immunotherapy trials.","summary":"Gynecologic Oncology (Gynecol Oncol) is the journal of the Society of Gynecologic Oncology (SGO), founded in 1972 and published monthly by Elsevier on a hybrid access model. It covers ovarian, endometrial, cervical and vulvar cancer research, surgery, and PARP-inhibitor and immunotherapy trials, publishing phase 2 trials, surgical outcome studies, HPV and cervical screening research and SGO clinical practice statements, with the SGO annual meeting abstracts as a supplement. Its readers are gynaecological oncologists and the surgeons and trialists working alongside them. Within OnCo it is linked from the Society of Gynecologic Oncology and GOG Foundation entries, and it is where a reader would look for society statements and gynaecological trial results.","asOf":"2026-09-09","links":[{"label":"SGO","url":"https://www.sgo.org"}],"tags":[],"related":[],"cancers":["vulvar"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["gog-foundation"],"institutions":["sgo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.gynecologiconcology-online.net","issn":"0090-8258","scope":"gynaecologic oncology","access":"hybrid","founded":1972,"matchNames":["Gynecologic Oncology","Gynecol Oncol"],"society":"Society of Gynecologic Oncology"},{"id":"haematologica","kind":"journal","name":"Haematologica","aka":["Haematologica"],"tldr":"The European Hematology Association's open-access journal, publishing haematological malignancy research from Europe and worldwide with no paywall.","summary":"Haematologica is the fully open-access journal of the European Hematology Association (EHA), founded in 1920 and published by the non-profit Ferrata Storti Foundation in Pavia on behalf of the society, with no paywall. It publishes clinical and translational studies in leukaemia, lymphoma, myeloma and MDS from Europe and worldwide, together with EHA guidelines and the EHA congress abstract book. Its readers are haematologists and researchers in haematological malignancy who want European society guidance and congress abstracts freely available. A reader of OnCo would use it for EHA guidelines and for open-access blood cancer research that can be read without a subscription.","asOf":"2026-09-09","links":[{"label":"European Hematology Association","url":"https://ehaweb.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Ferrata Storti Foundation","url":"https://haematologica.org","issn":"0390-6078","scope":"haematology","access":"open-access","founded":1920,"matchNames":["Haematologica"],"society":"European Hematology Association"},{"id":"head-and-neck-journal","kind":"journal","name":"Head & neck","aka":["Head Neck","Head & Neck","Head and Neck"],"tldr":"A Wiley journal for head and neck surgery and oncology, covering cancers of the mouth, throat, larynx, salivary glands and thyroid. Read by head and neck surgeons, radiation and medical oncologists.","summary":"Head & Neck is published by Wiley (John Wiley & Sons), which Crossref lists as its publisher. The NLM Catalog records that it began in 1989 as the continuation of Head & Neck Surgery, appears eight times a year, is affiliated with the New York Head and Neck Society and is indexed in MEDLINE under the abbreviation Head Neck. Volume numbering runs on from the earlier title, so the first issue under the present name is volume 11, number 1 (January/February 1989), published from New York.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10970347"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8902541"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10970347","issn":"1043-3074","scope":"head and neck oncology","founded":1989,"matchNames":["Head Neck","Head & neck","Head & Neck","Head and Neck"]},{"id":"head-and-neck-pathology","kind":"journal","name":"Head and neck pathology","aka":["Head Neck Pathol"],"tldr":"A Springer journal for pathologists who diagnose tumours and other disease of the mouth, sinuses, larynx, salivary glands, ear and neck. Read by surgical pathologists, cytologists and head and neck surgeons.","summary":"Head and Neck Pathology, published by Springer under a hybrid publishing model, presents scholarly papers, reviews and symposia covering surgical pathology of the oral cavity, sinonasal tract, larynx, hypopharynx, salivary gland, ear and temporal bone, and neck. Its aims list new diagnostic criteria, intraoperative consultation, immunohistochemistry, molecular techniques, genetic analyses, cytology, imaging and uniform terminology, supported by proceedings and symposia from international societies in the subspecialty. The NLM Catalog records a start in 2007 with Humana Press, a move to Springer in 2011, quarterly publication, print ceasing in 2008, and indexing in MEDLINE and PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/12105"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101304010"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["head-and-neck","salivary-gland"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/journal/12105","issn":"1936-055X","scope":"head and neck pathology","access":"hybrid","founded":2007,"matchNames":["Head Neck Pathol","Head and neck pathology","Head and Neck Pathology"]},{"id":"hematological-oncology","kind":"journal","name":"Hematological oncology","aka":["Hematol Oncol"],"tldr":"A Wiley journal on blood cancers such as lymphoma, leukaemia and myeloma. Read by haematologists and haemato-oncologists; it also publishes the abstracts of the International Conference on Malignant Lymphoma in supplement form.","summary":"Hematological Oncology is published by Wiley (John Wiley & Sons), which Crossref lists as its publisher. The NLM Catalog records that it began in 1983 in Oxford with what is now Wiley-Blackwell, was bimonthly until 1995 and has appeared four times a year since 1996, ceased print issues with volume 28 (2010) and is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10991069"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8307268"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10991069","issn":"0278-0232","scope":"haematological oncology","founded":1983,"matchNames":["Hematol Oncol","Hematological oncology","Hematological Oncology"]},{"id":"hematology-oncology-and-stem-cell-therapy","kind":"journal","name":"Hematology/oncology and stem cell therapy","aka":["Hematol Oncol Stem Cell Ther","HOSCT"],"tldr":"An open-access journal from King Faisal Specialist Hospital and Research Centre in Riyadh covering blood disorders, cancer and stem cell transplantation, with no author fees. Read by haematologists and transplant physicians, particularly in the Middle East.","summary":"Hematology/Oncology and Stem Cell Therapy is published by Wolters Kluwer Medknow for King Faisal Specialist Hospital and Research Centre (KFSHRC), which DOAJ lists as the journal's institution. DOAJ records it as open access since 2008 under a CC BY-NC-SA licence, with no article processing charge and double anonymous peer review; its keywords are haematology, oncology, stem cells, haematopoietic and solid tumours. The publisher page names Dr Mahmoud Aljurf as Editor-in-Chief and lists continuous publication. The NLM Catalog records a start in 2008 in Riyadh with the King Faisal Cancer Center, a move to Wolters Kluwer Medknow in 2024, quarterly issues and MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/hosct/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101468532"},{"label":"DOAJ record","url":"https://doaj.org/toc/1658-3876"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wolters Kluwer Medknow","url":"https://journals.lww.com/hosct/pages/default.aspx","issn":"1658-3876","scope":"haematology, oncology and stem cell transplantation","access":"open-access","founded":2008,"matchNames":["Hematol Oncol Stem Cell Ther","Hematology/oncology and stem cell therapy","Hematology/Oncology and Stem Cell Therapy"]},{"id":"hematology-oncology-clinics-of-north-america","kind":"journal","name":"Hematology/oncology clinics of North America","aka":["Hematol Oncol Clin North Am","Hematology/Oncology Clinics"],"tldr":"One of Elsevier's Clinics series: each issue is a guest-edited set of review articles on a single topic in blood disease or cancer. Read by clinicians and trainees wanting an up-to-date overview rather than primary research.","summary":"Hematology/Oncology Clinics of North America is published by Elsevier six times a year, in February, April, June, August, October and December. Elsevier describes it as updating readers on trends in patient management and the newest advances, with each issue focused on a single topic under an experienced guest editor; topics include haemostasis and thrombosis, the molecular and cellular basis of haematology, coagulation disorders and cancers of the bone, gastrointestinal tract, head and neck, lymphomas, neuroendocrine tumours, breast, kidney and melanoma. The NLM Catalog records that it began in 1987 with W.B. Saunders, formed by the union of part of Clinics in Haematology with Clinics in Oncology, and is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.hemonc.theclinics.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8709473"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.hemonc.theclinics.com/","issn":"0889-8588","scope":"haematology and oncology reviews","founded":1987,"matchNames":["Hematol Oncol Clin North Am","Hematology/oncology clinics of North America","Hematology/Oncology Clinics of North America"]},{"id":"in-vivo","kind":"journal","name":"In vivo","aka":["In Vivo"],"tldr":"A Greek-published bimonthly of experimental and clinical research from the International Institute of Anticancer Research, sister to Anticancer Research. Much of its content is cancer biology, animal models and clinical prognostic studies.","summary":"In Vivo is published by the International Institute of Anticancer Research (IIAR) in Attiki, Greece, alongside its sister titles Anticancer Research, Cancer Genomics & Proteomics and Cancer Diagnosis & Prognosis. Its homepage shows recent articles on prognostic biomarkers in cancer, tumour metastasis models, cell culture studies and population cohort studies, many labelled Open Access, and announces themed special issues. The NLM Catalog records that it began in 1987 in Athens, has been published by IIAR since 2000, appears bimonthly, ceased print issues with volume 30 (2016), has been the official journal of the International Society for the Study of Comparative Oncology since 1996, and is indexed in MEDLINE and PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://iv.iiarjournals.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8806809"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"International Institute of Anticancer Research (IIAR)","url":"https://iv.iiarjournals.org/","issn":"0258-851X","scope":"experimental and clinical biomedical research","founded":1987,"matchNames":["In Vivo","In vivo"]},{"id":"indian-journal-of-cancer","kind":"journal","name":"Indian journal of cancer","aka":["Indian J Cancer"],"tldr":"India's longest-running cancer journal, publishing clinical studies, case series and health-system papers from Indian centres. Read by oncologists and cancer-care planners in India and other low- and middle-income settings.","summary":"Indian Journal of Cancer is published by Wolters Kluwer Medknow in four issues a year, with Dr Vinay H Deshmane as Editor-in-Chief. Recent issues on the publisher page include rare tumour case series from regional cancer institutes, commentary on head and neck cancer care in India and a white paper on a district cancer control model for rural India. The NLM Catalog records that it began in 1963 in Bombay, published by the Indian Cancer Society, later moving to Medknow Publications in Mumbai; it was six issues a year until 1984, quarterly since 1985, and is indexed in MEDLINE. The publisher page does not state an access model.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/indianjcancer/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/112040"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wolters Kluwer Medknow","url":"https://journals.lww.com/indianjcancer/pages/default.aspx","issn":"0019-509X","scope":"clinical oncology","founded":1963,"matchNames":["Indian J Cancer","Indian journal of cancer","Indian Journal of Cancer"]},{"id":"integrative-cancer-therapies","kind":"journal","name":"Integrative cancer therapies","aka":["Integr Cancer Ther","ICT"],"tldr":"An open-access SAGE journal on integrative and complementary approaches in cancer care, such as exercise, nutrition, mind-body therapies and acupuncture alongside standard treatment. Read by integrative oncology clinicians, nurses and supportive-care researchers.","summary":"Integrative Cancer Therapies is published by SAGE Publishing. DOAJ records it as open access since 2002 under CC BY or CC BY-NC licences, with an article processing charge, a waiver policy and anonymous peer review; its keywords are oncology, integrative care, complementary medicine, alternative medicine and health psychology. The NLM Catalog records that it began in 2002 in Thousand Oaks, California, ceased print with volume 15 (2016) and has been online only since 2017, with articles published continuously and compiled into quarterly issues; it is indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/ict"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101128834"},{"label":"DOAJ record","url":"https://doaj.org/toc/1534-7354"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["standard-of-care"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publishing","url":"https://journals.sagepub.com/home/ict","issn":"1534-7354","scope":"integrative oncology","access":"open-access","founded":2002,"matchNames":["Integr Cancer Ther","Integrative cancer therapies","Integrative Cancer Therapies"]},{"id":"international-journal-of-cancer","kind":"journal","name":"International journal of cancer","aka":["Int J Cancer","IJC"],"tldr":"A long-established general cancer research journal founded by the International Union Against Cancer, spanning cancer biology, epidemiology and clinical research. Read by cancer researchers worldwide.","summary":"International Journal of Cancer is published by Wiley (John Wiley & Sons), which Crossref lists as its publisher. The NLM Catalog records that it began in 1966 in Geneva, issued by the International Union Against Cancer with assistance from the US National Institutes of Health and the Calouste Gulbenkian Foundation, moved to Wiley-Liss in New York in 1995, and now appears thirty times a year; articles have historically been in English or French with a summary in the other language, and the title is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10970215"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/42124"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10970215","issn":"0020-7136","scope":"cancer research","founded":1966,"matchNames":["Int J Cancer","International journal of cancer","International Journal of Cancer","IJC"]},{"id":"international-journal-of-clinical-oncology","kind":"journal","name":"International journal of clinical oncology","aka":["Int J Clin Oncol","IJCO"],"tldr":"The official journal of the Japan Society of Clinical Oncology, publishing clinical trials and other clinical cancer research in English. Read by oncologists in Japan and internationally.","summary":"International Journal of Clinical Oncology (IJCO) is the official journal of the Japan Society of Clinical Oncology and is published by Springer under a hybrid publishing model. Its aims welcome original and review papers on all aspects of clinical oncology reporting novel and timely investigations, encourage reports of clinical trials and give priority to high-quality clinical articles such as prospective randomised studies over retrospective ones; basic and translational studies are accepted only when they have obvious clinical significance, and society membership is not required to submit. Papers are peer reviewed by at least two referees and the Editors. The NLM Catalog records a start in 1996, publication for the society by Springer-Verlag Tokyo since 1998, six issues a year and MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10147"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9616295"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","randomised-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (Springer Japan)","url":"https://link.springer.com/journal/10147","issn":"1341-9625","scope":"clinical oncology","access":"hybrid","founded":1996,"matchNames":["Int J Clin Oncol","International journal of clinical oncology","International Journal of Clinical Oncology","IJCO"],"society":"Japan Society of Clinical Oncology"},{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","aka":["International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","Int J Gynecol Cancer","IJGC"],"tldr":"The official journal of the International Gynecologic Cancer Society and ESGO, covering cancers of the ovary, uterus, cervix, vulva and vagina. Read by gynaecological oncologists, medical and radiation oncologists and pathologists.","summary":"International Journal of Gynecological Cancer (IJGC) is the official journal of the European Society of Gynaecological Oncology (ESGO) and the International Gynecologic Cancer Society (IGCS). Elsevier describes it as the primary educational and informational publication on the detection, prevention, diagnosis and treatment of gynaecological malignancies, intended for gynaecologists, medical and radiation oncologists, radiologists, pathologists and research scientists, promoting a multidisciplinary approach and featuring original research, reviews and video articles. The NLM Catalog records a start in 1991 with Blackwell Scientific Publications, a move to Elsevier in 2025 after a period with BMJ, print ceasing in 2018 and MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://international-journal-of-gynecological-cancer.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9111626"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["ovarian","endometrial","cervical","vulvar","vaginal","uterine-sarcoma","gestational-trophoblastic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://international-journal-of-gynecological-cancer.com/","issn":"1048-891X","scope":"gynaecological oncology","founded":1991,"matchNames":["Int J Gynecol Cancer","International journal of gynecological cancer","International Journal of Gynecological Cancer","IJGC"],"society":"International Gynecologic Cancer Society (IGCS) and European Society of Gynaecological Oncology (ESGO)"},{"id":"international-journal-of-hyperthermia","kind":"journal","name":"International journal of hyperthermia","aka":["International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group","Int J Hyperthermia"],"tldr":"An open-access journal on the use of heat in medicine, especially hyperthermia and thermal ablation for cancer. Read by radiation oncologists, interventional radiologists, medical physicists and engineers.","summary":"International Journal of Hyperthermia is published by Taylor & Francis and is the official journal of the European Society for Hyperthermic Oncology and the North American Hyperthermia Group according to its NLM title; DOAJ lists the Society for Thermal Medicine, the European Society for Hyperthermic Oncology and the Japanese Society for Thermal Medicine as its societies. DOAJ records it as open access since 2019 under CC BY or CC BY-NC licences, with an article processing charge and anonymous peer review, with keywords hyperthermia, thermal therapy, heat treatment, thermal response and thermal energy treatment systems. The NLM Catalog records a start in 1985, eight issues a year since 2004, the Japanese Society of Hyperthermic Oncology as an additional sponsor from 1986 and MEDLINE indexing.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/ihyt"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8508395"},{"label":"DOAJ record","url":"https://doaj.org/toc/0265-6736"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/ihyt","issn":"0265-6736","scope":"hyperthermia and thermal therapies in oncology","access":"open-access","founded":1985,"matchNames":["Int J Hyperthermia","International journal of hyperthermia","International Journal of Hyperthermia"],"society":"European Society for Hyperthermic Oncology (ESHO), Society for Thermal Medicine and Japanese Society for Thermal Medicine"},{"id":"international-journal-of-oncology","kind":"journal","name":"International journal of oncology","aka":["Int J Oncol"],"tldr":"A monthly cancer research journal from the Athens-based publisher Spandidos, covering laboratory oncology and cancer treatment. Read by molecular and cellular cancer biologists, with a large share of authors from East Asia.","summary":"International Journal of Oncology is published monthly by Spandidos Publications in Athens, which describes it as an international journal devoted to oncology research and cancer treatment; it sits alongside the publisher's other titles such as Oncology Reports, Oncology Letters and Molecular and Clinical Oncology. The NLM Catalog records that it began in 1992 (first published by Lychnia, then D.A. Spandidos from 2003), was affiliated from its launch with the International Center for Cancer Research and the National Hellenic Research Foundation, ceased print issues with volume 57 (2020) and is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.spandidos-publications.com/ijo"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9306042"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Spandidos Publications","url":"https://www.spandidos-publications.com/ijo","issn":"1019-6439","scope":"cancer research","founded":1992,"matchNames":["Int J Oncol","International journal of oncology","International Journal of Oncology"]},{"id":"ijrobp","kind":"journal","name":"International Journal of Radiation Oncology, Biology, Physics","aka":["IJROBP","Int J Radiat Oncol Biol Phys","The Red Journal"],"tldr":"The International Journal of Radiation Oncology, Biology, Physics, known as the Red Journal, is the American Society for Radiation Oncology's journal and the main US venue for radiotherapy trials, dose and fractionation evidence, physics and toxicity research, including NRG and RTOG cooperative-group results. Access is hybrid.","summary":"The International Journal of Radiation Oncology, Biology, Physics (IJROBP), known as the Red Journal, is the journal of the American Society for Radiation Oncology (ASTRO), founded in 1975 and published by Elsevier on a hybrid access model. It is the main US venue for radiation oncology trials, dose-fractionation evidence, physics and toxicity research, publishing NRG and RTOG cooperative-group trials, stereotactic and hypofractionation studies, radiobiology and ASTRO clinical practice guidelines, with the ASTRO annual meeting abstracts as a supplement. Its readers are radiation oncologists, physicists and radiobiologists. Within OnCo it is related to the ASTRO Annual Meeting source and linked from the Albert Koong and Anthony Zietman biographies.","asOf":"2026-09-09","links":[{"label":"ASTRO","url":"https://www.astro.org"}],"tags":[],"related":["src-astro"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.redjournal.org","issn":"0360-3016","scope":"radiation oncology","access":"hybrid","founded":1975,"matchNames":["International Journal of Radiation Oncology, Biology, Physics","International Journal of Radiation Oncology Biology Physics","IJROBP","Int J Radiat Oncol Biol Phys"],"society":"American Society for Radiation Oncology"},{"id":"jama","kind":"journal","name":"JAMA","aka":["Journal of the American Medical Association","JAMA"],"tldr":"JAMA is the American Medical Association's flagship journal. It is strong on cancer screening, prevention, health-services and patient-reported-outcome research, and on the USPSTF recommendations.","summary":"JAMA is a weekly general-medicine journal. In oncology it carries screening and prevention trials, the US Preventive Services Task Force recommendation statements, health-policy and drug-pricing analyses, and landmark care-delivery studies such as Basch's 2017 electronic symptom-monitoring survival result. Hybrid access; research articles are free to read after 12 months.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/JAMA","links":[{"label":"JAMA Network oncology","url":"https://jamanetwork.com/collections/5644/oncology"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Medical Association (JAMA Network)","url":"https://jamanetwork.com/journals/jama","issn":"0098-7484","scope":"general medicine","access":"hybrid","founded":1883,"impactFactor":{"value":63.1,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["JAMA","Journal of the American Medical Association"],"society":"American Medical Association"},{"id":"jama-internal-medicine","kind":"journal","name":"JAMA Internal Medicine","aka":["JAMA Intern Med","Archives of Internal Medicine"],"tldr":"JAMA Internal Medicine is the JAMA Network's internal-medicine journal, known for sceptical, evidence-based analyses of overdiagnosis, surrogate endpoints and low-value care in cancer.","summary":"JAMA Internal Medicine was formerly Archives of Internal Medicine (renamed 2013). It is home to the 'Less Is More' series and of influential critiques of oncology evidence, including Prasad and colleagues' 2015 review of surrogate endpoints in cancer drug approvals, plus prevention studies such as the PREDIMED breast-cancer analysis. Hybrid access.","asOf":"2026-09-09","links":[{"label":"Less Is More series","url":"https://jamanetwork.com/collections/44045/less-is-more"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["overdiagnosis","screening","surrogate-endpoint","de-escalation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Medical Association (JAMA Network)","url":"https://jamanetwork.com/journals/jamainternalmedicine","issn":"2168-6106","scope":"general medicine","access":"hybrid","founded":1908,"impactFactor":{"value":22.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["JAMA Internal Medicine","JAMA Intern Med"],"society":"American Medical Association"},{"id":"jama-oncology","kind":"journal","name":"JAMA Oncology","aka":["JAMA Oncol","src-jama-oncology"],"tldr":"JAMA Oncology is the JAMA Network's cancer journal, publishing phase 2 trials, secondary analyses of big trials, epidemiology, health policy and drug-pricing research.","summary":"JAMA Oncology has appeared monthly since 2015 and is strong on population-based and health-services research (the Global Burden of Disease cancer updates, cost and value analyses of new drugs, disparities), single-arm phase 2 studies, and pooled or secondary analyses of large randomised trials. Hybrid access; research articles free after 12 months. Sceptical editorial tone on surrogate endpoints and accelerated approvals.","asOf":"2026-09-09","links":[{"label":"JAMA Network","url":"https://jamanetwork.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Trials, health-services research and epidemiology with a strong methods focus. Access: Paywalled; abstracts free; some open access."],"publisher":"American Medical Association (JAMA Network)","url":"https://jamanetwork.com/journals/jamaoncology","issn":"2374-2437","scope":"clinical oncology","access":"hybrid","founded":2015,"impactFactor":{"value":28.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["JAMA Oncology","JAMA Oncol"],"society":"American Medical Association"},{"id":"japanese-journal-of-clinical-oncology","kind":"journal","name":"Japanese journal of clinical oncology","aka":["Jpn J Clin Oncol","JJCO"],"tldr":"Japan's English-language clinical cancer journal, covering trials, surgery, radiology, epidemiology and palliative care with a focus on Asia. Read by clinical oncologists in Japan and across the region.","summary":"The Japanese Journal of Clinical Oncology describes itself as the first journal from Japan to publish clinical research on cancer in English. It began in 1971 and has been published by Oxford University Press since 1997; NLM records that it is supported by funds from the Society for Promotion of Cancer Research and that it appears monthly, online only since January 2018. It is multidisciplinary, covering medical oncology, clinical trials, radiology, surgery, basic research, epidemiology and palliative care, with particular emphasis on the Asian region. Article types include original articles, case reports, clinical trial notes, cancer genetics reports, epidemiology notes, technical notes, short communications, letters and solicited reviews. The access model is hybrid: current content is by subscription with an open access option, and articles become freely accessible between 12 months and 5 years after publication.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/jjco"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/313225"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","curative-intent","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/jjco","issn":"0368-2811","scope":"clinical oncology","access":"hybrid","founded":1971,"matchNames":["Jpn J Clin Oncol","Japanese journal of clinical oncology","Japanese Journal of Clinical Oncology","JJCO"]},{"id":"jco-clinical-cancer-informatics","kind":"journal","name":"JCO clinical cancer informatics","aka":["JCO Clin Cancer Inform","JCO CCI"],"tldr":"ASCO's journal for the data side of cancer care: electronic health records, real-world data, machine learning, clinical decision support and data sharing. Read by oncologists, informaticians and health-data scientists.","summary":"JCO Clinical Cancer Informatics is one of the JCO family of journals published by the American Society of Clinical Oncology in the United States. NLM catalogues it from 2017, indexed for MEDLINE under the subject headings Medical Informatics and Medical Oncology, and notes that articles are published as they become available and compiled into annual volumes. Crossref lists the American Society of Clinical Oncology as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://ascopubs.org/journal/cci"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101708809"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/cci","issn":"2473-4276","scope":"cancer informatics","founded":2017,"matchNames":["JCO Clin Cancer Inform","JCO clinical cancer informatics","JCO Clinical Cancer Informatics","JCO CCI"],"society":"American Society of Clinical Oncology"},{"id":"jco-global-oncology","kind":"journal","name":"JCO global oncology","aka":["JCO Glob Oncol","JCO GO","Journal of Global Oncology"],"tldr":"ASCO's open access journal for cancer care and research in low- and middle-income countries and other resource-limited settings. Read by oncologists and public-health researchers working on cancer worldwide.","summary":"JCO Global Oncology is published by the American Society of Clinical Oncology in the United States. NLM records that it continues the Journal of Global Oncology (ISSN 2378-9506), that some volume 6 articles appeared electronically in 2019, and that articles are published as they are accepted and compiled into annual volumes. The Directory of Open Access Journals lists it as a fully open access journal from 2020 with anonymous peer review, an article processing charge, and articles published under CC BY or CC BY-NC-ND licences. Indexed for MEDLINE under Medical Oncology and Neoplasms.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://ascopubs.org/journal/go"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101760170"},{"label":"DOAJ record","url":"https://doaj.org/toc/2687-8941"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/go","issn":"2687-8941","scope":"global oncology","access":"open-access","founded":2019,"matchNames":["JCO Glob Oncol","JCO global oncology","JCO Global Oncology","Journal of Global Oncology","J Glob Oncol"],"society":"American Society of Clinical Oncology"},{"id":"jco-oncology-practice","kind":"journal","name":"JCO Oncology Practice","aka":["JCO OP","Journal of Oncology Practice","JOP"],"tldr":"ASCO's journal about how cancer care is actually delivered and paid for: financial toxicity, workforce, quality measures, telehealth and payment reform.","summary":"JCO Oncology Practice was formerly Journal of Oncology Practice (renamed 2020). It publishes health-services research, quality-improvement studies, cost and financial-toxicity analyses, and policy pieces on the US oncology payment system. The main outlet for evidence on care-delivery bottlenecks rather than on drugs themselves.","asOf":"2026-09-09","links":[{"label":"ASCO Publications","url":"https://ascopubs.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":["financial-toxicity"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/op","issn":"2688-1527","scope":"oncology practice and policy","access":"hybrid","founded":2005,"matchNames":["JCO Oncology Practice","Journal of Oncology Practice","JCO OP"],"society":"American Society of Clinical Oncology"},{"id":"jco-precision-oncology","kind":"journal","name":"JCO Precision Oncology","aka":["JCO PO","JCO Precis Oncol"],"tldr":"ASCO's journal for genomics-guided cancer care: tumour sequencing studies, biomarker-selected trials, molecular tumour board case series and real-world genomic data.","summary":"JCO Precision Oncology is online-only and publishes analyses of large clinico-genomic datasets (AACR Project GENIE, Flatiron), basket and umbrella trial results, circulating tumour DNA studies and reports on rare fusions and resistance mutations. A good venue for the incremental evidence that connects a genomic test result to a treatment decision.","asOf":"2026-09-09","links":[{"label":"ASCO Publications","url":"https://ascopubs.org"}],"tags":[],"related":["genie"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/po","issn":"2473-4284","scope":"precision oncology","access":"hybrid","founded":2017,"matchNames":["JCO Precision Oncology","JCO PO","JCO Precis Oncol"],"society":"American Society of Clinical Oncology"},{"id":"jmir-cancer","kind":"journal","name":"JMIR cancer","aka":["JMIR Cancer","JC"],"tldr":"An open access journal about technology, apps, online tools and patient-centred innovation in cancer care and survivorship. Read by digital-health researchers, oncology clinicians and patient advocates.","summary":"JMIR Cancer is published by JMIR Publications in Canada and is a companion journal to the Journal of Medical Internet Research. Its own description calls it a peer-reviewed journal focusing on education, innovation and technology in cancer care, cancer survivorship and cancer research, and on participatory and patient-centred approaches, including research on non-Internet approaches to improving cancer care. It invites original research, viewpoints, reviews, tutorials, case studies and non-conventional articles such as open patient education material and software resources; a Patients' Corner section carries no article processing fee. The Directory of Open Access Journals lists it as fully open access since 2015 under a CC BY licence, with anonymous peer review and an article processing charge. NLM catalogues it from 2015.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://cancer.jmir.org"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101666844"},{"label":"DOAJ record","url":"https://doaj.org/toc/2369-1999"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"JMIR Publications","url":"https://cancer.jmir.org","issn":"2369-1999","scope":"digital health in cancer care","access":"open-access","founded":2015,"matchNames":["JMIR Cancer","JMIR cancer"]},{"id":"jnci-cancer-spectrum","kind":"journal","name":"JNCI cancer spectrum","aka":["JNCI Cancer Spectr","JNCICS"],"tldr":"The open access sister journal of JNCI, publishing clinical, translational, epidemiological and policy research across the whole of cancer. Read by cancer researchers and clinicians who want peer-reviewed findings without a paywall.","summary":"JNCI Cancer Spectrum is published by Oxford University Press and is the sister journal to the Journal of the National Cancer Institute; its about page notes that it is not affiliated with the US National Cancer Institute despite the name. It describes itself as a peer-reviewed, open access journal that publishes new findings across the full range of clinical and translational cancer research, including prevention, screening and treatment, as well as clinically relevant epidemiological, public health and policy research. Article types include original research, confirmatory and negative findings, systematic reviews and meta-analyses, expert reviews and manuscripts on emerging hypotheses, published in six issues a year with an emphasis on rigorous but rapid review. The Directory of Open Access Journals lists it as open access from 2017 with anonymous peer review, an article processing charge, and CC BY, CC BY-NC and CC BY-NC-ND licences. NLM catalogues it from 2017.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/jncics"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101721827"},{"label":"DOAJ record","url":"https://doaj.org/toc/2515-5091"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/jncics","issn":"2515-5091","scope":"clinical and translational cancer research","access":"open-access","founded":2017,"matchNames":["JNCI Cancer Spectr","JNCI cancer spectrum","JNCI Cancer Spectrum","JNCICS"]},{"id":"jnci","kind":"journal","name":"JNCI: Journal of the National Cancer Institute","aka":["JNCI","J Natl Cancer Inst","src-jnci"],"tldr":"JNCI began as the US National Cancer Institute's own journal and is now independent. It is strong on cancer epidemiology, screening, trial methodology and health disparities.","summary":"Founded in 1940 as the NCI's journal and now published by Oxford University Press with an independent editorial board. Publishes epidemiology and risk-factor studies, screening and surveillance research, trial-methods and trial-participation analyses (Unger's 2019 review of barriers to trial enrolment in this corpus), and the annual US 'Report to the Nation' on cancer status. Hybrid access.","asOf":"2026-09-09","links":[{"label":"JNCI Cancer Spectrum (open access sister)","url":"https://academic.oup.com/jncics"}],"tags":[],"related":["jnci-cancer-spectrum","jnci-monographs"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Epidemiology, screening, health policy and trials. Access: Paywalled; some open access."],"publisher":"Oxford University Press","url":"https://academic.oup.com/jnci","issn":"0027-8874","scope":"cancer epidemiology","access":"hybrid","founded":1940,"matchNames":["JNCI: Journal of the National Cancer Institute","Journal of the National Cancer Institute","JNCI","J Natl Cancer Inst"]},{"id":"jitc","kind":"journal","name":"Journal for ImmunoTherapy of Cancer","aka":["JITC","J Immunother Cancer"],"tldr":"SITC's fully open-access journal: checkpoint-inhibitor and cell-therapy trials, immune-related toxicity management guidelines and immunotherapy biomarkers.","summary":"Fully open access, published by BMJ on behalf of the Society for Immunotherapy of Cancer. Publishes phase 1 and 2 immunotherapy trials, SITC clinical practice guidelines on immune-related adverse events and biomarkers, and the SITC annual meeting abstracts. Strong on real-world toxicity and combination strategies.","asOf":"2026-09-09","links":[{"label":"SITC","url":"https://www.sitcancer.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sitc"],"pathways":[],"terms":["immune-checkpoint","irae","biomarker"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMJ Group","url":"https://jitc.bmj.com","issn":"2051-1426","scope":"immunotherapy","access":"open-access","founded":2013,"impactFactor":{"value":10.3,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Journal for ImmunoTherapy of Cancer","JITC","J Immunother Cancer"],"society":"Society for Immunotherapy of Cancer"},{"id":"journal-of-adolescent-and-young-adult-oncology","kind":"journal","name":"Journal of adolescent and young adult oncology","aka":["J Adolesc Young Adult Oncol","JAYAO"],"tldr":"The journal devoted to cancer in teenagers and young adults, a group whose tumours, treatment needs and life circumstances differ from both children and older adults. Read by paediatric and adult oncologists, nurses and psycho-oncology researchers.","summary":"The Journal of Adolescent and Young Adult Oncology is a United States journal catalogued by NLM from 2011, published quarterly from 2011 to 2017 and bimonthly since 2018, and indexed for MEDLINE under the subject headings Adolescent, Young Adult and Neoplasms. NLM and Crossref both list SAGE Publications as the current publisher, and NLM points to the journal's home on the SAGE Journals platform.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/jay"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101543508"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publications","url":"https://journals.sagepub.com/home/jay","issn":"2156-5333","scope":"adolescent and young adult oncology","founded":2011,"matchNames":["J Adolesc Young Adult Oncol","Journal of adolescent and young adult oncology","Journal of Adolescent and Young Adult Oncology","JAYAO"]},{"id":"journal-of-breast-imaging","kind":"journal","name":"Journal of breast imaging","aka":["J Breast Imaging","JBI"],"tldr":"The Society of Breast Imaging's journal on mammography, ultrasound, MRI and image-guided procedures for finding and managing breast cancer. Read by breast radiologists, technologists and screening researchers.","summary":"The Journal of Breast Imaging is the official journal of the Society of Breast Imaging, published by Oxford University Press and catalogued by NLM from 2019 under the subject headings Breast Diseases and Early Detection of Cancer. Its about page describes it as a peer-reviewed publication that aims to provide high quality, evidence-based content for the global breast imaging medical community, with a focus on improving patient care across screening, diagnosis, image-guided procedures and cancer management. It publishes original research together with reviews of important scientific, educational and clinical topics. The publisher page indicates a subscription model with open access options for individual articles, so the access model is recorded here as hybrid.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/jbi"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101752190"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["ductal-carcinoma-in-situ","breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/jbi","issn":"2631-6129","scope":"breast imaging","access":"hybrid","founded":2019,"matchNames":["J Breast Imaging","Journal of breast imaging","Journal of Breast Imaging","JBI"],"society":"Society of Breast Imaging"},{"id":"journal-of-cachexia-sarcopenia-and-muscle","kind":"journal","name":"Journal of cachexia, sarcopenia and muscle","aka":["J Cachexia Sarcopenia Muscle","JCSM"],"tldr":"The open access journal for wasting syndromes: the muscle and weight loss that accompanies advanced cancer and other chronic diseases. Read by oncologists, geriatricians, nutrition scientists and muscle biologists.","summary":"The Journal of Cachexia, Sarcopenia and Muscle is published by Wiley on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders, which describes it as a peer-reviewed international journal dedicated to publishing both research and clinical materials related to cachexia and sarcopenia from all fields of the life sciences. NLM catalogues it from 2010 as a quarterly, first published in Germany, indexed for MEDLINE under Cachexia, Muscles and Sarcopenia. The Directory of Open Access Journals lists it as fully open access since 2010 under a CC BY licence, with anonymous peer review and an article processing charge.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/1353921906009"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101552883"},{"label":"DOAJ record","url":"https://doaj.org/toc/2190-6009"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/1353921906009","issn":"2190-6009","scope":"cancer cachexia and muscle wasting","access":"open-access","founded":2010,"matchNames":["J Cachexia Sarcopenia Muscle","Journal of cachexia, sarcopenia and muscle","Journal of Cachexia, Sarcopenia and Muscle","JCSM"],"society":"Society on Sarcopenia, Cachexia and Wasting Disorders"},{"id":"journal-of-cancer-education","kind":"journal","name":"Journal of cancer education","aka":["Journal of cancer education : the official journal of the American Association for Cancer Education","J Cancer Educ"],"tldr":"The journal about teaching cancer: how to train clinicians, students and the public about prevention, screening and care. Read by medical educators, public-health workers and oncology training leads.","summary":"The Journal of Cancer Education is the official journal of the American Association for Cancer Education and is also associated with the European Association for Cancer Education; NLM records that it was the EACE's official journal in the mid 1990s. Published by Springer Nature and catalogued by NLM from 1986 as a quarterly, it describes itself as an international journal dedicated to original contributions dealing with the varied aspects of cancer education for professional audiences and the general public. It welcomes reports of original educational research and discussions of current problems and techniques in cancer education, including educational methods, instruments and evaluation of teaching initiatives. The publisher lists a hybrid publishing model, with subscription access and an open access option.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/13187"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8610343"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/13187","issn":"0885-8195","scope":"cancer education","access":"hybrid","founded":1986,"matchNames":["J Cancer Educ","Journal of cancer education","Journal of Cancer Education"],"society":"American Association for Cancer Education"},{"id":"journal-of-cancer-policy","kind":"journal","name":"Journal of cancer policy","aka":["J Cancer Policy"],"tldr":"A journal about the politics and economics of cancer: national cancer plans, drug pricing, access to care and health-system decisions. Read by policy makers, health economists and cancer-control researchers.","summary":"The Journal of Cancer Policy is published by Elsevier and catalogued by NLM from 2013 as an England-based journal appearing four times a year, indexed for MEDLINE under the subject headings Medical Oncology and Public Health. Crossref confirms Elsevier as the publisher. Elsevier describes it as an international journal, affiliated with the European Cancer Organisation, that publishes research and reviews on global cancer policy: cancer systems and services research, cancer economics and value-based care, inequalities in access and outcomes, regulatory issues for cancer drugs, radiotherapy and surgical technologies, and policy priorities for low, middle and high income countries.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/journal-of-cancer-policy"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101639933"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/journal-of-cancer-policy","issn":"2213-5383","scope":"cancer policy","founded":2013,"matchNames":["J Cancer Policy","Journal of cancer policy","Journal of Cancer Policy"]},{"id":"journal-of-cancer-research-and-clinical-oncology","kind":"journal","name":"Journal of cancer research and clinical oncology","aka":["J Cancer Res Clin Oncol","JCRCO"],"tldr":"The German Cancer Society's long-running journal covering both laboratory cancer research and clinical oncology. Read by oncologists and cancer researchers, especially in Europe.","summary":"The Journal of Cancer Research and Clinical Oncology is the official journal of the German Cancer Society (Deutsche Krebsgesellschaft), published by Springer Nature in Germany. NLM catalogues it from 1979, now at twelve issues a year, and notes that articles have appeared in English or German with summaries in both languages. The publisher describes it as containing significant and up-to-date articles within the fields of experimental and clinical oncology, covering carcinogenesis, molecular biology, developments in cancer therapy, diagnostic methods, oncological surgery and epidemiology, including precision medicine, targeted therapy, immuno-oncology and artificial intelligence. The Directory of Open Access Journals lists it as fully open access from 2024 under CC BY or CC BY-NC-ND licences, with anonymous peer review and an article processing charge.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/432"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7902060"},{"label":"DOAJ record","url":"https://doaj.org/toc/0171-5216"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/432","issn":"0171-5216","scope":"experimental and clinical oncology","access":"open-access","founded":1979,"matchNames":["J Cancer Res Clin Oncol","Journal of cancer research and clinical oncology","Journal of Cancer Research and Clinical Oncology"],"society":"Deutsche Krebsgesellschaft (German Cancer Society)"},{"id":"journal-of-cancer-research-and-therapeutics","kind":"journal","name":"Journal of cancer research and therapeutics","aka":["J Cancer Res Ther","JCRT"],"tldr":"An Indian clinical oncology journal, edited from AIIMS in New Delhi, that publishes research and case reports on cancer treatment with a strong radiotherapy presence. Read by oncologists in India and other Asian countries.","summary":"The Journal of Cancer Research and Therapeutics is a quarterly journal from India, catalogued by NLM from 2005 with Medknow Publications as publisher and indexed for MEDLINE under Neoplasms. Crossref lists the publisher as Ovid Technologies (Wolters Kluwer) Medknow Publications, and the journal's former web address now resolves to a Wolters Kluwer Ovid journal page that gives the editor-in-chief as Dr Daya Nand Sharma, four issues a year, and the ISSNs 0973-1482 (print) and 1998-4138 (online). The current issue at the time of writing (May 2026) is volume 22. The journal is not listed in the Directory of Open Access Journals and its access model is not stated on the pages reached, so none is recorded here.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ovid.com/jnls/cancerjournal"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101249598"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wolters Kluwer (Medknow Publications)","url":"https://www.ovid.com/jnls/cancerjournal","issn":"0973-1482","scope":"clinical oncology","founded":2005,"matchNames":["J Cancer Res Ther","Journal of cancer research and therapeutics","Journal of Cancer Research and Therapeutics"]},{"id":"journal-of-cancer-survivorship","kind":"journal","name":"Journal of cancer survivorship","aka":["Journal of cancer survivorship : research and practice","J Cancer Surviv"],"tldr":"The journal about life after a cancer diagnosis: late effects, quality of life, follow-up care and health policy for people living with and beyond cancer. Read by survivorship clinicians, nurses, psychologists and health-services researchers.","summary":"The Journal of Cancer Survivorship: Research and Practice is published by Springer Nature and catalogued by NLM from 2007 as a United States quarterly indexed under Neoplasms and Survivors. It publishes original research on cancer survivors, systematic, meta-analytic and scoping reviews that follow PRISMA reporting guidance, clinical investigations and policy-related research that can affect the quality of care and quality of life of survivors, spanning basic and epidemiological studies, clinical investigations and health-services research. The journal defines survivors broadly as people diagnosed with and treated for cancer, whether living with or free of disease, including those on prolonged treatment after primary therapy, from adolescents to older adults. The publisher lists a hybrid model and states that the journal will move to fully open access on 1 January 2027.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/11764"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101307557"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/11764","issn":"1932-2259","scope":"cancer survivorship","access":"hybrid","founded":2007,"matchNames":["J Cancer Surviv","Journal of cancer survivorship","Journal of Cancer Survivorship","Journal of Cancer Survivorship: Research and Practice"]},{"id":"jci","kind":"journal","name":"Journal of Clinical Investigation","aka":["JCI","J Clin Invest"],"tldr":"The Journal of Clinical Investigation is a century-old physician-scientist journal, free to read, publishing mechanistic disease biology including tumour immunology, metabolism and early CAR-T science.","summary":"Monthly and fully free to read, published by the non-profit American Society for Clinical Investigation. Publishes translational studies across medicine with a strong cancer immunology and haematology component, including early CAR-T and tumour-microenvironment work. JCI Insight is its open-access sister.","asOf":"2026-09-09","links":[{"label":"JCI Insight","url":"https://insight.jci.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Society for Clinical Investigation","url":"https://www.jci.org","issn":"0021-9738","scope":"translational medicine","access":"open-access","founded":1924,"matchNames":["Journal of Clinical Investigation","JCI","J Clin Invest"],"society":"American Society for Clinical Investigation"},{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","aka":["JCO","J Clin Oncol","src-jco"],"tldr":"The Journal of Clinical Oncology is ASCO's flagship journal and the workhorse of clinical oncology, publishing trials, ASCO guidelines, and the abstract supplements for the ASCO Annual Meeting.","summary":"JCO publishes three issues a month, carrying phase 2 and 3 trials across all tumour types, ASCO clinical practice guidelines (for example on immune-related adverse events), health-services and survivorship research, and the annual-meeting abstract supplements that make it the most cited oncology journal by volume. Hybrid access; guidelines are free. Sister titles include JCO Precision Oncology, JCO Oncology Practice and JCO Global Oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Journal_of_Clinical_Oncology","links":[{"label":"ASCO guidelines","url":"https://www.asco.org/practice-patients/guidelines"}],"tags":[],"related":["src-asco-meeting-library","asco-guidelines","jco-precision-oncology","jco-clinical-cancer-informatics"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["asco"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: ASCO flagship journal: trials, guidelines (including living guidelines) and long-term follow-up of cooperative-group studies. Access: Paywalled; guidelines and many trials free."],"publisher":"American Society of Clinical Oncology","url":"https://ascopubs.org/journal/jco","issn":"0732-183X","scope":"clinical oncology","access":"hybrid","founded":1983,"impactFactor":{"value":42.1,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Journal of Clinical Oncology","JCO","J Clin Oncol","Journal of Clinical Oncology (ASCO Annual Meeting abstract)"],"society":"American Society of Clinical Oncology"},{"id":"journal-of-environmental-pathology-toxicology-and-oncology","kind":"journal","name":"Journal of environmental pathology, toxicology and oncology","aka":["Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer","J Environ Pathol Toxicol Oncol","JEPTO"],"tldr":"A journal on how chemicals, pollutants and other environmental exposures damage tissues and cause cancer. Read by toxicologists, pathologists and experimental cancer researchers.","summary":"The Journal of Environmental Pathology, Toxicology and Oncology is, according to its full title, the official organ of the International Society for Environmental Toxicology and Cancer. It is published by Begell House in the United States and catalogued by NLM from 1984, now quarterly after periods of bimonthly and eight-issue publication in the 1980s and early 1990s, and is indexed for MEDLINE under Environmental Pollutants, Medical Oncology, Pathology and Toxicology. Crossref confirms Begell House as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.dl.begellhouse.com/journals/0ff459a57a4c08d0.html"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8501420"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["histology"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Begell House","url":"https://www.dl.begellhouse.com/journals/0ff459a57a4c08d0.html","issn":"0731-8898","scope":"environmental carcinogenesis and toxicology","founded":1984,"matchNames":["J Environ Pathol Toxicol Oncol","Journal of environmental pathology, toxicology and oncology","Journal of Environmental Pathology, Toxicology and Oncology"],"society":"International Society for Environmental Toxicology and Cancer"},{"id":"journal-of-experimental-and-clinical-cancer-research","kind":"journal","name":"Journal of experimental & clinical cancer research","aka":["Journal of experimental & clinical cancer research : CR","J Exp Clin Cancer Res","JECCR"],"tldr":"An Italian-rooted open access journal for bench-to-bedside cancer research, from tumour models to early clinical studies. Read by translational cancer biologists and clinician scientists.","summary":"The Journal of Experimental & Clinical Cancer Research describes itself as an online peer-reviewed journal publishing original research papers, reviews and commentaries in cancer research from bench to bedside, seeking to bridge laboratory discoveries with the understanding, prevention, diagnosis and treatment of cancer. It is the official journal of the Regina Elena National Cancer Institute in Rome and is owned by the Association for the Promotion of International Tumor Studies; it is published by BMC, part of Springer Nature. Submissions are expected to report findings not previously published in the same model, studies performed in multiple cell lines, and conclusions that go beyond incremental results. NLM catalogues it from 1982 and notes that print issues ceased with volume 26 in 2007. The Directory of Open Access Journals lists it as fully open access since 2008 with anonymous peer review, an article processing charge, and CC BY and CC0 licences.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://jeccr.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8308647"},{"label":"DOAJ record","url":"https://doaj.org/toc/1756-9966"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://jeccr.biomedcentral.com/","issn":"0392-9078","scope":"translational cancer research","access":"open-access","founded":1982,"matchNames":["J Exp Clin Cancer Res","Journal of experimental & clinical cancer research","Journal of Experimental & Clinical Cancer Research","Journal of Experimental and Clinical Cancer Research","JECCR"],"society":"Regina Elena National Cancer Institute"},{"id":"journal-of-gastric-cancer","kind":"journal","name":"Journal of gastric cancer","aka":["J Gastric Cancer","JGC"],"tldr":"The Korean Gastric Cancer Association's open access journal on stomach cancer, from prevention and screening to surgery and drug treatment. Read by gastric surgeons, gastroenterologists and oncologists, especially in East Asia.","summary":"The Journal of Gastric Cancer is the official journal of the Korean Gastric Cancer Association, which also publishes it. Its homepage describes it as open access and peer-reviewed, indexed in MEDLINE, PubMed Central, SCIE and Scopus, and it publishes original articles, review articles, special articles, guidelines, letters to the editor and a How I Do It category, including the Korean practice guidelines for gastric cancer. NLM catalogues it from 2010 as a quarterly and records that volume 10 numbers 2 and 3 (2010) were issued in Korean with English summaries and that the journal has been issued in English from volume 10 number 4 onwards. The homepage states that an article processing charge applies to original articles, reviews and How I Do It papers, revised to US $3,000 in 2026. The journal is not listed in the Directory of Open Access Journals; the open access label here rests on the publisher's own statement.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://jgc-online.org"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101559430"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Korean Gastric Cancer Association","url":"https://jgc-online.org","issn":"2093-582X","scope":"gastric cancer","access":"open-access","founded":2010,"matchNames":["J Gastric Cancer","Journal of gastric cancer","Journal of Gastric Cancer","JGC"],"society":"Korean Gastric Cancer Association"},{"id":"journal-of-gastrointestinal-cancer","kind":"journal","name":"Journal of gastrointestinal cancer","aka":["J Gastrointest Cancer"],"tldr":"A clinical journal for cancers of the digestive tract: oesophagus, stomach, liver, gallbladder, pancreas, bowel and rectum. Read by GI oncologists, surgeons and gastroenterologists.","summary":"The Journal of Gastrointestinal Cancer is published by Springer Nature and catalogued by NLM from 2007 as a United States journal indexed under Gastrointestinal Neoplasms. The publisher describes it as dedicated to understanding and treating cancers arising in the gastrointestinal tract, publishing clinical and translational research on cancers of the oesophagus, stomach, liver, gallbladder, pancreas, colon, rectum and related organs, together with work on epidemiology, prevention, diagnosis, technology and survivorship. Article types include research papers, state-of-the-art reviews, editorials, case reports and letters to the editor; the journal states that basic science and preclinical studies are no longer accepted. It uses a hybrid publishing model allowing either subscription-based or open access publication.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/12029"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101479627"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["esophageal","gastric","hcc","cholangiocarcinoma","gallbladder","pancreatic","colorectal","anal","small-bowel","gist"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/12029","issn":"1941-6628","scope":"gastrointestinal oncology","access":"hybrid","founded":2007,"matchNames":["J Gastrointest Cancer","Journal of gastrointestinal cancer","Journal of Gastrointestinal Cancer"]},{"id":"journal-of-geriatric-oncology","kind":"journal","name":"Journal of geriatric oncology","aka":["J Geriatr Oncol","JGO"],"tldr":"The journal for cancer in older people: frailty assessment, treatment tolerance, care of patients with several conditions and clinical trials in the over-65s. Read by geriatric oncologists, geriatricians and oncology nurses.","summary":"The Journal of Geriatric Oncology is published by Elsevier, catalogued by NLM from 2010 as a Netherlands-based journal and indexed for MEDLINE under the subject headings Aged and Neoplasms. Crossref confirms Elsevier as the publisher, and NLM points to the journal's ScienceDirect listing; the journal also has its own site at geriatriconcology.net.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.geriatriconcology.net/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101534770"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.geriatriconcology.net/","issn":"1879-4068","scope":"geriatric oncology","founded":2010,"matchNames":["J Geriatr Oncol","Journal of geriatric oncology","Journal of Geriatric Oncology"]},{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","aka":["J Gynecol Oncol","JGO"],"tldr":"An open access Asian journal on cancers of the cervix, womb, ovaries, vulva and vagina, run by the Asian Society of Gynecologic Oncology with its Korean and Japanese partner societies. Read by gynaecological oncologists and surgeons, especially in Asia.","summary":"The journal is published by the Asian Society of Gynecologic Oncology and its homepage also lists the Korean Society of Gynecologic Oncology, the Japan Society of Gynecologic Oncology and the Society of Gynecologic Oncology of Canada as publishing partners. It describes itself as open access and peer-reviewed, publishing original articles organised by disease site such as cervix and uterine corpus, and it runs an ASGO webinar series, a journal club and a podcast. NLM catalogues it from 2008, records that it continues an earlier Korean-language title (Puin chongyang, ISSN 1738-6543), and notes that print issues ceased with volume 26 in 2015. The Directory of Open Access Journals lists it as open access since 2011 under a CC BY-NC licence, with double anonymous peer review and an article processing charge of US $1,000.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://ejgo.org"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101483150"},{"label":"DOAJ record","url":"https://doaj.org/toc/2005-0380"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["cervical","endometrial","ovarian","vulvar","vaginal","uterine-sarcoma","gestational-trophoblastic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Asian Society of Gynecologic Oncology","url":"https://ejgo.org","issn":"2005-0380","scope":"gynaecological oncology","access":"open-access","founded":2008,"matchNames":["J Gynecol Oncol","Journal of gynecologic oncology","Journal of Gynecologic Oncology"],"society":"Asian Society of Gynecologic Oncology"},{"id":"journal-of-hematology-and-oncology","kind":"journal","name":"Journal of hematology & oncology","aka":["J Hematol Oncol","JHO"],"tldr":"A large open access journal spanning blood cancers and solid tumours, from laboratory mechanisms to clinical trials. Read by haematologists, oncologists and translational researchers.","summary":"The journal is published by BMC, part of Springer Nature, and describes itself as an open access journal publishing top-quality research encompassing all aspects of haematology and oncology, serving as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, haematologists and oncologists. It publishes research articles, reviews and research highlights on topical subjects from leading experts. NLM catalogues it from 2008 as a free open access electronic journal published by BioMed Central, noting that as an online journal it has no issue numbers and each volume corresponds to a calendar year. The Directory of Open Access Journals lists it as open access since 2008 with anonymous peer review, an article processing charge, and CC BY and CC BY-NC-ND licences.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://jhoonline.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101468937"},{"label":"DOAJ record","url":"https://doaj.org/toc/1756-8722"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://jhoonline.biomedcentral.com/","issn":"1756-8722","scope":"haematological oncology and oncology","access":"open-access","founded":2008,"matchNames":["J Hematol Oncol","Journal of hematology & oncology","Journal of Hematology & Oncology","Journal of Hematology and Oncology"]},{"id":"journal-of-immunotherapy","kind":"journal","name":"Journal of immunotherapy","aka":["J Immunother","Journal of Immunotherapy with Emphasis on Tumor Immunology"],"tldr":"A long-established journal on using the immune system against cancer, edited by Steven Rosenberg of the US National Cancer Institute. Read by tumour immunologists and clinicians working on checkpoint inhibitors, vaccines and cell therapies.","summary":"The Journal of Immunotherapy is published by Lippincott Williams & Wilkins, part of Wolters Kluwer, and its journal page on the Ovid platform gives Steven A. Rosenberg, MD, PhD as editor-in-chief, nine issues a year, and the ISSNs 1524-9557 (print) and 1537-4513 (online); the current issue at the time of writing is volume 49 (September 2026). NLM catalogues the title from 1997 as the continuation of the Journal of Immunotherapy with Emphasis on Tumor Immunology (ISSN 1067-5582), records it as the official journal of the Society for Biological Therapy, and indexes it for MEDLINE under Immunotherapy and Neoplasms. The journal is not listed in the Directory of Open Access Journals and its access model is not stated on the pages reached, so none is recorded here.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ovid.com/jnls/immunotherapy-journal"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9706083"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://www.ovid.com/jnls/immunotherapy-journal","issn":"1524-9557","scope":"cancer immunotherapy","founded":1997,"matchNames":["J Immunother","Journal of immunotherapy","Journal of Immunotherapy"]},{"id":"journal-of-mammary-gland-biology-and-neoplasia","kind":"journal","name":"Journal of mammary gland biology and neoplasia","aka":["J Mammary Gland Biol Neoplasia","JMGBN"],"tldr":"A specialist journal on how the breast develops, lactates and turns cancerous, bringing together mammary gland biology and breast cancer research. Read by developmental biologists, breast cancer researchers and lactation scientists.","summary":"The Journal of Mammary Gland Biology and Neoplasia is published by Springer Nature and catalogued by NLM from 1996 as a United States quarterly indexed under Breast Neoplasms, Breast, Mammary Glands (Animal) and Mammary Neoplasms (Animal). The publisher describes it as the leading journal in the field of mammary gland biology, providing researchers within and outside the field with an integrated source of information on the development, function and pathology of the mammary gland. It publishes peer-reviewed original research, reviews, commentaries and perspectives on mammary development, breast cancer biology, lactation and milk composition, including environmental, endocrine, nutritional and molecular factors. The publisher's journal page lists open access as its publishing model; the journal is not listed in the Directory of Open Access Journals.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/10911"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9601804"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["ductal-carcinoma-in-situ","breast-hr-positive","breast-her2-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/10911","issn":"1083-3021","scope":"breast cancer biology","access":"open-access","founded":1996,"matchNames":["J Mammary Gland Biol Neoplasia","Journal of mammary gland biology and neoplasia","Journal of Mammary Gland Biology and Neoplasia"]},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","aka":["J Med Imaging Radiat Oncol","JMIRO"],"tldr":"The journal of the Australian and New Zealand college for radiologists and radiation oncologists, covering diagnostic imaging, nuclear medicine and radiotherapy. Read by radiologists and radiation oncologists in Australasia and beyond.","summary":"The Journal of Medical Imaging and Radiation Oncology, also known as JMIRO, is recorded by NLM as the official journal of the Royal Australian and New Zealand College of Radiologists. It is published by Wiley (NLM lists Wiley-Blackwell Publishing Asia) and catalogued from 2008 as an Australian bimonthly, indexed for MEDLINE under Diagnostic Imaging, Neoplasms, Nuclear Medicine and Radiation Oncology. Crossref confirms Wiley as the publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/17549485"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101469340"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/17549485","issn":"1754-9477","scope":"radiology and radiation oncology","founded":2008,"matchNames":["J Med Imaging Radiat Oncol","Journal of medical imaging and radiation oncology","Journal of Medical Imaging and Radiation Oncology","JMIRO"],"society":"Royal Australian and New Zealand College of Radiologists"},{"id":"journal-of-neuro-oncology","kind":"journal","name":"Journal of neuro-oncology","aka":["J Neurooncol","J Neuro-Oncol"],"tldr":"A high-volume journal on brain and spinal cord tumours, from glioma biology to surgery, radiotherapy and drug trials. Read by neuro-oncologists, neurosurgeons and brain tumour researchers.","summary":"The Journal of Neuro-Oncology is published by Springer Nature and catalogued by NLM from 1983 as a United States journal, now at fifteen issues a year after starting as a quarterly, indexed for MEDLINE under Nervous System Neoplasms. The publisher describes it as a multidisciplinary journal encompassing basic, applied and clinical investigations in all research areas as they relate to cancer and the central nervous system. It lists a hybrid publishing model, with subscription access and an open access option; the journal is not listed in the Directory of Open Access Journals. Not to be confused with Neuro-Oncology, the Society for Neuro-Oncology journal published by Oxford University Press, which has its own record in this corpus.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/11060"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8309335"}],"tags":[],"related":["pubmed-europepmc","neuro-oncology"],"cancers":["glioblastoma","medulloblastoma","ependymoma","dipg-dmg","primary-cns-lymphoma","paediatric-low-grade-glioma","craniopharyngioma","pituitary-tumours","atrt"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/11060","issn":"0167-594X","scope":"neuro-oncology","access":"hybrid","founded":1983,"matchNames":["J Neurooncol","J Neuro-Oncol","Journal of neuro-oncology","Journal of Neuro-Oncology","Journal of Neurooncology"]},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","aka":["JNM","J Nucl Med"],"tldr":"The Journal of Nuclear Medicine is the SNMMI's journal and the core venue for PET tracers and radioligand therapy: PSMA and somatostatin imaging, lutetium and actinium dosimetry, and theranostics trials.","summary":"The Journal of Nuclear Medicine appears monthly and publishes first-in-human tracer studies, PSMA PET diagnostic accuracy trials, radioligand-therapy dosimetry and outcomes (lutetium-177 PSMA and DOTATATE, actinium-225), and SNMMI procedure standards. Articles become free to read after a delay; the SNMMI annual meeting abstracts are published as a supplement.","asOf":"2026-09-09","links":[{"label":"SNMMI","url":"https://www.snmmi.org"}],"tags":[],"related":["src-snmmi"],"cancers":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Society of Nuclear Medicine and Molecular Imaging","url":"https://jnm.snmjournals.org","issn":"0161-5505","scope":"nuclear medicine","access":"hybrid","founded":1960,"matchNames":["Journal of Nuclear Medicine","JNM","J Nucl Med","The Journal of Nuclear Medicine"],"society":"Society of Nuclear Medicine and Molecular Imaging"},{"id":"journal-of-oncology-pharmacy-practice","kind":"journal","name":"Journal of oncology pharmacy practice","aka":["Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners","J Oncol Pharm Pract","JOPP"],"tldr":"The official journal of the International Society of Oncology Pharmacy Practitioners, covering how cancer medicines are prepared, dosed, handled and used safely. Read by oncology pharmacists and pharmacy technicians.","summary":"Journal of Oncology Pharmacy Practice (JOPP) is published by SAGE Publications and is the official publication of the International Society of Oncology Pharmacy Practitioners (ISOPP). ISOPP describes it as a peer-reviewed, scholarly journal dedicated to educating health professionals about providing pharmaceutical care to patients with cancer. It publishes original research, reviews and practice-issues papers, including comprehensive and critical reviews of drug use in cancer care, institutional medication-use policies with outcome indicators, reports of innovative services and outcome measurement tools, opinions on controversial therapeutic areas, and updates on ISOPP activities. The journal is a member of the Committee on Publication Ethics and is free to ISOPP members. NLM records it as starting in 1995, published in London, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/opp"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9511372"},{"label":"ISOPP: About JOPP","url":"https://www.isopp.org/about-jopp"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publications","url":"https://journals.sagepub.com/home/opp","issn":"1078-1552","scope":"oncology pharmacy","founded":1995,"matchNames":["J Oncol Pharm Pract","Journal of oncology pharmacy practice","Journal of Oncology Pharmacy Practice","JOPP"],"society":"International Society of Oncology Pharmacy Practitioners (ISOPP)"},{"id":"journal-of-pediatric-hematology-oncology","kind":"journal","name":"Journal of pediatric hematology/oncology","aka":["J Pediatr Hematol Oncol","JPHO"],"tldr":"A clinical journal for doctors and nurses who treat children with cancer and blood disorders, carrying case reports, cohort studies and treatment series.","summary":"Journal of Pediatric Hematology/Oncology is published by Lippincott Williams & Wilkins, part of Wolters Kluwer, and is hosted on the Ovid journals platform. The journal page lists eight issues a year under Editor-in-Chief Bruce M. Camitta and carries clinical papers on childhood blood disorders and cancers; recent issue highlights include a case report on immunotherapy for constitutional mismatch repair deficiency-associated bowel adenocarcinoma in a child, and a retrospective cohort study of vaccine immunity to measles, mumps, rubella and varicella in childhood leukaemia survivors after chemotherapy. NLM records the journal as starting in 1995 (print ISSN 1077-4114, electronic ISSN 1536-3678), published in Hagerstown, Maryland, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/jpho-online/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9505928"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://journals.lww.com/jpho-online/pages/default.aspx","issn":"1077-4114","scope":"paediatric haematology and oncology","founded":1995,"matchNames":["J Pediatr Hematol Oncol","Journal of pediatric hematology/oncology","Journal of Pediatric Hematology/Oncology","JPHO"]},{"id":"journal-of-pediatric-hematology-oncology-nursing","kind":"journal","name":"Journal of pediatric hematology/oncology nursing","aka":["J Pediatr Hematol Oncol Nurs","JOPHON","Journal of Pediatric Oncology Nursing"],"tldr":"The nursing journal of the Association of Pediatric Hematology/Oncology Nurses, publishing research and reviews on caring for children with cancer and blood disorders. Read by paediatric oncology nurses, social workers and child life specialists.","summary":"Journal of Pediatric Hematology/Oncology Nursing (JOPHON) is a peer-reviewed bi-monthly journal published by SAGE Publications, with copyright held by the Association of Pediatric Hematology/Oncology Nurses. SAGE describes it as offering paediatric haematology, oncology and immunology nurses in clinical practice and research, paediatric social workers, epidemiologists, clinical psychologists, child life specialists and nursing educators original research and definitive reviews on the whole spectrum of nursing care of childhood cancers, including leukaemias, solid tumours and lymphomas, and haematological disorders. The journal is a member of the Committee on Publication Ethics. It continues the Journal of Pediatric Oncology Nursing, which changed its name on 1 January 2022; NLM lists the new title from 2022 and records it as currently indexed in MEDLINE. Its article listing mixes open access and restricted access papers.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/jpo"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/489718"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publications","url":"https://journals.sagepub.com/home/jpo","issn":"2752-7549","scope":"paediatric oncology nursing","founded":2022,"matchNames":["J Pediatr Hematol Oncol Nurs","Journal of pediatric hematology/oncology nursing","Journal of Pediatric Hematology/Oncology Nursing","JOPHON","Journal of Pediatric Oncology Nursing","J Pediatr Oncol Nurs"],"society":"Association of Pediatric Hematology/Oncology Nurses (APHON)"},{"id":"journal-of-psychosocial-oncology","kind":"journal","name":"Journal of psychosocial oncology","aka":["J Psychosoc Oncol"],"tldr":"A journal about the emotional, social and practical side of cancer: counselling, family support, coping and survivorship. Read by oncology social workers, psychologists and nurses.","summary":"Journal of Psychosocial Oncology is published by Routledge, part of Taylor & Francis, and is affiliated with the Association of Oncology Social Work. The publisher describes it as a single source of integrated information on providing the best psychosocial care possible, drawing on knowledge from many disciplines and emphasising an interdisciplinary approach to care and research in oncology, and as an essential source of up-to-date clinical and research material for health professionals who provide psychosocial services to cancer patients, their families and caregivers. It is an Open Select (hybrid) journal, so authors may choose to publish open access while other content is available by subscription. NLM records the journal as starting in 1983, published in Philadelphia, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/wjpo20"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8309337"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Routledge (Taylor & Francis)","url":"https://www.tandfonline.com/journals/wjpo20","issn":"0734-7332","scope":"psychosocial oncology","access":"hybrid","founded":1983,"matchNames":["J Psychosoc Oncol","Journal of psychosocial oncology","Journal of Psychosocial Oncology"]},{"id":"journal-of-radiation-research","kind":"journal","name":"Journal of radiation research","aka":["J Radiat Res","JRR"],"tldr":"A fully open access Japanese journal on radiation science, from radiobiology and physics to radiotherapy for cancer. Read by radiation oncologists, medical physicists and radiation biologists.","summary":"Journal of Radiation Research is published by Oxford University Press and is affiliated with the Japanese Radiation Research Society and the Japanese Society for Radiation Oncology. The journal describes itself as a fully open access multidisciplinary journal publishing articles in radiation science in the fields of biology, chemistry, physics, epidemiology, environmental sciences and oncology, accepting high quality clinical and scientific papers on all aspects of the field as well as supplement issues; the annual Terasima Award recognises its most prominent paper. DOAJ lists it with CC BY and CC BY-NC licences, an article processing charge, double anonymous peer review and open access content from 1999. NLM records the journal as starting in 1960 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/jrr"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/376611"},{"label":"DOAJ record","url":"https://doaj.org/toc/0449-3060"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/jrr","issn":"0449-3060","scope":"radiation research and radiation oncology","access":"open-access","founded":1960,"matchNames":["J Radiat Res","Journal of radiation research","Journal of Radiation Research","JRR"],"society":"Japanese Radiation Research Society and Japanese Society for Radiation Oncology"},{"id":"journal-of-registry-management","kind":"journal","name":"Journal of registry management","aka":["J Registry Manag","JRM"],"tldr":"The journal of the US cancer registrars' association, about how cancer and other health registries collect, manage and use their data. Read by registrars, epidemiologists and public health staff.","summary":"Journal of Registry Management (JRM) is the official journal of the National Cancer Registrars Association (NCRA), which publishes it quarterly from Alexandria, Virginia. NCRA describes it as an open access, peer-reviewed journal that publishes papers on topics related to the management of health registries and to the collection, management and use of cancer, trauma, birth defects, HIV/AIDS and other health registry data. Its readers are cancer registrars, the data specialists who capture a complete history, diagnosis, treatment and health status for every cancer patient in the United States, and the researchers, clinicians and public health officials who use registry data to monitor treatment, conduct research and improve prevention and screening programmes. NCRA also offers continuing education quizzes based on JRM articles. The journal is currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ncra-usa.org/About/Publications/Journal-of-Registry-Management"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9804163"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"National Cancer Registrars Association","url":"https://www.ncra-usa.org/About/Publications/Journal-of-Registry-Management","issn":"1945-6123","scope":"cancer registries and health data management","access":"open-access","matchNames":["J Registry Manag","Journal of registry management","Journal of Registry Management","JRM"],"society":"National Cancer Registrars Association (NCRA)"},{"id":"journal-of-surgical-oncology","kind":"journal","name":"Journal of surgical oncology","aka":["J Surg Oncol","JSO"],"tldr":"A long-running surgical journal for cancer surgeons, covering operations, multimodality treatment and the laboratory science behind them, with themed Seminars issues.","summary":"Journal of Surgical Oncology is published by Wiley (copyright Wiley Periodicals) and edited by David J. Bentrem. The journal states that it publishes research in the field of surgical and clinical oncology and broadly related surgical sciences, including experimental and laboratory studies on cancer research and treatment, pathology, radiology, multimodality treatment and more, and that it encourages participation from leading surgeons and cancer specialists around the world. Guest editors from the editorial board oversee several special Seminars issues each year, including congress proceedings such as those of the Brazilian Congress of Surgical Oncology. The journal offers an open access publishing route alongside its subscription content and warns authors about an unrelated journal using a similar name. NLM records it as starting in 1969, published in Hoboken, New Jersey, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10969098"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/222643"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10969098","issn":"0022-4790","scope":"surgical oncology","founded":1969,"matchNames":["J Surg Oncol","Journal of surgical oncology","Journal of Surgical Oncology","JSO"]},{"id":"journal-of-the-egyptian-national-cancer-institute","kind":"journal","name":"Journal of the Egyptian National Cancer Institute","aka":["J Egypt Natl Canc Inst","JENCI"],"tldr":"The open access journal of Egypt's National Cancer Institute in Cairo, publishing cancer research with a focus on applied work from developing countries. No fee to publish.","summary":"Journal of the Egyptian National Cancer Institute (JENCI) is the official publication of the National Cancer Institute, Cairo University, published open access by SpringerOpen, part of Springer Nature, with Hussein Khaled as Editor. It describes itself as an open access peer-reviewed journal publishing the latest innovations in oncology and welcoming submissions in all fields of basic, applied and clinical cancer research, with particular interest in local and systemic anticancer therapy from developing countries, experimental oncology, early cancer detection, randomised trials including negative ones, and personalised medicine fields such as molecular pathology, bioinformatics and biotechnology. DOAJ lists it with CC BY and CC BY-NC-ND licences, no article processing charge, double anonymous peer review and open access content from 2011. NLM records the journal as starting in 1982 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://jenci.springeropen.com"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9424566"},{"label":"DOAJ record","url":"https://doaj.org/toc/1110-0362"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SpringerOpen (Springer Nature)","url":"https://jenci.springeropen.com","issn":"1110-0362","scope":"clinical and experimental oncology","access":"open-access","founded":1982,"matchNames":["J Egypt Natl Canc Inst","Journal of the Egyptian National Cancer Institute","JENCI"],"society":"National Cancer Institute, Cairo University"},{"id":"jnci-monographs","kind":"journal","name":"Journal of the National Cancer Institute. Monographs","aka":["JNCI Monographs","J Natl Cancer Inst Monogr"],"tldr":"The monograph series of the JNCI family: each issue is a set of papers on one cancer topic or from one conference, such as cervical screening in HPV-vaccinated populations.","summary":"JNCI Monographs is published by Oxford University Press as part of the Journal of the National Cancer Institute family of journals, alongside JNCI and JNCI Cancer Spectrum, with Eduardo L. Franco as Editor-in-Chief. The journal states that it publishes manuscript collections on specific subjects of importance to cancer research, as well as manuscript collections from key conferences dealing with cancer and closely related research fields; each issue is a themed monograph rather than a set of unrelated articles, and the journal invites monograph proposals. A recent issue covered cervical cancer screening in HPV-vaccinated populations. Content is subscription based with an open access option. NLM records the series as starting in 1990 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/jncimono"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9011255"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/jncimono","issn":"1052-6773","scope":"cancer research monographs","access":"hybrid","founded":1990,"matchNames":["J Natl Cancer Inst Monogr","Journal of the National Cancer Institute. Monographs","JNCI Monographs","JNCI Monogr"]},{"id":"jnccn","kind":"journal","name":"Journal of the National Comprehensive Cancer Network","aka":["JNCCN","J Natl Compr Canc Netw"],"tldr":"JNCCN is the NCCN's journal, where the US treatment guidelines are published in article form alongside real-world practice and cost studies.","summary":"JNCCN appears monthly and publishes NCCN Guidelines Insights explaining panel changes, guideline-concordance and real-world outcome studies, and health-policy and economics research from US cancer centres. The bridge between the NCCN algorithms that drive US reimbursement and the evidence behind them.","asOf":"2026-09-09","links":[{"label":"NCCN Guidelines","url":"https://www.nccn.org/guidelines"}],"tags":[],"related":["nccn"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Harborside","url":"https://jnccn.org","issn":"1540-1405","scope":"oncology practice and policy","founded":2003,"matchNames":["Journal of the National Comprehensive Cancer Network","JNCCN","J Natl Compr Canc Netw"],"society":"National Comprehensive Cancer Network"},{"id":"journal-of-thoracic-oncology","kind":"journal","name":"Journal of Thoracic Oncology","aka":["JTO","J Thorac Oncol"],"tldr":"The Journal of Thoracic Oncology is the IASLC's journal and the leading specialist venue for lung cancer and mesothelioma: staging, biomarkers, targeted-therapy and screening research.","summary":"Publishes the IASLC TNM staging proposals, lung-cancer screening implementation studies, biomarker testing guidelines and phase 2 trials and long-term follow-up in EGFR, ALK, KRAS and other molecularly defined lung cancers. Hybrid access via Elsevier; the World Conference on Lung Cancer abstracts appear here.","asOf":"2026-09-09","links":[{"label":"IASLC","url":"https://www.iaslc.org"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.jto.org","issn":"1556-0864","scope":"thoracic oncology","access":"hybrid","founded":2006,"impactFactor":{"value":21,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Journal of Thoracic Oncology","JTO","J Thorac Oncol"],"society":"International Association for the Study of Lung Cancer"},{"id":"klinicka-onkologie","kind":"journal","name":"Klinická onkologie","aka":["Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti","Klin Onkol","Klinicka onkologie"],"tldr":"The journal of the Czech and Slovak oncology societies, publishing clinical research, reviews and case reports in Czech, Slovak and English. Read by oncologists and radiotherapists in central Europe.","summary":"Klinická onkologie is the journal of the Czech Society of Oncology and the Slovak Oncology Society, published six times a year by the Czech Medical Association of J. E. Purkyně with Care Comm s.r.o. as publishing house; its editorial office is at the Masaryk Memorial Cancer Institute in Brno. The journal describes itself as a supranational professional journal covering oncology in its full breadth, aiming to publish original and review papers reporting basic and, above all, clinical research and so help improve prevention, diagnosis and treatment of cancer in a central European region with high cancer incidence. It also carries case reports, short communications, letters and discussion, in Czech, Slovak and English, and all contributions other than news, discussion and letters undergo external peer review. The online edition appears two months after print. NLM records the journal as starting in 1988 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.linkos.cz/casopis-klinicka-onkologie/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9425213"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mou-brno"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Czech Medical Association of J. E. Purkyně (Care Comm s.r.o.)","url":"https://www.linkos.cz/casopis-klinicka-onkologie/","issn":"0862-495X","scope":"clinical oncology (Czech and Slovak)","founded":1988,"matchNames":["Klin Onkol","Klinická onkologie","Klinicka onkologie","Klinicka Onkologie"],"society":"Czech Society of Oncology and Slovak Oncology Society"},{"id":"leukemia","kind":"journal","name":"Leukemia","aka":["Leukemia (Springer Nature)"],"tldr":"Leukemia is a Springer Nature haematology journal covering leukaemia, lymphoma and myeloma biology and clinical research, including the International Myeloma Working Group consensus papers.","summary":"Leukemia is a Springer Nature haematology journal, founded in 1987, appearing monthly and published on a hybrid access model. It covers leukaemia, lymphoma and myeloma biology and clinical research, publishing genomic and clonal-evolution studies of leukaemia, myeloma and MDS, phase 2 trials and long-term follow-up, and the International Myeloma Working Group and European LeukemiaNet consensus and response criteria. Its readers are haematologists and translational researchers in blood cancers who need the consensus definitions that trials are built on. Within OnCo it is linked from the Katayoun Rezvani biography, and it is where a reader would look for myeloma and leukaemia consensus papers and clonal-evolution studies.","asOf":"2026-09-09","links":[{"label":"Springer Nature","url":"https://www.springernature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["leukaemia-type","interim-analysis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/leu/","issn":"0887-6924","scope":"haematology","access":"hybrid","founded":1987,"impactFactor":{"value":12.8,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Leukemia"]},{"id":"leukemia-and-lymphoma","kind":"journal","name":"Leukemia & lymphoma","aka":["Leuk Lymphoma","Leukemia and Lymphoma"],"tldr":"A journal for haematologists and scientists working on blood cancers, from leukaemia and lymphoma biology to new drugs and clinical outcomes.","summary":"Leukemia & Lymphoma is published by Taylor & Francis. The publisher describes it as an international peer reviewed journal that publishes research on all aspects of haematological malignancies, addressing the needs of physicians and scientists interested in clinical, translational, laboratory and basic science research as well as the clinical diagnosis and treatment of patients with malignant haematological disorders; coverage includes disease biology, novel agents, chemotherapy, pharmacology and pharmacogenomics, ethics and epidemiology. It is an Open Select (hybrid) journal, so authors may choose to publish open access alongside subscription content. NLM records the journal as starting in 1989 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/ilal20"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9007422"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["all-leukemia","aml","cll","cml","mds","myeloproliferative-neoplasms","dlbcl","follicular-lymphoma","hodgkin-lymphoma","mantle-cell-lymphoma","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/ilal20","issn":"1042-8194","scope":"haematological oncology","access":"hybrid","founded":1989,"matchNames":["Leuk Lymphoma","Leukemia & lymphoma","Leukemia & Lymphoma","Leukemia and Lymphoma"]},{"id":"leukemia-research","kind":"journal","name":"Leukemia research","aka":["Leuk Res"],"tldr":"An Elsevier journal on leukaemia and related blood cancers, and the official journal of the Myelodysplastic Syndromes Foundation. Read by haematologists and laboratory researchers.","summary":"Leukemia Research is published by Elsevier and is the official journal of the Myelodysplastic Syndromes Foundation. The journal describes itself as an international journal bringing comprehensive and current information to all health care professionals involved in basic and applied clinical research in haematological malignancies, with a scope that includes cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation and therapy of these diseases; it has an open access companion title, Leukemia Research Reports. Elsevier lists it as supporting open access with an open archive, offering authors a choice between paying an article publishing charge for open access and subscription publication with no fee. NLM records the journal as starting in 1977, originally under Pergamon Press in Oxford, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/leukemia-research"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7706787"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["all-leukemia","aml","cll","cml","cmml","mds","myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/leukemia-research","issn":"0145-2126","scope":"haematological oncology","access":"hybrid","founded":1977,"matchNames":["Leuk Res","Leukemia research","Leukemia Research"],"society":"Myelodysplastic Syndromes Foundation"},{"id":"lung-cancer-journal","kind":"journal","name":"Lung cancer","aka":["Lung cancer : journal of the International Association for the Study of Lung Cancer","Lung Cancer (Amsterdam, Netherlands)"],"tldr":"The main specialist journal for lung cancer and other chest tumours, publishing trials, translational studies and reviews. Read by thoracic oncologists, surgeons and pulmonologists.","summary":"Lung Cancer is published by Elsevier and is described on its ScienceDirect page as an international journal for lung cancer and other thoracic malignancies and an official journal of the European Society for Medical Oncology, the ETOP IBCSG Partners Foundation and the British Thoracic Oncology Group; NLM catalogues it under its older subtitle as the journal of the International Association for the Study of Lung Cancer. It covers the clinical, translational and basic science of malignancies of the lung and chest region, welcoming original research articles, early reports, review articles, editorials and correspondence on prevention, epidemiology and aetiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined modality treatment and outcomes. Elsevier lists it as supporting open access with an open archive, with a choice of open access (article publishing charge) or subscription publication. NLM records it as starting in 1985 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/lung-cancer"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8800805"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["nsclc","sclc","mesothelioma","thymic-epithelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/lung-cancer","issn":"0169-5002","scope":"thoracic oncology","access":"hybrid","founded":1985,"matchNames":["Lung Cancer","Lung cancer","Lung Cancer (Amsterdam, Netherlands)"],"society":"European Society for Medical Oncology, ETOP IBCSG Partners Foundation and British Thoracic Oncology Group"},{"id":"magyar-onkologia","kind":"journal","name":"Magyar onkologia","aka":["Magyar Onkológia","Magy Onkol","Hungarian Oncology"],"tldr":"The official journal of the Hungarian Society of Oncologists, publishing reviews, recommendations, original papers and case reports in Hungarian and English, plus Hungarian congress abstracts.","summary":"Magyar Onkológia (Hungarian Oncology) is the official journal of the Hungarian Society of Oncologists (Magyar Onkológusok Társasága), published quarterly in Budapest by Professional Publishing Hungary Kft. The author guidelines state that it publishes original Hungarian- and English-language papers, with summaries in both languages, on the practice and theory of oncology: invited reviews, professional recommendations, original articles and clinicopathological case presentations. It also carries abstracts of Hungarian oncology conferences, including the society's congresses, the meetings of its Young Oncologists Section and the Hungarian Society for Radiation Oncology congresses. Submitted manuscripts are reviewed by the editorial board with the help of experts in a single anonymous review. The journal website offers full-text search of articles and publication statistics. NLM records the journal as starting in 1957 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://huon.hu"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9313833"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Professional Publishing Hungary Kft.","url":"https://huon.hu","issn":"0025-0244","scope":"clinical oncology (Hungarian)","founded":1957,"matchNames":["Magy Onkol","Magyar onkologia","Magyar Onkológia","Magyar Onkologia","Hungarian Oncology"],"society":"Hungarian Society of Oncologists (Magyar Onkológusok Társasága)"},{"id":"medical-oncology","kind":"journal","name":"Medical oncology","aka":["Med Oncol"],"tldr":"A broad Springer journal reporting clinical and preclinical research in cancer and blood disorders, with reviews and perspective pieces. Read by medical oncologists and translational researchers.","summary":"Medical Oncology is published by Springer (Springer Science+Business Media, part of Springer Nature) under Editor-in-Chief Sarah R. Amend, with a hybrid publishing model that combines subscription content with an open access option. The journal describes itself as a forum to communicate the results of clinical and preclinical experimental research in oncology and haematology, and as a forum for state-of-the-art reviews in oncology and haematology; it introduced a Perspectives in Oncology article type in 2020 and also publishes comments and themed collections. It is abstracted and indexed in Medline, Embase, Scopus and the Science Citation Index Expanded among others. NLM records the journal as starting in 1994, published in New York, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/12032"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9435512"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["first-in-human","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (Springer Nature)","url":"https://link.springer.com/journal/12032","issn":"1357-0560","scope":"clinical and experimental oncology","access":"hybrid","founded":1994,"matchNames":["Med Oncol","Medical oncology","Medical Oncology","Medical Oncology (Northwood, London, England)"]},{"id":"medrxiv","kind":"journal","name":"medRxiv","aka":["medRxiv","src-medrxiv"],"tldr":"medRxiv is the preprint server for medicine and health sciences. Clinical cancer studies appear here weeks or months before journal publication, unreviewed.","summary":"Free, non-profit preprint server launched in 2019 by Cold Spring Harbor Laboratory, BMJ and Yale. Posts full-text manuscripts after a basic screen but before peer review, so findings are provisional; many oncology trial secondary analyses, epidemiology and AI studies appear here first. Indexed by Europe PMC and linked to the final published version when available.","asOf":"2026-09-09","links":[{"label":"About medRxiv","url":"https://www.medrxiv.org/about-medrxiv"},{"label":"medRxiv oncology collection","url":"https://www.medrxiv.org/collection/oncology"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Clinical preprints before peer review; the oncology collection. Access: Open (author-chosen CC licences)."],"publisher":"Cold Spring Harbor Laboratory, BMJ and Yale University","url":"https://www.medrxiv.org","scope":"preprints","access":"open-access","founded":2019,"matchNames":["medRxiv"]},{"id":"melanoma-research","kind":"journal","name":"Melanoma research","aka":["Melanoma Res"],"tldr":"A specialist journal devoted to melanoma, from tumour genetics and immunology to case reports and clinical studies of targeted and immune therapies.","summary":"Melanoma Research is published by Lippincott Williams & Wilkins, part of Wolters Kluwer, and is hosted on the Ovid journals platform. The journal page lists six issues a year under Editors-in-Chief F. J. Lejeune and W. J. Storkus and shows a mix of clinical and laboratory papers on melanoma: recent issue highlights include a case report of haemophagocytic lymphohistiocytosis and posterior reversible encephalopathy syndrome during BRAF/MEK inhibitor therapy after immune checkpoint blockade, and a study associating chemokine and chemokine receptor gene variants with multiple primary melanoma. NLM records the journal as starting in 1991 (print ISSN 0960-8931, electronic ISSN 1473-5636), published in London, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/melanomaresearch/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9109623"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["melanoma","uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Lippincott Williams & Wilkins (Wolters Kluwer)","url":"https://journals.lww.com/melanomaresearch/pages/default.aspx","issn":"0960-8931","scope":"melanoma","founded":1991,"matchNames":["Melanoma Res","Melanoma research","Melanoma Research"]},{"id":"molecular-cancer","kind":"journal","name":"Molecular cancer","aka":["Mol Cancer"],"tldr":"A large open access journal for laboratory cancer research, from tumour signalling and the microenvironment to biomarkers and new therapeutic approaches.","summary":"Molecular Cancer is an open access, peer-reviewed journal published by BMC, part of Springer Nature, with Christophe Nicot of Kansas University Medical Center as Editor-in-Chief. The journal states that it is interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science, and it runs themed article collections, for example on nanomedicine for cancer therapy, cellular senescence and cancer, immunotherapy, liquid biopsy, genome editing and phase 2 and 3 studies. DOAJ lists it with CC BY and CC BY-NC-ND licences, an article processing charge, anonymous peer review and open access content from 2002. NLM records the journal as starting in 2002, published in London, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://molecular-cancer.biomedcentral.com"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101147698"},{"label":"DOAJ record","url":"https://doaj.org/toc/1476-4598"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://molecular-cancer.biomedcentral.com","issn":"1476-4598","scope":"cancer biology","access":"open-access","founded":2002,"matchNames":["Mol Cancer","Molecular cancer","Molecular Cancer"]},{"id":"molecular-cancer-research","kind":"journal","name":"Molecular cancer research","aka":["Molecular cancer research : MCR","Mol Cancer Res","MCR"],"tldr":"The AACR's basic-science journal for discoveries about how cancer cells work: cell cycle, DNA repair, gene regulation, oncogenes and signalling.","summary":"Molecular Cancer Research is published by the American Association for Cancer Research (AACR) as one of its family of journals alongside Cancer Research, Cancer Discovery and Clinical Cancer Research, with Massimo Loda as Editor-in-Chief. The journal states that it publishes articles featuring novel, basic cancer research discoveries that prioritise broad molecular and cellular processes, with areas of emphasis including cell cycle and senescence, cell death and survival, chromatin, gene and RNA regulation, DNA damage and repair, genomics, oncogenes and tumour suppressors, and signal transduction. It also publishes Cancer Research Resources articles, editors' picks and meeting abstracts. NLM records the journal as starting in 2002, published in Philadelphia, and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://aacrjournals.org/mcr"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101150042"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/mcr","issn":"1541-7786","scope":"cancer biology","founded":2002,"matchNames":["Mol Cancer Res","Molecular cancer research","Molecular Cancer Research","MCR"],"society":"American Association for Cancer Research (AACR)"},{"id":"molecular-cancer-therapeutics","kind":"journal","name":"Molecular Cancer Therapeutics","aka":["Mol Cancer Ther","MCT"],"tldr":"AACR's preclinical therapeutics journal: where new small molecules, ADCs and combination strategies are first characterised in cells and mice.","summary":"Molecular Cancer Therapeutics (Mol Cancer Ther, MCT) is the preclinical therapeutics journal of the American Association for Cancer Research (AACR), founded in 2001, appearing monthly and published by the society on a hybrid access model. It is where new small molecules, antibody-drug conjugates and combination strategies are first characterised in cells and mice, publishing preclinical pharmacology of new agents (including many ADC payload and linker studies), mechanism-of-action and resistance work, and companion-biomarker development. Its readers are drug discovery scientists and translational pharmacologists. Within OnCo it is linked from the Antibody-drug conjugate (ADC) entry and the Eric Haura biography, and a reader would use it for the preclinical evidence behind a new agent.","asOf":"2026-09-09","links":[{"label":"AACR Journals","url":"https://aacrjournals.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":["aacr"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for Cancer Research","url":"https://aacrjournals.org/mct","issn":"1535-7163","scope":"drug discovery","access":"hybrid","founded":2001,"matchNames":["Molecular Cancer Therapeutics","Mol Cancer Ther"],"society":"American Association for Cancer Research"},{"id":"molecular-carcinogenesis","kind":"journal","name":"Molecular carcinogenesis","aka":["Mol Carcinog"],"tldr":"A Wiley laboratory journal on the molecular mechanisms by which cancers arise and progress. Read by cancer biologists and toxicologists.","summary":"Molecular Carcinogenesis is published by Wiley (John Wiley & Sons), the publisher recorded in Crossref for both its print ISSN 0899-1987 and its electronic ISSN 1098-2744. NLM catalogues the journal as starting in 1988 under the Wiley-Liss imprint in Hoboken, New Jersey, and lists it as currently indexed in MEDLINE with the abbreviation Mol Carcinog. Its title places it in the field of molecular carcinogenesis, the study of how normal cells become malignant. The journal is not listed in the Directory of Open Access Journals.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10982744"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8811105"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["risk-factor"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10982744","issn":"0899-1987","scope":"cancer biology and carcinogenesis","founded":1988,"matchNames":["Mol Carcinog","Molecular carcinogenesis","Molecular Carcinogenesis"]},{"id":"molecular-oncology","kind":"journal","name":"Molecular oncology","aka":["Mol Oncol"],"tldr":"An open access FEBS journal spanning basic, translational and clinical cancer research plus policy pieces on prevention and care. Read by cancer researchers across Europe and beyond.","summary":"Molecular Oncology is an open access journal owned by the Federation of European Biochemical Societies (FEBS) and published by Wiley as one of the FEBS Press titles, with Kevin Ryan as Editor-in-Chief. The journal describes itself as covering basic, translational and clinical cancer research as well as cancer diagnosis, prevention and care, and FEBS lists diverse article formats including research articles, reviews and policy papers, a fast-track option, and affiliate status with the European Association for Cancer Research (EACR) and the EACS. It runs an annual writing competition launched on World Cancer Day and awards prizes for posters and short talks at key meetings. DOAJ lists it with a CC BY licence, an article processing charge, open peer review and open access content from 2017. NLM records the journal as starting in 2007 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://febs.onlinelibrary.wiley.com/journal/18780261"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101308230"},{"label":"DOAJ record","url":"https://doaj.org/toc/1574-7891"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley on behalf of FEBS","url":"https://febs.onlinelibrary.wiley.com/journal/18780261","issn":"1574-7891","scope":"cancer biology and translational oncology","access":"open-access","founded":2007,"matchNames":["Mol Oncol","Molecular oncology","Molecular Oncology"],"society":"Federation of European Biochemical Societies (FEBS)"},{"id":"nar-cancer","kind":"journal","name":"NAR cancer","aka":["NAR Cancer"],"tldr":"The cancer sister journal of Nucleic Acids Research: fully open access papers on DNA, RNA and genomics in cancer, including data resource articles.","summary":"NAR Cancer is a fully open access journal published by Oxford University Press as part of the NAR journals family alongside Nucleic Acids Research, NAR Genomics and Bioinformatics and NAR Molecular Medicine, with William Dynan as Editor-in-Chief. The journal states that it publishes original research and review articles at the intersection of the nucleic acids and cancer fields, in the form of standard articles, critical reviews, perspectives and short reviews, and Cancer Data Resource articles that briefly describe a resource with a focus on factual content and methods; its editors say they are committed to rapid publication, a transparent and fair editorial process and open science. DOAJ lists it with CC BY and CC BY-NC licences, an article processing charge and open access content from 2020. NLM records the journal as starting in 2019 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/narcancer"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101769553"},{"label":"DOAJ record","url":"https://doaj.org/toc/2632-8674"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/narcancer","issn":"2632-8674","scope":"cancer genomics and nucleic acids","access":"open-access","founded":2019,"matchNames":["NAR Cancer","NAR cancer"]},{"id":"nature","kind":"journal","name":"Nature","aka":["Nature"],"tldr":"Nature is the world's leading multidisciplinary science journal. The big cancer biology discoveries land here: cancer genome atlases, tumour evolution, new drug targets and early first-in-human results.","summary":"Nature appears weekly. In cancer it publishes the discovery papers that later become drugs and tests (KRAS G12C inhibition, Ostrem 2013), large sequencing consortia (TCGA, PCAWG, TRACERx), the mRNA neoantigen vaccine and menin-inhibitor first-in-human reports, and foundational tools such as AlphaFold. Hybrid since 2021 with an open-access option; news and comment pages shape research policy debates.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Nature_(journal)","links":[{"label":"Nature cancer subject page","url":"https://www.nature.com/subjects/cancer"}],"tags":[],"related":["src-nature-briefing-cancer","pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nature/","issn":"0028-0836","scope":"general science","access":"hybrid","founded":1869,"impactFactor":{"value":50.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature"]},{"id":"nature-biotechnology","kind":"journal","name":"Nature Biotechnology","aka":["Nat Biotechnol"],"tldr":"Nature Biotechnology is the leading biotechnology journal, covering new sequencing and single-cell methods, CAR-T and gene-editing engineering, ADC and protein design, plus biotech industry analysis.","summary":"Nature Biotechnology (Nat Biotechnol) is the leading biotechnology journal, founded in 1983, appearing monthly and published by Springer Nature on a hybrid access model. It publishes methods and tools such as single-cell and spatial omics, base and prime editing and protein design, together with engineered therapeutics including next-generation CAR-T cells, bispecifics and ADCs, and its news section tracks the biotech industry and regulation. Its readers are technologists, cell and gene therapy engineers and industry watchers. Within OnCo it is linked from the Andreas Trumpp biography, and a reader would use it for new sequencing and single-cell methods and for the engineering behind cell therapies and antibody constructs.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["genomic-profiling"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nbt/","issn":"1087-0156","scope":"biotechnology","access":"hybrid","founded":1983,"matchNames":["Nature Biotechnology","Nat Biotechnol"]},{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","aka":["Nat Cancer","src-nature-cancer"],"tldr":"Nature Cancer is Nature's cancer-specific research journal, launched in 2020, spanning basic biology to translational and clinical cancer studies.","summary":"Nature Cancer (Nat Cancer) is Nature's cancer-specific research journal, launched in 2020, appearing monthly and published by Springer Nature on a hybrid access model. It spans basic biology to translational and clinical cancer studies, publishing tumour biology, immuno-oncology, computational and AI methods for cancer, and early-phase trial correlative science, with a deliberate remit to cover health-policy and access issues as well. Its readers are cancer researchers across the basic-to-clinical spectrum. Within OnCo it has its own Nature Cancer source feed and is linked from the biographies of Todd Golub and Jakob Nikolas Kather, and it is where a reader would look for computational and AI cancer methods and correlative trial science.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":["src-npj-precision-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Cancer biology and translational studies across the spectrum. Access: Paywalled."],"publisher":"Springer Nature","url":"https://www.nature.com/natcancer/","issn":"2662-1347","scope":"basic cancer biology","access":"hybrid","founded":2020,"impactFactor":{"value":23.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Cancer","Nat Cancer"]},{"id":"nature-communications","kind":"journal","name":"Nature Communications","aka":["Nat Commun"],"tldr":"Springer Nature's large fully open-access multidisciplinary journal, carrying a high volume of cancer genomics, immunology, AI and translational papers.","summary":"Nature Communications (Nat Commun) is Springer Nature's large, fully open-access multidisciplinary journal, founded in 2010, publishing under CC BY licences with peer-review files often published alongside the article. It publishes thousands of articles a year across science, and in cancer it is a major venue for genomic and single-cell studies, immunology, AI and computational methods, and secondary analyses of trial biospecimens. Its readers are researchers across disciplines who want open-access primary research. Within OnCo it is linked from the biographies of Woong-Yang Park, Robert Gatenby, Giovanni Blandino and Viktor Adalsteinsson, and a reader would use it for the high volume of cancer genomics and translational papers it carries.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/ncomms/","issn":"2041-1723","scope":"general science","access":"open-access","founded":2010,"matchNames":["Nature Communications","Nat Commun"]},{"id":"nature-genetics","kind":"journal","name":"Nature Genetics","aka":["Nat Genet"],"tldr":"Nature Genetics is the top genetics journal, publishing cancer genome-wide association studies, polygenic risk scores, cancer gene discovery and mutational-signature work.","summary":"Nature Genetics (Nat Genet) is the leading genetics journal, founded in 1992, appearing monthly and published by Springer Nature on a hybrid access model. It publishes germline cancer susceptibility genome-wide association studies and polygenic risk models, somatic driver-gene discovery and mutational-signature analyses, tumour evolution and single-cell genomics methods. Its readers are cancer geneticists and genomics researchers, and the Mutational signature entry in OnCo draws on the kind of work it publishes. Within OnCo it is linked from the biographies of Mu-Sheng Zeng, Malachi Griffith, Obi Griffith, Cheryl Willman, Christina Curtis and Rebecca Fitzgerald, and a reader would use it for cancer gene discovery, polygenic risk and mutational-signature papers.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/ng/","issn":"1061-4036","scope":"genetics","access":"hybrid","founded":1992,"impactFactor":{"value":31.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Genetics","Nat Genet"]},{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","aka":["Nat Med","src-nature-medicine"],"tldr":"Nature Medicine is Nature's clinical journal and now a top venue for early-phase and biomarker-rich cancer trials, medical AI studies and cell-therapy reports.","summary":"Nature Medicine appears monthly and publishes phase 1 and 2 trials with deep translational analysis (MagnetisMM-3 elranatamab in this corpus), circulating tumour DNA and multi-cancer early-detection studies, large medical-AI validations and consensus reporting guidelines for AI in medicine. Hybrid access with a Springer Nature open-access option.","asOf":"2026-09-09","links":[{"label":"Nature Medicine cancer","url":"https://www.nature.com/nm/research-articles?subject=cancer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Translational medicine including cancer vaccines, AI diagnostics and phase 1 to 3 trials with mechanistic depth. Access: Paywalled; abstracts free; some open access."],"publisher":"Springer Nature","url":"https://www.nature.com/nm/","issn":"1078-8956","scope":"translational medicine","access":"hybrid","founded":1995,"impactFactor":{"value":58.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Medicine","Nat Med"]},{"id":"nature-reviews-cancer","kind":"journal","name":"Nature Reviews Cancer","aka":["Nat Rev Cancer"],"tldr":"Commissioned expert reviews on cancer biology. The place to start when learning a new area of tumour biology, from metabolism to metastasis.","summary":"Nature Reviews Cancer (Nat Rev Cancer) is a monthly review-only journal from Springer Nature, founded in 2001, publishing commissioned, peer-reviewed reviews by leading groups on cancer biology, plus shorter Perspectives and Comments. It does not publish primary research; its value lies in authoritative syntheses that define fields, which makes it the place to start when learning a new area of tumour biology, from metabolism to metastasis. Access is by subscription, with some content free. Within OnCo it is linked from the biographies of Mel Greaves, Erik Sahai, Drew Pardoll, Stephen Baylin, Charles Rudin and Alan D'Andrea, and a reader would use it for an expert overview before turning to primary papers.","asOf":"2026-09-09","links":[{"label":"Nature Reviews","url":"https://www.nature.com/nrc/about"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nrc/","issn":"1474-175X","scope":"basic cancer biology","founded":2001,"impactFactor":{"value":72.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Reviews Cancer","Nat Rev Cancer"]},{"id":"nature-reviews-clinical-oncology","kind":"journal","name":"Nature Reviews Clinical Oncology","aka":["Nat Rev Clin Oncol"],"tldr":"Commissioned clinical reviews for oncologists: treatment landscapes, biomarker strategies and trial-design critique, with the highest impact factor of any oncology journal.","summary":"Nature Reviews Clinical Oncology (Nat Rev Clin Oncol) is a monthly review-only journal from Springer Nature, launched in 2004 as Nature Clinical Practice Oncology and renamed in 2009, and it holds the highest impact factor of any oncology journal. It publishes commissioned clinical reviews for oncologists on treatment landscapes, biomarker strategies and trial-design critique, including Perspectives on treatment paradigms, drug classes such as ADCs and bispecifics, trial methodology and health policy, plus Year in Review pieces. It does not carry primary trials. Within OnCo it is linked from the biographies of Klaus Pantel, Alan Ashworth, Sapna Patel, Jason Luke, Sattva Neelapu and Ignacio Melero, and a reader would use it for an authoritative summary of where a treatment field stands.","asOf":"2026-09-09","links":[{"label":"Nature Reviews","url":"https://www.nature.com/nrclinonc/about"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nrclinonc/","issn":"1759-4774","scope":"clinical oncology","founded":2004,"impactFactor":{"value":81.1,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Reviews Clinical Oncology","Nat Rev Clin Oncol"]},{"id":"nature-reviews-drug-discovery","kind":"journal","name":"Nature Reviews Drug Discovery","aka":["Nat Rev Drug Discov"],"tldr":"Nature Reviews Drug Discovery is Springer Nature's monthly review journal on how drugs are discovered and developed. Its News and Analysis pieces are the usual source for the pipeline, clinical success-rate and attrition statistics quoted about oncology development, so investors and policy analysts read it as much as scientists.","summary":"Nature Reviews Drug Discovery (Nat Rev Drug Discov) is a monthly review journal from Springer Nature, founded in 2002, covering how drugs are discovered and developed. It publishes commissioned reviews on drug targets and modalities, plus News and Analysis pieces tracking pipelines, approvals, clinical success rates and R&D costs. It is a major source for the 'probability of success' and pipeline-attrition statistics that frame oncology development, so its readers include drug developers, investors and policy analysts as well as scientists. Within OnCo it is linked from the Howard Kaufman biography, and a reader would use it for pipeline and success-rate data and for reviews of new therapeutic modalities.","asOf":"2026-09-09","links":[{"label":"Nature Reviews","url":"https://www.nature.com/nrd/about"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://www.nature.com/nrd/","issn":"1474-1776","scope":"drug discovery","founded":2002,"matchNames":["Nature Reviews Drug Discovery","Nat Rev Drug Discov"]},{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","aka":["NEJM Evid"],"tldr":"NEJM Group's newer journal for clinical trials and trial methodology, publishing rigorous randomised studies that fall just outside the parent journal's remit.","summary":"NEJM Evidence (NEJM Evid) is the NEJM Group's newer journal for clinical trials and trial methodology, appearing monthly since 2022 and published by the NEJM Group / Massachusetts Medical Society on a subscription basis with the group's editorial standards. It publishes rigorous randomised trials that fall just outside the parent journal's remit, pragmatic and adaptive designs, and methods pieces including the Stats, STAT! series and trial-design tutorials, with oncology studies on dosing, de-escalation and screening. Its readers are clinicians and trialists who care about trial design as much as results. Within OnCo it is linked from the biographies of Do-Youn Oh, Ghassan Abou-Alfa and Daniel Spratt, and a reader would use it for oncology trials on dosing and de-escalation.","asOf":"2026-09-09","links":[{"label":"NEJM Group","url":"https://www.nejmgroup.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"NEJM Group / Massachusetts Medical Society","url":"https://evidence.nejm.org","issn":"2766-5526","scope":"general medicine","access":"subscription","founded":2022,"matchNames":["NEJM Evidence","NEJM Evid"],"society":"Massachusetts Medical Society"},{"id":"neoplasia","kind":"journal","name":"Neoplasia","aka":["Neoplasia : an international journal for oncology research","Neoplasia (New York, N.Y.)"],"tldr":"An open access Elsevier journal for laboratory and translational cancer research across all tumour types, with a policy of sharing the cell lines and reagents it describes.","summary":"Neoplasia: An International Journal for Oncology Research is an open access journal published by Elsevier with A. Rehemtulla of the University of Michigan as Editor-in-Chief. The journal states that it publishes the results of novel investigations in all areas of oncology research, its title chosen to convey a breadth spanning traditional cancer research disciplines, emerging fields and interdisciplinary work; it is interested in new molecular and genetic findings on the neoplastic phenotype and in laboratory and clinical studies applying advances in basic science to risk assessment, prognosis, detection, diagnosis and treatment. Besides research reports it publishes reviews and meeting reports, and it encourages the free exchange of the clones, cell lines and biological reagents described in its pages. DOAJ lists it with CC BY, CC BY-NC and CC BY-NC-ND licences, an article processing charge, anonymous peer review and open access content from 1999. NLM records it as starting in 1999 and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/neoplasia"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100886622"},{"label":"DOAJ record","url":"https://doaj.org/toc/1522-8002"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cell-line","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/neoplasia","issn":"1522-8002","scope":"cancer research","access":"open-access","founded":1999,"matchNames":["Neoplasia","Neoplasia (New York, N.Y.)"]},{"id":"neoplasma","kind":"journal","name":"Neoplasma","aka":[],"tldr":"A Slovak English-language cancer journal, edited by the Cancer Research Institute of the Slovak Academy of Sciences, covering experimental oncology, clinical oncology and epidemiology.","summary":"Neoplasma is published in Bratislava by AEPress, s.r.o. and edited by the Cancer Research Institute of the Biomedical Research Center of the Slovak Academy of Sciences, which also sponsors it; Ján Sedlák is Editor-in-Chief. The publisher states that the journal publishes articles on experimental and clinical oncology and cancer epidemiology, appearing six times a year in English, with an online version, ahead-of-print articles and an archive back to 2003 on the publisher's ELiS platform. Its editorial and advisory boards draw on institutions in Slovakia, the Czech Republic, Poland, Croatia, Belgium, Spain, Taiwan, China and the United States. NLM records the journal as starting in 1957 (print ISSN 0028-2685, electronic ISSN 1338-4317) and currently indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.elis.sk/index.php?option=com_content&view=article&id=4:neoplasma&catid=4:journals"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/377266"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["biomedical-research-center-sas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"AEPress, s.r.o.","url":"https://www.elis.sk/index.php?option=com_content&view=article&id=4:neoplasma&catid=4:journals","issn":"0028-2685","scope":"experimental and clinical oncology","founded":1957,"matchNames":["Neoplasma"]},{"id":"neuro-oncology","kind":"journal","name":"Neuro-Oncology","aka":["Neuro Oncol"],"tldr":"Neuro-Oncology is the Society for Neuro-Oncology's journal, publishing glioma, brain metastasis and paediatric brain tumour research, response criteria and the CBTRUS statistical reports.","summary":"Publishes the annual CBTRUS statistical report on US brain tumours, the RANO response-assessment criteria, molecular classification work that feeds the WHO CNS tumour classification, and phase 2 trials in glioma. Hybrid access via Oxford University Press; the SNO annual meeting abstracts appear as a supplement.","asOf":"2026-09-09","links":[{"label":"Society for Neuro-Oncology","url":"https://www.soc-neuro-onc.org"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/neuro-oncology","issn":"1522-8517","scope":"neuro-oncology","access":"hybrid","founded":1999,"impactFactor":{"value":16.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Neuro-Oncology","Neuro Oncol","Neuro-oncology"],"society":"Society for Neuro-Oncology"},{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","aka":["NEJM","N Engl J Med","src-nejm"],"tldr":"NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.","summary":"Weekly general-medicine journal with the highest bar for randomised evidence and the largest share of practice-changing oncology phase 3 trials (IRIS imatinib, KEYNOTE-189, DESTINY-Breast04, CheckMate 067, ZUMA-1 and dozens more in this corpus). Editorials and correspondence often carry the critical reading of a trial. Paywalled, with abstracts free and many trial papers free six months after publication; requires a data-sharing statement for clinical trials under ICMJE rules.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_New_England_Journal_of_Medicine","links":[{"label":"Hematology/Oncology specialty page","url":"https://www.nejm.org/browse/specialty/hematology-oncology"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: The practice-changing phase 3 trials, most published simultaneously with ASCO, ESMO and ASH presentations. Access: Paywalled; abstracts free; many trial papers free after 6 months."],"publisher":"NEJM Group / Massachusetts Medical Society","url":"https://www.nejm.org","issn":"0028-4793","scope":"general medicine","access":"subscription","founded":1812,"impactFactor":{"value":96.2,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["NEJM","N Engl J Med","New England Journal of Medicine","The New England Journal of Medicine"],"society":"Massachusetts Medical Society"},{"id":"nutrition-and-cancer","kind":"journal","name":"Nutrition and cancer","aka":["Nutr Cancer"],"tldr":"A journal on how diet and nutrients affect cancer risk, treatment and prevention, from laboratory carcinogenesis studies to dietetics and food policy.","summary":"Nutrition and Cancer is published by Routledge, part of Taylor & Francis. The publisher describes it as reporting research on the impact of nutrition on cancer aetiology, therapy and prevention, covering topics such as carcinogenesis, dietetics and food policies. It is an Open Select (hybrid) journal, so authors may choose to publish open access while other content remains available by subscription. NLM records the journal as starting in 1978, published in Philadelphia, with print ISSN 0163-5581 and electronic ISSN 1532-7914, and currently indexed in MEDLINE; Crossref lists Informa UK (Taylor & Francis) as the publisher for both ISSNs.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/hnuc20"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7905040"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Routledge (Taylor & Francis)","url":"https://www.tandfonline.com/journals/hnuc20","issn":"0163-5581","scope":"nutrition and cancer","access":"hybrid","founded":1978,"matchNames":["Nutr Cancer","Nutrition and cancer","Nutrition and Cancer"]},{"id":"oncogene-journal","kind":"journal","name":"Oncogene","aka":["Oncogene","Oncogene reviews"],"tldr":"Oncogene is a long-running cancer biology journal from the Nature stable. It publishes molecular and cellular research on how cancers arise, spread and resist treatment, and is read mainly by laboratory cancer researchers.","summary":"Oncogene was launched in 1987 by the Scientific and Medical Division of Macmillan Press in Basingstoke and has been published by Nature Publishing Group, now Springer Nature, since the early 2000s. The journal states that it aims to make substantial advances in knowledge of the processes that contribute to cancer, with a remit that runs from fundamental cellular and molecular biology, including resistance to cancer therapies and the drivers of metastatic spread, through to translational, applied and clinical research, including early and late phase trials with biological endpoints. It appears 50 times a year and, according to the NLM Catalog, some issues each year are published under the title Oncogene reviews. Access is hybrid: the journal is sold by subscription and also offers open access publication with article fees.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.nature.com/onc/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8711562"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["metastasis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (Nature Portfolio)","url":"https://www.nature.com/onc/","issn":"0950-9232","scope":"cancer biology","access":"hybrid","founded":1987,"matchNames":["Oncogene"]},{"id":"oncoimmunology","kind":"journal","name":"Oncoimmunology","aka":["OncoImmunology","Oncoimmunology"],"tldr":"OncoImmunology is an open access journal devoted to the immune system's role in cancer and to immunotherapy. It is read by tumour immunologists and by clinicians developing immune-based treatments.","summary":"OncoImmunology began in 2012 with Landes Bioscience in Austin, Texas, and has been published by Taylor & Francis since 2015; print issues ceased after the first volume and the journal is online only. It covers cancer immunology and immunotherapy. According to the Directory of Open Access Journals the journal is fully open access, publishes under Creative Commons CC BY or CC BY-NC licences, charges an article processing fee and uses anonymous peer review, with its DOAJ-recorded open access start in 2020. The NLM Catalog lists it as bimonthly, indexed in MEDLINE and deposited in PubMed Central.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/koni"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101570526"},{"label":"DOAJ record","url":"https://doaj.org/toc/2162-402X"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis","url":"https://www.tandfonline.com/journals/koni","issn":"2162-4011","scope":"cancer immunology and immunotherapy","access":"open-access","founded":2012,"matchNames":["Oncoimmunology","OncoImmunology"]},{"id":"oncology-karger","kind":"journal","name":"Oncology","aka":["Oncology (Basel)","Oncology (Karger)","Oncologia"],"tldr":"Oncology is a Swiss clinical cancer journal from Karger that has been running since 1967. It carries clinical studies, translational research and short trial reports for oncologists.","summary":"Oncology has been published by S. Karger AG in Basel since 1967 and was earlier known under the parallel title Oncologia. The journal's stated aim is to accelerate the translation of experimental results into the clinic and back again into the laboratory. It publishes clinical studies, translational laboratory findings, invited and submitted mini-reviews, and short reports of phase 1 and phase 2 clinical trials across cancer prevention, diagnosis and treatment; the editor is Maurie Markman of Philadelphia. The NLM Catalog records eight issues a year since 2007. Karger runs the journal on a hybrid model, with subscription access and an open access publishing option.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://karger.com/ocl"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/135054"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"S. Karger AG","url":"https://karger.com/ocl","issn":"0030-2414","scope":"clinical and translational oncology","access":"hybrid","founded":1967,"matchNames":["Oncology","Oncology (Basel)"]},{"id":"oncology-williston-park","kind":"journal","name":"Oncology (Williston Park)","aka":["Oncology","ONCOLOGY","Oncology (Williston Park)"],"tldr":"ONCOLOGY, known in PubMed as Oncology (Williston Park), is an American clinical review journal for practising cancer doctors. It is now part of the CancerNetwork site run by MJH Life Sciences.","summary":"This journal started in 1987 in Williston Park, New York, published by Dominus Publishing, which is why PubMed cites it as Oncology (Williston Park) to distinguish it from the Karger journal of the same name. It later moved to MultiMedia Healthcare in Cranbury, New Jersey, and today is published by MJH Life Sciences on its CancerNetwork website, where issues of volume 40 (2026) can be read online or downloaded as PDFs. Content is organised by cancer type, including breast, lung, gastrointestinal and haematological malignancies, and is aimed at practising oncologists. The NLM Catalog records it as monthly from 1987 to 2003 and fourteen issues a year from 2004, with supplements accompanying some volumes; Crossref lists MJH Life Sciences as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.cancernetwork.com/journals/oncology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8712059"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["leukaemia-type"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"MJH Life Sciences","url":"https://www.cancernetwork.com/journals/oncology","issn":"0890-9091","scope":"clinical oncology","founded":1987,"matchNames":["Oncology (Williston Park)","Oncology (Williston Park, N.Y.)","ONCOLOGY"]},{"id":"oncology-nursing-forum","kind":"journal","name":"Oncology nursing forum","aka":["Oncol Nurs Forum","ONF","Oncology Nursing Forum"],"tldr":"The Oncology Nursing Forum is the research journal of the Oncology Nursing Society in the United States. Cancer nurses read it for studies on symptom management, care delivery and health equity.","summary":"Oncology Nursing Forum is an official publication of the Oncology Nursing Society (ONS), published from Pittsburgh, Pennsylvania. Its stated mission is to amplify oncology nursing science and support the translation of research evidence to practice and policy, with the intent of fostering health equity for individuals, families and communities affected by cancer. The NLM Catalog dates it to 1977 as the continuation of the Oncology Nursing Society newsletter. It uses a continuous publishing model with bimonthly issues (January, March, May, July, September and November); print issues ceased in 2024 and articles are posted online as they complete editing and peer review. ONS members receive the journal as a benefit of membership and non-members subscribe; the editor is Janine Overcash of Ohio State University.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.ons.org/publications-research/onf"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7809033"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oncology Nursing Society","url":"https://www.ons.org/publications-research/onf","issn":"0190-535X","scope":"oncology nursing","access":"subscription","founded":1977,"matchNames":["Oncol Nurs Forum","Oncology nursing forum","Oncology Nursing Forum"],"society":"Oncology Nursing Society"},{"id":"oncology-reports","kind":"journal","name":"Oncology reports","aka":["Oncol Rep","Oncology Reports"],"tldr":"Oncology Reports is a Greek-based monthly journal of basic and applied cancer research, with a focus on how cancers start and spread. It is read by laboratory cancer researchers.","summary":"Oncology Reports describes itself as a monthly, peer-reviewed journal devoted to high quality original studies and reviews covering fundamental and applied research in oncology, focusing on carcinogenesis, metastasis and epidemiology. It was founded in 1994 in Athens, first under the imprint of the National Hellenic Research Foundation and, since 2003, published by D. A. Spandidos as Spandidos Publications. The NLM Catalog records six issues a year until 2003 and monthly publication since 2004, with print issues ceasing after volume 44 in 2020. Articles on the journal website are labelled open access, though the journal is not listed in the Directory of Open Access Journals.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.spandidos-publications.com/or"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9422756"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["metastasis","risk-factor"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Spandidos Publications","url":"https://www.spandidos-publications.com/or","issn":"1021-335X","scope":"cancer research","founded":1994,"matchNames":["Oncol Rep","Oncology reports","Oncology Reports"]},{"id":"oncology-research","kind":"journal","name":"Oncology research","aka":["Oncol Res","Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics","Oncology Research"],"tldr":"Oncology Research is a monthly journal of basic, translational and clinical cancer research with a particular interest in new treatments. It is now published by Tech Science Press.","summary":"Oncology Research states that it is committed to publishing high quality, innovative research across the entire range of basic, translational and clinical cancer research, with a particular interest in cancer therapeutics, to support the understanding, prevention, diagnosis and treatment of cancer. It began in 1992 with Pergamon Press in New York, absorbed the journal Anti-cancer drug design, and has been published by Tech Science Press of Henderson, Nevada, since 2021; Crossref records the extended title Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. The journal is monthly and is indexed in MEDLINE and PubMed Central according to the NLM Catalog. The publisher's site presents the journal as open access, but it is not listed in the Directory of Open Access Journals.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.techscience.com/journal/or"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9208097"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["first-in-human","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Tech Science Press","url":"https://www.techscience.com/journal/or","issn":"0965-0407","scope":"cancer therapeutics research","founded":1992,"matchNames":["Oncol Res","Oncology research","Oncology Research"]},{"id":"oncology-research-and-treatment","kind":"journal","name":"Oncology research and treatment","aka":["Oncol Res Treat","Onkologie","Oncology Research and Treatment"],"tldr":"Oncology Research and Treatment is the German-speaking haematology and oncology societies' journal, published in English by Karger. Clinicians read it for clinical and translational studies across the cancer specialties.","summary":"Oncology Research and Treatment is published monthly by S. Karger AG in Basel and is affiliated with the German (DGHO), Austrian (OeGHO) and Swiss (SGH/SSH) societies for haematology and medical oncology. It took its present title in 2014 as the continuation of Onkologie. The journal describes itself as an interdisciplinary forum for cancer research and treatment, addressed to clinicians and practitioners in haematology and oncology, and publishes peer-reviewed articles on medical haematology and oncology, surgical, gynaecological, paediatric, urological and dermatological oncology, diagnostics, radiation oncology, pathology, clinical and translational research and rehabilitation, with an emphasis on clinical rather than basic research. Editors are Ralf-Dieter Hofheinz (Mannheim) and Sylvie Lorenzen (Munich). Karger runs it on a hybrid model with subscription access and an open access option.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://karger.com/ort"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101627692"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"S. Karger AG","url":"https://karger.com/ort","issn":"2296-5270","scope":"clinical haematology and oncology","access":"hybrid","founded":2014,"matchNames":["Oncol Res Treat","Oncology research and treatment","Oncology Research and Treatment"],"society":"Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO), Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie (OeGHO) and Schweizerische Gesellschaft für Hämatologie (SGH/SSH)"},{"id":"oncotarget","kind":"journal","name":"Oncotarget","aka":["Oncotarget"],"tldr":"Oncotarget is a large online cancer research journal that publishes on anything that can be viewed as a target relevant to cancer, from molecules and pathways to cell types. It is read by basic and translational cancer researchers.","summary":"Oncotarget describes itself as a primarily oncology-focused, peer-reviewed, open access journal that aims to maximise research impact through insightful peer review, to eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences, and to foster the application of basic and clinical science. The term oncotarget, introduced in the inaugural editorial, covers all molecules, pathways, cellular functions, cell types and tissues that can be viewed as targets relevant to cancer and other diseases. The journal started in 2009 and is published from Albany, New York, by Impact Journals (Rapamycin Press LLC). Since 1 January 2022 it has used a continuous publishing model, releasing papers in final form within yearly volumes. The NLM Catalog quotes its self-description as an open access impact journal and lists it in MEDLINE and PubMed Central; it is not currently listed in the Directory of Open Access Journals.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.oncotarget.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101532965"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Impact Journals (Rapamycin Press LLC)","url":"https://www.oncotarget.com/","issn":"1949-2553","scope":"cancer research and oncology targets","founded":2009,"matchNames":["Oncotarget"]},{"id":"oral-oncology","kind":"journal","name":"Oral oncology","aka":["Oral Oncol","Oral Oncology","European journal of cancer. Part B, Oral oncology"],"tldr":"Oral Oncology is Elsevier's monthly journal on cancers of the mouth, throat and head and neck region. It is read by head and neck surgeons, oncologists and oral pathologists.","summary":"Oral Oncology started in 1997 as the successor to European Journal of Cancer Part B, Oral Oncology, and the NLM Catalog notes that it is described as an EJC publication. It was first issued by Pergamon in Oxford and New York and is now published by Elsevier in Amsterdam; Crossref lists Elsevier as publisher. The NLM record shows publication frequency rising from bimonthly (1997 to 2000) to eight issues a year (2001 to 2003), ten a year (2004 to 2007) and monthly since 2008, with a supplement series and an online companion, Oral Oncology Extra, published between 2004 and 2006. The journal is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/oral-oncology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9709118"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/oral-oncology","issn":"1368-8375","scope":"head and neck oncology","founded":1997,"matchNames":["Oral Oncol","Oral oncology","Oral Oncology"]},{"id":"pathology-and-oncology-research","kind":"journal","name":"Pathology oncology research","aka":["Pathology oncology research : POR","Pathology & Oncology Research","Pathology and Oncology Research","POR","Pathol Oncol Res"],"tldr":"Pathology and Oncology Research (POR) is a Hungarian-founded, fully open access journal spanning tumour pathology, molecular diagnostics and clinical oncology. It is read by pathologists and experimental and clinical oncologists.","summary":"Pathology and Oncology Research (POR) was established in 1995 in Budapest by its founding editors László Kopper, Judit Nagy, Zsolt Orosz and József Tímár, and has carried the title Pathology & Oncology Research since 1998. Since 2021 it has been published by Frontiers Media SA in Lausanne and is supported by the Arányi Foundation for Modern Pathology. The journal welcomes work on the understanding, diagnosis, classification, prognosis and treatment of neoplasms, including tumour biology and mechanisms of progression, tumour pathology and molecular diagnostics, clinical and translational oncology, and digital pathology and artificial intelligence; purely computational studies without validation are not considered. POR provides gold open access under the Creative Commons Attribution (CC BY) licence with authors retaining copyright; DOAJ records an article processing charge and anonymous peer review. The NLM Catalog lists it as quarterly.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.por-journal.com/journals/pathology-and-oncology-research"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9706087"},{"label":"DOAJ record","url":"https://doaj.org/toc/1532-2807"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["histology","progression"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Frontiers Media SA","url":"https://www.por-journal.com/journals/pathology-and-oncology-research","issn":"1219-4956","scope":"pathology and oncology","access":"open-access","founded":1995,"matchNames":["Pathol Oncol Res","Pathology oncology research","Pathology and Oncology Research","Pathology & Oncology Research"]},{"id":"pediatric-blood-and-cancer","kind":"journal","name":"Pediatric Blood & Cancer","aka":["Pediatr Blood Cancer"],"tldr":"Pediatric Blood & Cancer is the joint ASPHO and SIOP journal for childhood cancer and blood disorders, publishing cooperative-group trial reports, late effects and supportive care.","summary":"Pediatric Blood & Cancer appears monthly and publishes Children's Oncology Group and SIOP trial analyses, survivorship and late-effects cohorts, supportive-care guidelines and global paediatric oncology research. Formed in 2004 from Medical and Pediatric Oncology and the Journal of Pediatric Hematology/Oncology lineage. Hybrid access via Wiley.","asOf":"2026-09-09","links":[{"label":"SIOP","url":"https://siop-online.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["late-effects","palliative-treatment"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/15455017","issn":"1545-5009","scope":"paediatric oncology","access":"hybrid","founded":2004,"matchNames":["Pediatric Blood & Cancer","Pediatric Blood and Cancer","Pediatr Blood Cancer"],"society":"American Society of Pediatric Hematology/Oncology; International Society of Paediatric Oncology"},{"id":"pediatric-hematology-and-oncology","kind":"journal","name":"Pediatric hematology and oncology","aka":["Pediatr Hematol Oncol","Pediatric hematology-oncology","Pediatric Hematology and Oncology"],"tldr":"Pediatric Hematology and Oncology is a Taylor & Francis journal on blood disorders and cancers in children. It is read by paediatric oncologists and haematologists.","summary":"Pediatric Hematology and Oncology began in 1986 with Hemisphere Publishing in Washington, DC, moved to Informa Healthcare in London in 2006, and is now published by Taylor & Francis (Informa UK), which Crossref lists as publisher. The NLM Catalog records that the online version carries the title Pediatric hematology-oncology, that frequency rose from quarterly (1986 to 1993) through bimonthly to eight issues a year, and that the online and print frequencies differ. Related titles noted by NLM include European paediatric haematology and oncology and the International journal of pediatric hematology/oncology. The journal is indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.tandfonline.com/journals/ipho20"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8700164"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Taylor & Francis (Informa UK)","url":"https://www.tandfonline.com/journals/ipho20","issn":"0888-0018","scope":"paediatric haematology and oncology","founded":1986,"matchNames":["Pediatr Hematol Oncol","Pediatric hematology and oncology","Pediatric Hematology and Oncology"]},{"id":"pigment-cell-and-melanoma-research","kind":"journal","name":"Pigment cell & melanoma research","aka":["Pigment Cell Melanoma Res","Pigment Cell & Melanoma Research","Pigment Cell and Melanoma Research","Pigment cell research"],"tldr":"Pigment Cell & Melanoma Research is a Wiley journal covering the biology of pigment cells and melanoma. Its readers are melanoma researchers, dermatologists and pigment cell biologists.","summary":"Pigment Cell & Melanoma Research has been published since 2008 as the continuation of Pigment Cell Research, first under the Blackwell Munksgaard imprint in Oxford and now by Wiley, which Crossref lists as publisher. The NLM Catalog records it as bimonthly, issued in print and online, and indexed in MEDLINE. As the title indicates, the journal covers pigment cell biology and melanoma, bringing together laboratory and clinical work on melanocytes and pigmentation disorders alongside melanoma research.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/1755148x"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101318927"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/1755148x","issn":"1755-1471","scope":"melanoma and pigment cell biology","founded":2008,"matchNames":["Pigment Cell Melanoma Res","Pigment cell & melanoma research","Pigment Cell & Melanoma Research","Pigment Cell and Melanoma Research"]},{"id":"plos-medicine","kind":"journal","name":"PLOS Medicine","aka":["PLoS Med"],"tldr":"A fully open-access general medical journal that favours studies with global public-health impact, including cancer epidemiology, screening and health-policy work.","summary":"Publishes under CC BY with a mandatory data-availability policy, so cancer epidemiology, risk-prediction and health-system studies here come with the underlying data. Less clinical-trial-heavy than NEJM or Lancet; strong on low- and middle-income-country cancer burden, alcohol and obesity attributable fractions, and research-integrity commentary.","asOf":"2026-09-09","links":[{"label":"PLOS Medicine cancer (page moved; nearest live section)","url":"https://journals.plos.org/plosmedicine/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["risk-factor"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Public Library of Science","url":"https://journals.plos.org/plosmedicine/","issn":"1549-1277","scope":"general medicine","access":"open-access","founded":2004,"matchNames":["PLOS Medicine","PLoS Medicine","PLoS Med"]},{"id":"practical-radiation-oncology","kind":"journal","name":"Practical radiation oncology","aka":["Pract Radiat Oncol","PRO","Practical Radiation Oncology"],"tldr":"Practical Radiation Oncology is a clinically oriented radiotherapy journal published by Elsevier. Radiation oncologists read it for guidance on day-to-day treatment practice and quality.","summary":"Practical Radiation Oncology started in 2011 and is published by Elsevier in New York; Crossref lists Elsevier as publisher. The NLM Catalog records it as quarterly from 2011 to 2013 and bimonthly since 2014, issued in print and online and indexed in MEDLINE. NLM also notes that it is complemented by two sister radiation oncology journals, the International Journal of Radiation Oncology, Biology, Physics and Advances in Radiation Oncology. The journal's focus, as its title states, is on the practical clinical side of radiation oncology.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.practicalradonc.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101558279"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.practicalradonc.org/","issn":"1879-8500","scope":"radiation oncology","founded":2011,"matchNames":["Pract Radiat Oncol","Practical radiation oncology","Practical Radiation Oncology"]},{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","aka":["PNAS","Proc Natl Acad Sci U S A"],"tldr":"PNAS is the US National Academy of Sciences' weekly multidisciplinary journal, free to read six months after publication. Its cancer landmarks include the early oncogene and tumour-suppressor papers, the first PROTAC concept paper and the Iwai and Honjo paper showing that tumours use PD-L1 to escape T cells.","summary":"The Proceedings of the National Academy of Sciences (PNAS) is the multidisciplinary journal of the US National Academy of Sciences, founded in 1915, appearing weekly and available on a hybrid model with free access after six months. It publishes across all sciences, and its cancer landmarks include early oncogene, tumour-suppressor and cancer-evolution modelling papers, mutational-signature methods, and statistical work on cancer risk and screening. Its readers are scientists of every discipline, which is why foundational cancer biology often appeared here. Within OnCo it is the journal of the first PROTAC concept paper and of the Iwai and Honjo paper showing that tumours use PD-L1 to escape T cells, and a reader would use it for foundational cancer biology and modelling work.","asOf":"2026-09-09","links":[{"label":"National Academy of Sciences","url":"https://www.nasonline.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["tumour-suppressor-gene"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"National Academy of Sciences","url":"https://www.pnas.org","issn":"0027-8424","scope":"general science","access":"hybrid","founded":1915,"impactFactor":{"value":9.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["PNAS","Proceedings of the National Academy of Sciences","Proceedings of the National Academy of Sciences of the United States of America","Proc Natl Acad Sci U S A"],"society":"National Academy of Sciences"},{"id":"prostate-cancer-and-prostatic-diseases","kind":"journal","name":"Prostate cancer and prostatic diseases","aka":["Prostate Cancer Prostatic Dis","Prostate Cancer and Prostatic Diseases"],"tldr":"Prostate Cancer and Prostatic Diseases is a Nature-family journal covering prostate cancer together with benign prostate conditions. Urologists, oncologists and prostate researchers read it.","summary":"Prostate Cancer and Prostatic Diseases was launched in 1997 by Stockton Press in Basingstoke and has been published by Nature Publishing Group, now Springer Nature, since the early 2000s. The journal states that it covers all aspects of prostatic diseases, in particular prostate cancer, along with male lower urinary tract symptoms and prostatitis, and reports developments in diagnosis, surgery, radiotherapy, drug discovery and medical management. It publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and books, with a fast track for topical articles, and says it is of interest to surgeons, oncologists and clinicians treating patients as well as prostate researchers. The NLM Catalog records four issues a year since 2001. Access is hybrid: subscription with funder-compliant open access options.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.nature.com/pcan/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9815755"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (Nature Portfolio)","url":"https://www.nature.com/pcan/","issn":"1365-7852","scope":"prostate cancer","access":"hybrid","founded":1997,"matchNames":["Prostate Cancer Prostatic Dis","Prostate cancer and prostatic diseases","Prostate Cancer and Prostatic Diseases"]},{"id":"psycho-oncology-journal","kind":"journal","name":"Psycho-oncology","aka":["Psychooncology","Psycho-Oncology"],"tldr":"Psycho-Oncology is the main journal for research on the psychological, social and behavioural side of cancer. Psychologists, nurses, social workers and oncologists read it.","summary":"Psycho-Oncology has been published by Wiley in Chichester since 1992; Crossref lists John Wiley & Sons as publisher. The NLM Catalog shows its frequency growing from four issues a year until 1997, to six (1998 to 2002), eight (2003) and twelve a year since 2004, with print issues ceasing after volume 21 in 2012 so that it is now online only. It is indexed in MEDLINE. The journal covers the psychological, social and behavioural dimensions of cancer, from distress and coping to survivorship and end of life care.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/10991611"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9214524"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/10991611","issn":"1057-9249","scope":"psycho-oncology","founded":1992,"matchNames":["Psychooncology","Psycho-oncology","Psycho-Oncology"]},{"id":"radiation-and-environmental-biophysics","kind":"journal","name":"Radiation and environmental biophysics","aka":["Radiat Environ Biophys","Biophysik","Radiation and Environmental Biophysics"],"tldr":"Radiation and Environmental Biophysics is a German-based Springer journal on the biological effects of radiation and environmental agents. Radiation biologists, dosimetrists and epidemiologists of radiation-induced cancer read it.","summary":"Radiation and Environmental Biophysics has been published by Springer-Verlag in Berlin and New York since 1974, when it continued the earlier journal Biophysik; Crossref lists Springer-Verlag as publisher. The NLM Catalog records it as quarterly, issued in print and online, indexed in MEDLINE, with articles in English or German. Its subject area, as the title states, is the biophysics of radiation and environmental exposures, including their biological effects, a topic that underpins radiation protection and the study of radiation-induced cancers.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/411"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/415677"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["secondary-malignancy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer (Springer-Verlag)","url":"https://link.springer.com/journal/411","issn":"0301-634X","scope":"radiation biology and biophysics","founded":1974,"matchNames":["Radiat Environ Biophys","Radiation and environmental biophysics","Radiation and Environmental Biophysics"]},{"id":"radiation-oncology","kind":"journal","name":"Radiation oncology","aka":["Radiat Oncol","Radiation Oncology (London)","Radiation Oncology"],"tldr":"Radiation Oncology is a fully open access radiotherapy journal from BMC. Radiation oncologists and medical physicists read it for clinical and technical studies on radiation treatment.","summary":"Radiation Oncology is an online-only, fully open access journal launched in 2006 by BioMed Central in London, now part of Springer Nature; the NLM Catalog notes that articles are added consecutively to the current annual volume and that the journal is indexed in MEDLINE and deposited in PubMed Central. According to the Directory of Open Access Journals it has been open access since its start in 2006, publishes under Creative Commons CC BY or CC BY-NC-ND licences, charges an article processing fee and uses anonymous peer review; DOAJ classifies it under medical radiology and oncology. It covers clinical and translational radiation oncology, radiotherapy techniques and medical physics.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://ro-journal.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101265111"},{"label":"DOAJ record","url":"https://doaj.org/toc/1748-717X"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://ro-journal.biomedcentral.com/","issn":"1748-717X","scope":"radiation oncology","access":"open-access","founded":2006,"matchNames":["Radiat Oncol","Radiation oncology","Radiation Oncology","Radiation Oncology (London, England)"]},{"id":"radiology","kind":"journal","name":"Radiology","aka":["Radiology (RSNA)"],"tldr":"Radiology is the RSNA's flagship journal, publishing imaging research including cancer screening performance, AI image analysis and response assessment.","summary":"Radiology appears monthly. In oncology it publishes mammography and lung CT screening performance studies, AI reader studies, contrast and radiation-dose research and imaging-based response and prognosis work. Hybrid access via RSNA; sister titles include Radiology: Artificial Intelligence and Radiology: Imaging Cancer.","asOf":"2026-09-09","links":[{"label":"RSNA","url":"https://www.rsna.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["screening"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Radiological Society of North America","url":"https://pubs.rsna.org/journal/radiology","issn":"0033-8419","scope":"radiology","access":"hybrid","founded":1923,"matchNames":["Radiology"],"society":"Radiological Society of North America"},{"id":"radiology-and-oncology","kind":"journal","name":"Radiology and oncology","aka":["Radiol Oncol","Radiology and Oncology","Radiologia Iugoslavica"],"tldr":"Radiology and Oncology is a Slovenian open access journal covering cancer imaging, interventional radiology, nuclear medicine, radiotherapy and clinical and experimental oncology. It is read by radiologists and oncologists, particularly in central and south-east Europe.","summary":"Radiology and Oncology is the journal of the Association of Radiology and Oncology in Ljubljana, Slovenia, and is distributed on the Sciendo (De Gruyter) platform. It began in 1992 as the continuation of Radiologia Iugoslavica, first issued by the Slovenian Medical Society's Section of Radiology together with the Croatian Society of Radiology. The journal describes itself as multidisciplinary, publishing original scientific papers and review articles on oncologic imaging, interventional radiology, nuclear medicine, radiotherapy, clinical and experimental oncology, radiobiology, medical physics and radiation protection; case reports are not accepted. It is quarterly, provides immediate open access under the Creative Commons CC BY 4.0 licence with authors retaining copyright, charges an article processing fee of 1500 EUR plus VAT, and is subsidised by the Slovenian Research and Innovation Agency (ARIS). It is listed in DOAJ and indexed in MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.radioloncol.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9317213"},{"label":"DOAJ record","url":"https://doaj.org/toc/1581-3207"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Association of Radiology and Oncology (Ljubljana), on the Sciendo platform","url":"https://www.radioloncol.com/","issn":"1318-2099","scope":"radiology and oncology","access":"open-access","founded":1992,"matchNames":["Radiol Oncol","Radiology and oncology","Radiology and Oncology"],"society":"Association of Radiology and Oncology"},{"id":"radiology-imaging-cancer","kind":"journal","name":"Radiology. Imaging cancer","aka":["Radiology: Imaging Cancer","Radiol Imaging Cancer"],"tldr":"Radiology: Imaging Cancer is the Radiological Society of North America's journal dedicated to imaging in cancer. Radiologists and oncologists read it for work on detection, staging and response assessment.","summary":"Radiology: Imaging Cancer was launched in 2019 by the Radiological Society of North America (RSNA) in Oak Brook, Illinois, as a subject-focused companion to the society's flagship journal Radiology and to Radiology: Artificial Intelligence, according to the NLM Catalog. It is bimonthly, indexed in MEDLINE and deposited in PubMed Central; Crossref lists RSNA as publisher. As the title indicates, the journal concentrates on the use of imaging in cancer, from detection and characterisation to staging and treatment response.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://pubs.rsna.org/journal/radiology-ic"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101765309"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Radiological Society of North America","url":"https://pubs.rsna.org/journal/radiology-ic","issn":"2638-616X","scope":"cancer imaging","founded":2019,"matchNames":["Radiol Imaging Cancer","Radiology. Imaging cancer","Radiology: Imaging Cancer"],"society":"Radiological Society of North America"},{"id":"radiotherapy-and-oncology","kind":"journal","name":"Radiotherapy and Oncology","aka":["Radiother Oncol","The Green Journal"],"tldr":"ESTRO's journal, known as the Green Journal: European radiotherapy trials, contouring guidelines, physics and the evidence base for hypofractionation and proton therapy.","summary":"Radiotherapy and Oncology (Radiother Oncol), known as the Green Journal, is the journal of the European Society for Radiotherapy and Oncology (ESTRO), founded in 1983 and published by Elsevier on a hybrid access model. It publishes ESTRO consensus contouring guidelines, randomised radiotherapy trials, normal-tissue toxicity modelling, adaptive and image-guided radiotherapy studies, physics and health-economic analyses of radiotherapy access in Europe, and the evidence base for hypofractionation and proton therapy. Its readers are radiation oncologists, medical physicists and trialists. Within OnCo it is linked from the FLASH radiotherapy entry and the Jens Overgaard and Jean Bourhis biographies, and it is the place to look for European radiotherapy trials and contouring consensus.","asOf":"2026-09-09","links":[{"label":"ESTRO","url":"https://www.estro.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["flash-rt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thegreenjournal.com","issn":"0167-8140","scope":"radiation oncology","access":"hybrid","founded":1983,"matchNames":["Radiotherapy and Oncology","Radiother Oncol"],"society":"European Society for Radiotherapy and Oncology"},{"id":"recent-patents-on-anti-cancer-drug-discovery","kind":"journal","name":"Recent patents on anti-cancer drug discovery","aka":["Recent Pat Anticancer Drug Discov","Recent Patents on Anti-Cancer Drug Discovery"],"tldr":"Recent Patents on Anti-Cancer Drug Discovery is a Bentham Science review journal that tracks patented advances in cancer drug development. It is read by medicinal chemists and pharmacologists working on new cancer treatments.","summary":"Recent Patents on Anti-Cancer Drug Discovery has been published since 2006 by Bentham Science Publishers, with imprints in Sharjah, United Arab Emirates, and San Francisco; Crossref lists Bentham Science Publishers Ltd as publisher. The NLM Catalog records it as issued four times a year since 2016, in print and online, and indexed in MEDLINE. As its title states, the journal reviews recent patents and patent-related developments in anticancer drug discovery, covering new chemical entities, targets, formulations and delivery methods.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.benthamscience.com/journal/38"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101266081"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Bentham Science Publishers","url":"https://www.benthamscience.com/journal/38","issn":"1574-8928","scope":"anticancer drug discovery and patents","founded":2006,"matchNames":["Recent Pat Anticancer Drug Discov","Recent patents on anti-cancer drug discovery","Recent Patents on Anti-Cancer Drug Discovery"]},{"id":"recent-results-in-cancer-research","kind":"journal","name":"Recent results in cancer research","aka":["Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer","Recent Results Cancer Res","Fortschritte der Krebsforschung","Recent Results in Cancer Research"],"tldr":"Recent Results in Cancer Research is a Springer book series, indexed like a journal, in which each volume is a monograph or edited collection on one cancer topic. Clinicians and researchers use it for in-depth reviews.","summary":"Recent Results in Cancer Research, also carrying the parallel titles Fortschritte der Krebsforschung and Progrès dans les recherches sur le cancer, has been published by Springer in Berlin since 1965. The NLM Catalog treats it as a serial, indexed in MEDLINE, but records that it appears irregularly and that each volume has its own distinctive title, reflecting its nature as a book series of monographs and edited volumes on single cancer topics; text is in English or French, and the founding editors were listed as P. Rentchnick and colleagues. Springer hosts the series on its SpringerLink platform.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/bookseries/392"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/44671"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer","url":"https://link.springer.com/bookseries/392","issn":"0080-0015","scope":"cancer research monographs","founded":1965,"matchNames":["Recent Results Cancer Res","Recent results in cancer research","Recent Results in Cancer Research"]},{"id":"science","kind":"journal","name":"Science","aka":["Science (AAAS)"],"tldr":"Science is the AAAS flagship and Nature's main rival. It is home to landmark cancer papers on mismatch repair and immunotherapy, cancer genome sequencing, liquid biopsy and the microbiome.","summary":"Science is a weekly multidisciplinary journal. Cancer landmarks include the Vogelstein group's tumour sequencing and CancerSEEK papers, the mismatch-repair deficiency and PD-1 tumour-agnostic work, gut microbiome and immunotherapy response studies, and the ecDNA and chromothripsis discoveries. Subscription with free access after 12 months and a green open-access policy; Science Translational Medicine and Science Immunology are sister titles.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Science_(journal)","links":[{"label":"Science cancer collection","url":"https://www.science.org/topic/category/cancer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for the Advancement of Science","url":"https://www.science.org/journal/science","issn":"0036-8075","scope":"general science","access":"subscription","founded":1880,"impactFactor":{"value":44.7,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Science"],"society":"American Association for the Advancement of Science"},{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","aka":["Sci Transl Med"],"tldr":"Science Translational Medicine is AAAS's translational journal, publishing the bench-to-bedside cancer papers on liquid biopsy, CAR-T engineering, tumour-immune biology and new imaging agents.","summary":"Science Translational Medicine (Sci Transl Med) is the translational journal of the American Association for the Advancement of Science (AAAS), founded in 2009, appearing weekly and available by subscription with delayed free access. It publishes bench-to-bedside studies with strong mechanistic grounding, including early circulating tumour DNA detection methods, CAR-T design and toxicity work, tumour-immune biology and PET tracer development. Its readers are translational researchers moving discoveries toward the clinic. Within OnCo it is linked from the biographies of Lecia Sequist, Jeanne Tie, Michel Sadelain, Marcela Maus, Marie-Catherine Vozenin and Constance Lehman, and a reader would use it for the liquid biopsy, CAR-T and imaging papers that precede trials.","asOf":"2026-09-09","links":[{"label":"Science journals","url":"https://www.science.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"American Association for the Advancement of Science","url":"https://www.science.org/journal/stm","issn":"1946-6234","scope":"translational medicine","founded":2009,"matchNames":["Science Translational Medicine","Sci Transl Med"],"society":"American Association for the Advancement of Science"},{"id":"seminars-in-cancer-biology","kind":"journal","name":"Seminars in cancer biology","aka":["Semin Cancer Biol","Seminars in Cancer Biology"],"tldr":"Seminars in Cancer Biology is an Elsevier review journal in which each issue is a themed collection of expert reviews on one area of cancer biology. Cancer researchers use it to get up to speed on a field.","summary":"Seminars in Cancer Biology began in 1990 with Saunders Scientific Publications (W. B. Saunders) in Philadelphia and is now published by Elsevier under its Academic Press imprint in London; Crossref lists Elsevier as publisher. The NLM Catalog records it as bimonthly, in print and online, indexed in MEDLINE, and notes that each issue also has a distinctive title, reflecting the journal's format of thematic issues made up of invited reviews on a single topic in cancer biology.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/seminars-in-cancer-biology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9010218"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier (Academic Press)","url":"https://www.sciencedirect.com/journal/seminars-in-cancer-biology","issn":"1044-579X","scope":"cancer biology reviews","founded":1990,"matchNames":["Semin Cancer Biol","Seminars in cancer biology","Seminars in Cancer Biology"]},{"id":"seminars-in-oncology","kind":"journal","name":"Seminars in oncology","aka":["Semin Oncol","Seminars in Oncology"],"tldr":"Seminars in Oncology is a long-established American review journal that publishes themed issues on clinical cancer topics. Oncologists read it for expert overviews of treatment areas.","summary":"Seminars in Oncology has been published since 1974, first by Grune & Stratton in New York and later by W. B. Saunders in Philadelphia, and today by Elsevier; Crossref lists Elsevier (W. B. Saunders) as publisher. The NLM Catalog records it as quarterly from 1974 to 1987 and bimonthly since, issued in print and online and indexed in MEDLINE. The journal follows the Seminars format of issues devoted to reviews on a chosen clinical oncology theme.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/seminars-in-oncology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/420432"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier (W. B. Saunders)","url":"https://www.sciencedirect.com/journal/seminars-in-oncology","issn":"0093-7754","scope":"clinical oncology reviews","founded":1974,"matchNames":["Semin Oncol","Seminars in oncology","Seminars in Oncology"]},{"id":"seminars-in-oncology-nursing","kind":"journal","name":"Seminars in oncology nursing","aka":["Semin Oncol Nurs","Seminars in Oncology Nursing"],"tldr":"Seminars in Oncology Nursing is an Elsevier review journal for cancer nurses. Each issue gathers articles on one theme in the nursing care of people with cancer.","summary":"Seminars in Oncology Nursing is published by Elsevier (Crossref and the NLM Catalog both list Elsevier as the current publisher; the journal was launched in 1985 by Grune and Stratton and the publisher has changed over time). The NLM Catalog records it as a United States serial, bimonthly since 2019, indexed for MEDLINE under the subject heading Oncology Nursing, and issued in print and online.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/seminars-in-oncology-nursing"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8504688"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/seminars-in-oncology-nursing","issn":"0749-2081","scope":"oncology nursing","founded":1985,"matchNames":["Semin Oncol Nurs","Seminars in oncology nursing","Seminars in Oncology Nursing"]},{"id":"seminars-in-radiation-oncology","kind":"journal","name":"Seminars in radiation oncology","aka":["Semin Radiat Oncol","Seminars in Radiation Oncology"],"tldr":"Seminars in Radiation Oncology is a quarterly Elsevier review journal for radiation oncologists, medical physicists and radiobiologists. Every issue is devoted to a single topic.","summary":"Seminars in Radiation Oncology started in October 1991 under the W.B. Saunders imprint in Philadelphia and is now published by Elsevier (Crossref publisher record). The NLM Catalog lists it as a quarterly United States serial, indexed for MEDLINE under Neoplasms/radiotherapy, and notes that each issue also carries its own distinctive title, reflecting the themed-issue format. It is issued in print and online.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/seminars-in-radiation-oncology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9202882"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/seminars-in-radiation-oncology","issn":"1053-4296","scope":"radiation oncology","founded":1991,"matchNames":["Semin Radiat Oncol","Seminars in radiation oncology","Seminars in Radiation Oncology"]},{"id":"strahlentherapie-und-onkologie","kind":"journal","name":"Strahlentherapie und Onkologie","aka":["Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]","Strahlenther Onkol","Journal of Radiation Oncology, Biology, Physics"],"tldr":"Strahlentherapie und Onkologie is the German radiation oncology journal, now published in English by Springer. It carries original research, reviews and society communications for radiation oncologists, radiobiologists and physicists.","summary":"Strahlentherapie und Onkologie describes itself as a monthly scientific journal covering all aspects of oncology with a focus on radio-oncology, radiation biology and radiation physics. It publishes peer-reviewed original articles, review articles, case studies and short communications, plus an annotated literature review. Founded in 1912, it calls itself the oldest oncological journal in the world; the current title dates from 1986 (NLM Catalog) and contributions are now published in English. It is the official publication of several radio-oncological societies (the NLM title names the Deutsche Röntgengesellschaft). Springer Nature Link lists the publishing model as hybrid; Crossref lists Springer-Verlag as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/66"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8603469"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (Springer Medizin)","url":"https://link.springer.com/journal/66","issn":"0179-7158","scope":"radiation oncology","access":"hybrid","founded":1986,"matchNames":["Strahlenther Onkol","Strahlentherapie und Onkologie"],"society":"Deutsche Röntgengesellschaft and other radiation oncology societies"},{"id":"supportive-care-in-cancer","kind":"journal","name":"Supportive care in cancer","aka":["Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer","Support Care Cancer","Supportive Care in Cancer","SCC"],"tldr":"Supportive Care in Cancer is the MASCC journal on managing symptoms and side effects across the cancer journey. It is read by oncologists, nurses, palliative care teams and researchers.","summary":"Supportive Care in Cancer is the official journal of the Multinational Association of Supportive Care in Cancer (MASCC), published by Springer (Crossref: Springer-Verlag). Its aims and scope page says it provides MASCC members and others with the most recent scientific and social information on all aspects of supportive care, covering the physical, psychosocial and spiritual aspects of the patient journey from diagnosis to end-of-life care, with a focus on interventions to mitigate symptoms and side effects. It publishes original research, reviews and clinical guidance; it does not normally accept unmet-needs papers, pilot or feasibility studies, instrument development studies or case studies. The journal began in January 1993 and, per the NLM Catalog, has appeared twelve times a year since 2003. Springer lists the publishing model as hybrid.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/520"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9302957"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature","url":"https://link.springer.com/journal/520","issn":"0941-4355","scope":"supportive care in cancer","access":"hybrid","founded":1993,"matchNames":["Support Care Cancer","Supportive care in cancer","Supportive Care in Cancer"],"society":"Multinational Association of Supportive Care in Cancer (MASCC)"},{"id":"surgical-oncology","kind":"journal","name":"Surgical oncology","aka":["Surg Oncol","Surgical Oncology"],"tldr":"Surgical Oncology is an Elsevier journal of cancer surgery research, read by surgical oncologists and the multidisciplinary teams they work with.","summary":"Surgical Oncology began in February 1992 (first published by Blackwell Scientific Publications in Oxford and Boston) and is now published by Elsevier from Amsterdam, which is the publisher recorded by both Crossref and the NLM Catalog. NLM lists it as a Netherlands serial, quarterly since about 1999, indexed for MEDLINE under Neoplasms/surgery, and available online as well as in print.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/surgical-oncology"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9208188"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/surgical-oncology","issn":"0960-7404","scope":"surgical oncology","founded":1992,"matchNames":["Surg Oncol","Surgical oncology","Surgical Oncology"]},{"id":"surgical-oncology-clinics-of-north-america","kind":"journal","name":"Surgical oncology clinics of North America","aka":["Surg Oncol Clin N Am","Surgical Oncology Clinics of North America","Surgical oncology clinics"],"tldr":"Surgical Oncology Clinics of North America is one of Elsevier's Clinics review series. Each quarterly issue is a guest-edited set of reviews on one surgical oncology topic.","summary":"Surgical Oncology Clinics of North America is part of the Clinics series published by Elsevier (Crossref publisher record); it began in July 1992 under the Saunders imprint in Philadelphia. The NLM Catalog lists it as a quarterly United States serial, indexed for MEDLINE under Neoplasms/surgery, and notes that each issue also has a distinctive title, reflecting the single-topic issue format of the Clinics series. It is issued in print and online. The theclinics.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.surgonc.theclinics.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9211789"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.surgonc.theclinics.com/","issn":"1055-3207","scope":"surgical oncology","founded":1992,"matchNames":["Surg Oncol Clin N Am","Surgical oncology clinics of North America","Surgical Oncology Clinics of North America"]},{"id":"targeted-oncology","kind":"journal","name":"Targeted oncology","aka":["Target Oncol","Targeted Oncology"],"tldr":"Targeted Oncology is a Springer (Adis) journal about drugs aimed at specific molecular targets, including checkpoint inhibitors. It is read by oncologists and pharmacologists following new agents and pathways.","summary":"Targeted Oncology, launched in January 2006 by Springer-Verlag France in Paris (NLM Catalog) and published today by Springer (Crossref), addresses physicians and scientists with a programme of articles on molecularly targeted pharmacotherapy in oncology. Its aims and scope page lists original research on molecularly targeted agents including immune checkpoint inhibitors, narrative reviews and shorter leading articles on established and emerging agents and pathways, current opinion pieces, Therapy in Practice guides, PRISMA-based systematic reviews, and Adis Drug Reviews of targeted drugs. Springer Nature Link lists the publishing model as hybrid. NLM records it as quarterly and indexed for MEDLINE.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://link.springer.com/journal/11523"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101270595"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["immune-checkpoint","checkpoint-inhibitor","targeted-therapy-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Springer Nature (Adis)","url":"https://link.springer.com/journal/11523","issn":"1776-2596","scope":"molecularly targeted cancer therapy","access":"hybrid","founded":2006,"matchNames":["Target Oncol","Targeted oncology","Targeted Oncology"]},{"id":"technology-in-cancer-research-and-treatment","kind":"journal","name":"Technology in cancer research & treatment","aka":["Technol Cancer Res Treat","Technology in Cancer Research & Treatment","Technology in cancer research and treatment","TCRT"],"tldr":"Technology in Cancer Research and Treatment is an open access SAGE journal on technologies used to diagnose and treat cancer, from imaging and radiotherapy physics to computational methods.","summary":"Technology in Cancer Research and Treatment began in February 2002 with Adenine Press in Schenectady, New York, and has been published by SAGE since 2015 (NLM Catalog; Crossref lists SAGE Publications). NLM indexes it for MEDLINE under Biomedical Technology, Neoplasms/therapy and Research, and records it as bimonthly. DOAJ lists the journal as fully open access since 2018 with articles under CC BY or CC BY-NC licences, an article processing charge, and double anonymous peer review.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/tct"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101140941"},{"label":"DOAJ record","url":"https://doaj.org/toc/1533-0346"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publishing","url":"https://journals.sagepub.com/home/tct","issn":"1533-0346","scope":"cancer technology and treatment research","access":"open-access","founded":2002,"matchNames":["Technol Cancer Res Treat","Technology in cancer research & treatment","Technology in Cancer Research & Treatment","Technology in Cancer Research and Treatment"]},{"id":"the-breast","kind":"journal","name":"The Breast","aka":["The Breast : official journal of the European Society of Mastology","Breast","Breast (Edinburgh, Scotland)"],"tldr":"The Breast is the European Society of Mastology's open access journal on breast disease and breast cancer, covering surgery, oncology, screening and survivorship.","summary":"The Breast is the official journal of the European Society of Mastology (its NLM title) and, per an NLM note, an associate journal of the Australasian Society for Breast Disease, which DOAJ also lists as an associated institution. It began in March 1992 with Churchill Livingstone in Edinburgh and has been published by Elsevier from Amsterdam since 2002 (NLM Catalog; Crossref lists Elsevier). NLM records it as bimonthly, indexed for MEDLINE under Breast, Breast Diseases and Breast Neoplasms. DOAJ lists the journal as open access since 2020 with CC BY, CC BY-NC and CC BY-NC-ND licences, an article processing charge and anonymous peer review. The publisher's thebreastonline.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.thebreastonline.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9213011"},{"label":"DOAJ record","url":"https://doaj.org/toc/1532-3080"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thebreastonline.com/","issn":"0960-9776","scope":"breast cancer","access":"open-access","founded":1992,"matchNames":["Breast","The Breast","Breast (Edinburgh, Scotland)"],"society":"European Society of Mastology (EUSOMA)"},{"id":"the-breast-journal","kind":"journal","name":"The breast journal","aka":["Breast J","The Breast Journal"],"tldr":"The Breast Journal is a US-founded journal on breast disease and breast cancer, now a fully open access Wiley title, read by breast surgeons, oncologists, radiologists and pathologists.","summary":"The Breast Journal started in 1995 with Blackwell Science in Cambridge, Massachusetts; since 2022 the NLM Catalog records the Hindawi imprint of Wiley as publisher, and Crossref lists Hindawi Limited. NLM indexes it for MEDLINE under Breast Diseases and Breast Neoplasms, records it as bimonthly, and notes (from 2000 onward) that it is the official journal of the American Society of Breast Disease, the Senologic International Society and the International Society of Breast Pathology. DOAJ lists the journal as open access since 2022 with a CC BY licence, an article processing charge and anonymous peer review.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/15244741"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9505539"},{"label":"DOAJ record","url":"https://doaj.org/toc/1075-122X"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ","male-breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley (Hindawi)","url":"https://onlinelibrary.wiley.com/journal/15244741","issn":"1075-122X","scope":"breast cancer","access":"open-access","founded":1995,"matchNames":["Breast J","The breast journal","The Breast Journal"]},{"id":"the-cancer-journal","kind":"journal","name":"The cancer journal","aka":["Cancer J","The Cancer Journal","Cancer journal (Sudbury, Mass.)","Cancer journal from Scientific American"],"tldr":"The Cancer Journal is a bimonthly review journal from Lippincott Williams and Wilkins, edited by Vincent DeVita, Theodore Lawrence and Steven Rosenberg, with each issue focused on one clinical theme.","summary":"The Cancer Journal has been published under this title since 2000 (volume 6), continuing the earlier Cancer Journal from Scientific American (NLM other titles); Jones and Bartlett was the first publisher and Lippincott Williams and Wilkins has published it since 2007. Crossref lists Ovid Technologies (Wolters Kluwer) as publisher. The NLM Catalog names it the official journal of the American Radium Society and notes that print issues ceased with 2024. The journal page lists six issues per year and Vincent T. DeVita Jr, Theodore S. Lawrence and Steven A. Rosenberg as Editors-in-Chief; the July/August 2026 issue, for example, is a set of reviews on non-small cell lung cancer. Indexed for MEDLINE under Neoplasms.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.lww.com/journalppo/pages/default.aspx"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/100931981"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wolters Kluwer (Lippincott Williams & Wilkins)","url":"https://journals.lww.com/journalppo/pages/default.aspx","issn":"1528-9117","scope":"clinical oncology","founded":2000,"matchNames":["Cancer J","The cancer journal","The Cancer Journal","Cancer Journal"],"society":"American Radium Society"},{"id":"gulf-journal-of-oncology","kind":"journal","name":"The Gulf journal of oncology","aka":["Gulf J Oncolog","Gulf Journal of Oncology","GJO"],"tldr":"The Gulf Journal of Oncology is the journal of the Gulf Federation for Cancer Control in Kuwait, publishing cancer research and news from the Gulf and wider Arab region three times a year.","summary":"The Gulf Journal of Oncology (GJO) is published from Safat, Kuwait, by the Gulf Federation for Cancer Control; its website says publication is supported by the Kuwait Foundation for the Advancement of Science. It began with volume 1, issue 1 in January 2007 (NLM Catalog) and, per the journal site, issues appear every January, May and September. The site states that articles are indexed in the PubMed/MEDLINE database of the US National Library of Medicine and listed in Scopus, and it carries an Editor's Word from Editor-in-Chief Dr Khaled Ahmed Al Saleh alongside cancer news from the Gulf and Arab region. NLM indexes it under Neoplasms. No access model or licence is stated on the pages read.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.gffcc.org/journal/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101500911"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Gulf Federation for Cancer Control","url":"https://www.gffcc.org/journal/","issn":"2078-2101","scope":"clinical oncology in the Gulf and Arab region","founded":2007,"matchNames":["Gulf J Oncolog","The Gulf journal of oncology","Gulf Journal of Oncology","The Gulf Journal of Oncology"],"society":"Gulf Federation for Cancer Control"},{"id":"international-journal-of-biological-markers","kind":"journal","name":"The International journal of biological markers","aka":["Int J Biol Markers","The International Journal of Biological Markers","International Journal of Biological Markers","JBM"],"tldr":"The International Journal of Biological Markers is an open access SAGE journal on tumour markers and other biomarkers used in cancer diagnosis, prognosis and treatment monitoring.","summary":"The International Journal of Biological Markers (JBM) was founded in 1986 by Wichtig Editore in Milan and has been published by SAGE since 2018 (NLM Catalog; Crossref lists SAGE Publications). NLM records four issues a year, notes that print ceased with volume 26 in 2011 so the title is online only, and indexes it for MEDLINE under headings including Antigens, Neoplasm/analysis, Cell Transformation, Neoplastic, Immunologic Techniques and Receptors, Cell Surface. DOAJ lists the journal as open access since 2019 with CC BY and CC BY-NC licences, an article processing charge and anonymous peer review.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/jbm"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8712411"},{"label":"DOAJ record","url":"https://doaj.org/toc/1724-6008"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publishing","url":"https://journals.sagepub.com/home/jbm","issn":"0393-6155","scope":"cancer biomarkers","access":"open-access","founded":1986,"matchNames":["Int J Biol Markers","The International journal of biological markers","The International Journal of Biological Markers","International Journal of Biological Markers"]},{"id":"lancet","kind":"journal","name":"The Lancet","aka":["Lancet"],"tldr":"The Lancet is Britain's leading general medical journal and the other main home of practice-changing cancer trials, with a stronger global-health and policy voice than NEJM.","summary":"The Lancet appears weekly and publishes practice-changing oncology phase 3 trials (CheckMate 649, KEYNOTE-048, CARTITUDE-1, TRANSFORM), the Global Burden of Disease series, and Lancet Commissions that shape cancer policy. Elsevier hybrid model: subscription with an open-access option; abstracts free. Known for editorial campaigning on health inequality and for the HPV-vaccination and cancer-survival population studies that appear in this corpus.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_Lancet","links":[{"label":"Oncology collection","url":"https://www.thelancet.com/clinical/diseases/cancer"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lancet/home","issn":"0140-6736","scope":"general medicine","access":"hybrid","founded":1823,"impactFactor":{"value":98.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["The Lancet","Lancet"]},{"id":"lancet-digital-health","kind":"journal","name":"The Lancet Digital Health","aka":["Lancet Digit Health"],"tldr":"The Lancet's open-access digital-health journal: AI diagnostics, pathology and radiology algorithms, prediction models and the reporting standards for them.","summary":"Fully open access since launch in 2019. Publishes external validations of cancer AI (mammography, pathology, dermatology), prediction-model studies, and methodological pieces on AI trial design and reporting (for example the CONSORT-AI and SPIRIT-AI extensions). Frequent critical reviews of the evidence quality behind medical AI.","asOf":"2026-09-09","links":[{"label":"Lancet journals","url":"https://www.thelancet.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/landig/home","issn":"2589-7500","scope":"digital health","access":"open-access","founded":2019,"matchNames":["The Lancet Digital Health","Lancet Digital Health","Lancet Digit Health"]},{"id":"lancet-global-health","kind":"journal","name":"The Lancet Global Health","aka":["Lancet Glob Health"],"tldr":"The Lancet's open-access global-health journal: where the numbers on cancer burden, survival gaps and treatment access in low- and middle-income countries are published.","summary":"Fully open access. Carries GLOBOCAN-based incidence and mortality analyses, the CONCORD cancer-survival programme, cervical-cancer elimination modelling and costing studies for scaling radiotherapy and chemotherapy access. Essential reading for anyone working on the 70 percent of cancer deaths that occur outside high-income countries.","asOf":"2026-09-09","links":[{"label":"Cancer collection","url":"https://www.thelancet.com/journals/langlo/collections"}],"tags":[],"related":["globocan"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mortality","radiotherapy","chemotherapy-term"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/langlo/home","issn":"2214-109X","scope":"global health","access":"open-access","founded":2013,"matchNames":["The Lancet Global Health","Lancet Global Health","Lancet Glob Health"]},{"id":"lancet-haematology","kind":"journal","name":"The Lancet Haematology","aka":["Lancet Haematol"],"tldr":"The Lancet Haematology is the Lancet's haematology journal, publishing phase 2 and 3 trials in leukaemia, lymphoma and myeloma, transplant studies and global-access commentary on blood cancers.","summary":"The Lancet Haematology (Lancet Haematol) is the Lancet's haematology journal, appearing monthly since 2014 and published by Elsevier on a hybrid model. It publishes randomised and single-arm phase 2 and 3 trials in leukaemia, lymphoma and myeloma, including CAR-T and bispecific follow-up and MDS and myelofibrosis studies, together with transplant studies, long-term outcomes, Commissions on haematological care in low-income settings and global-access commentary on blood cancers. Its readers are haematologists and trialists who follow the clinical evidence in blood cancers. Within OnCo it is the journal of the phase 1/2 paper on talicabtagene autoleucel for relapsed or refractory B-cell malignancies, and it is where a reader would look for CAR-T and bispecific trial follow-up.","asOf":"2026-09-09","links":[{"label":"Lancet journals","url":"https://www.thelancet.com"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["clinical-trial","randomised-trial","relapsed-refractory"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lanhae/home","issn":"2352-3026","scope":"haematology","access":"hybrid","founded":2014,"impactFactor":{"value":15.4,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["The Lancet Haematology","Lancet Haematology","Lancet Haematol"]},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","aka":["Lancet Oncol","src-lancet-oncology"],"tldr":"The Lancet Oncology is the leading specialist cancer journal for clinical trials. It publishes phase 2 and 3 trials, long-term follow-up, quality-of-life analyses and global-oncology policy Commissions.","summary":"The Lancet Oncology appears monthly plus online-first and publishes a large share of randomised oncology trials that do not go to NEJM, with particular strength in radiotherapy, surgery, supportive care and health-system studies (IBIS-I tamoxifen prevention, MASAI AI mammography, GAP70 geriatric assessment in this corpus). Its Commissions and Series drive policy debates on drug pricing, radiotherapy access and cancer in low-income countries. Elsevier hybrid model; abstracts free.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/The_Lancet_Oncology","links":[{"label":"Lancet Oncology Commissions","url":"https://www.thelancet.com/journals/lanonc/commissions"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Phase 2 and 3 trials, meta-analyses, global oncology policy and the ESMO-aligned commentaries. Access: Paywalled; abstracts free."],"publisher":"Elsevier","url":"https://www.thelancet.com/journals/lanonc/home","issn":"1470-2045","scope":"clinical oncology","access":"hybrid","founded":2000,"impactFactor":{"value":41.6,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Lancet Oncology","The Lancet Oncology","Lancet Oncol"]},{"id":"the-oncologist","kind":"journal","name":"The oncologist","aka":["Oncologist","The Oncologist","The oncologist (Dayton, Ohio)"],"tldr":"The Oncologist is a fully open access monthly journal from Oxford University Press and the Society for Translational Oncology, aimed at translating research into better multidimensional care for cancer patients.","summary":"The Oncologist describes itself as dedicated to translating the latest research developments into the best multidimensional care for cancer patients, spanning basic science, translational research, clinical practice and socioeconomic and psychosocial factors across oncology and haematology. It publishes reviews, original studies and commentaries across more than thirty subject areas, from breast and lung cancer to immuno-oncology, paediatric oncology and medical ethics. Since 2022 it has been published by Oxford University Press for the Society for Translational Oncology as a peer-reviewed, fully open access, online-only journal with twelve issues a year; articles are published under CC BY or CC BY-NC licences with an article processing charge (society members receive a discount). It began in 1996 with AlphaMed Press in Dayton, Ohio; print ceased with volume 25 in 2020 (NLM Catalog).","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://academic.oup.com/oncolo"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9607837"},{"label":"DOAJ record","url":"https://doaj.org/toc/1549-490X"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Oxford University Press","url":"https://academic.oup.com/oncolo","issn":"1083-7159","scope":"clinical and translational oncology","access":"open-access","founded":1996,"matchNames":["Oncologist","The oncologist","The Oncologist"],"society":"Society for Translational Oncology"},{"id":"thoracic-cancer","kind":"journal","name":"Thoracic cancer","aka":["Thorac Cancer","Thoracic Cancer"],"tldr":"Thoracic Cancer is an open access Wiley journal on lung and other chest cancers, produced with the Tianjin Lung Cancer Institute and the China Lung Oncology Group since 2010. It is indexed in MEDLINE, online only since 2014, and its authors and readers are mainly Chinese and Asia-Pacific thoracic oncologists.","summary":"Thoracic Cancer began with volume 1 in May 2010 and has been published since November 2012 by Wiley Publishing Asia together with the Tianjin Lung Cancer Institute (NLM Catalog; Crossref lists Wiley, Blackwell Publishing). NLM lists it as a Singapore serial indexed for MEDLINE under Thoracic Neoplasms and notes that print ceased with volume 5 in 2014, so it is online only. DOAJ records it as open access since 2015 with CC BY, CC BY-NC and CC BY-NC-ND licences, an article processing charge, anonymous peer review and the China Lung Oncology Group as an associated organisation.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/17597714"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101531441"},{"label":"DOAJ record","url":"https://doaj.org/toc/1759-7714"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["nsclc","sclc","mesothelioma","thymic-epithelial","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/17597714","issn":"1759-7706","scope":"thoracic oncology","access":"open-access","founded":2010,"matchNames":["Thorac Cancer","Thoracic cancer","Thoracic Cancer"]},{"id":"trends-in-cancer","kind":"journal","name":"Trends in cancer","aka":["Trends Cancer","Trends in Cancer"],"tldr":"Trends in Cancer is the Cell Press Trends-series title for cancer, a monthly online journal read by cancer biologists and translational researchers who want an overview of where the field is moving.","summary":"Trends in Cancer is published by Cell Press in Cambridge, Massachusetts, the Elsevier imprint recorded by the NLM Catalog. It began with volume 1, number 1 in September 2015 (volume 1 was completed in four issues) and is now monthly. NLM lists it as a United States serial available as an online resource and indexed for MEDLINE under Neoplasms.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.cell.com/trends/cancer/home"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101665956"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["preclinical"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Cell Press (Elsevier)","url":"https://www.cell.com/trends/cancer/home","issn":"2405-8025","scope":"cancer biology","founded":2015,"matchNames":["Trends Cancer","Trends in cancer","Trends in Cancer"]},{"id":"tumori","kind":"journal","name":"Tumori","aka":["Tumori Journal","TUMORI","Tumori, Milano"],"tldr":"Tumori Journal is Italy's long-running oncology journal, founded in 1911 in Milan and now published in English by SAGE for the Italian cancer research community.","summary":"Tumori was founded in 1911; the NLM Catalog records it as issued from Rome in 1911 to 1926 and then from Milan by the Istituto Nazionale per lo Studio e la Cura dei Tumori, with articles in English since 1977 and the title Tumori Journal used from January 2015. SAGE has published it since 2018 (NLM; Crossref lists SAGE Publications). NLM notes it is the official organ of the Società Italiana di Cancerologia, among others, lists it as bimonthly and indexes it for MEDLINE under Neoplasms. It is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/tmj"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/111356"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publishing","url":"https://journals.sagepub.com/home/tmj","issn":"0300-8916","scope":"clinical oncology","founded":1911,"matchNames":["Tumori","Tumori Journal","Tumori J"],"society":"Società Italiana di Cancerologia"},{"id":"tumour-biology","kind":"journal","name":"Tumour biology","aka":["Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","Tumour Biol","Tumor Biology","Tumour Biology"],"tldr":"Tumour Biology is the open access journal of the International Society of Oncology and Biomarkers, covering tumour markers, cancer biology and their clinical use.","summary":"Tumour Biology is the journal of the International Society for Oncodevelopmental Biology and Medicine (its NLM title), the society DOAJ now lists as the International Society of Oncology and Biomarkers (ISOBM). It began in 1984 with Saikon Publishing in Tokyo, has been titled Tumor Biology on its issues since 1987, and has been published by SAGE since 2025 (NLM Catalog; Crossref and DOAJ also list SAGE). NLM lists it as bimonthly and indexes it for MEDLINE under Carcinoembryonic Antigen, alpha-Fetoproteins, Medical Oncology and Neoplasms/immunology. DOAJ records it as open access since 2017 under a CC BY-NC licence with an article processing charge and anonymous peer review.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://journals.sagepub.com/home/tub"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/8409922"},{"label":"DOAJ record","url":"https://doaj.org/toc/1010-4283"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["biomarker","tumour-markers"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"SAGE Publishing","url":"https://journals.sagepub.com/home/tub","issn":"1010-4283","scope":"cancer biology and biomarkers","access":"open-access","founded":1984,"matchNames":["Tumour Biol","Tumour biology","Tumour Biology","Tumor Biology","Tumor Biol"],"society":"International Society of Oncology and Biomarkers (ISOBM)"},{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","aka":["Tumour Virus Res","Tumour Virus Research","Tumor virus research","Papillomavirus Research"],"tldr":"Tumour Virus Research is an open access Elsevier journal on viruses that cause cancer, such as HPV, EBV, hepatitis viruses and KSHV. It grew out of Papillomavirus Research in 2021.","summary":"Tumour Virus Research is an online-only open access journal published by Elsevier from Amsterdam. It began in June 2021 with volume 11, continuing the numbering of its predecessor Papillomavirus Research (NLM Catalog other titles), and is indexed for MEDLINE under Medical Oncology and Neoplasms. DOAJ lists it as open access from 2021 with CC BY, CC BY-NC and CC BY-NC-ND licences, an article processing charge and anonymous peer review; Crossref also records Elsevier as publisher.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.sciencedirect.com/journal/tumour-virus-research"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101775149"},{"label":"DOAJ record","url":"https://doaj.org/toc/2666-6790"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["cervical","head-and-neck","nasopharyngeal","hcc","kaposi-sarcoma","merkel-cell-carcinoma","burkitt-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.sciencedirect.com/journal/tumour-virus-research","issn":"2666-6790","scope":"tumour virology","access":"open-access","founded":2021,"matchNames":["Tumour Virus Res","Tumour virus research","Tumour Virus Research","Papillomavirus Research","Papillomavirus Res"]},{"id":"urologic-oncology","kind":"journal","name":"Urologic oncology","aka":["Urol Oncol","Urologic Oncology: Seminars and Original Investigations","Urologic Oncology","Seminars in urologic oncology"],"tldr":"Urologic Oncology: Seminars and Original Investigations is an Elsevier journal on prostate, bladder, kidney, testicular and penile cancers, mixing topical seminar sections with original research.","summary":"Urologic Oncology began with volume 1 in January/February 1995 and has carried the subtitle Seminars and Original Investigations since 2003, when Elsevier became publisher (NLM Catalog; Crossref lists Elsevier). NLM records it as a United States serial, published eight times a year since 2013 with no issues in 1999, and indexes it for MEDLINE under Urologic Neoplasms and Genital Neoplasms, Male.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.urologiconcology.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9805460"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["prostate","urothelial","rcc","testicular","penile"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Elsevier","url":"https://www.urologiconcology.org/","issn":"1078-1439","scope":"urologic oncology","founded":1995,"matchNames":["Urol Oncol","Urologic oncology","Urologic Oncology","Urologic Oncology: Seminars and Original Investigations","Urol Oncol Semin Orig Investig"]},{"id":"veterinary-and-comparative-oncology","kind":"journal","name":"Veterinary and comparative oncology","aka":["Vet Comp Oncol","Veterinary and Comparative Oncology"],"tldr":"Veterinary and Comparative Oncology is the Wiley journal of the veterinary cancer societies, covering cancer in companion animals and what it can teach about human disease.","summary":"Veterinary and Comparative Oncology began in March 2003 with Blackwell in Oxford and is now published by Wiley (Crossref lists Wiley, Blackwell Publishing). The NLM Catalog records it as the official journal of the Veterinary Cancer Society, the Japanese Veterinary Cancer Society and the European Society of Veterinary Oncology, lists it as a quarterly serial published in England, and indexes it for MEDLINE under Neoplasms/veterinary. It is not listed in DOAJ.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://onlinelibrary.wiley.com/journal/14765829"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101185242"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Wiley","url":"https://onlinelibrary.wiley.com/journal/14765829","issn":"1476-5810","scope":"veterinary and comparative oncology","founded":2003,"matchNames":["Vet Comp Oncol","Veterinary and comparative oncology","Veterinary and Comparative Oncology"],"society":"Veterinary Cancer Society, Japanese Veterinary Cancer Society and European Society of Veterinary Oncology"},{"id":"world-journal-of-surgical-oncology","kind":"journal","name":"World journal of surgical oncology","aka":["World J Surg Oncol","World Journal of Surgical Oncology","WJSO"],"tldr":"World Journal of Surgical Oncology is a fully open access BMC journal for surgical oncologists, publishing original research, case reports and reviews across the whole continuum of cancer care.","summary":"World Journal of Surgical Oncology is an open access journal launched by BioMed Central in London in February 2003 and now hosted on Springer Nature Link (Crossref: Springer, BioMed Central). Its aims and scope page says it publishes articles on surgical oncology and allied subjects such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology, with emphasis on original research plus significant clinical case reports and reviews on selected topics; it aims to keep surgical oncologists abreast of developments across the continuum of care. DOAJ lists it as open access since 2003 with CC BY and CC BY-NC-ND licences, an article processing charge and anonymous peer review. Indexed for MEDLINE under Neoplasms/surgery.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://wjso.biomedcentral.com/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101170544"},{"label":"DOAJ record","url":"https://doaj.org/toc/1477-7819"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["biomarker","clinical-trial","systemic-vs-local-therapy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"BMC (Springer Nature)","url":"https://wjso.biomedcentral.com/","issn":"1477-7819","scope":"surgical oncology","access":"open-access","founded":2003,"matchNames":["World J Surg Oncol","World journal of surgical oncology","World Journal of Surgical Oncology"]},{"id":"chinese-journal-of-lung-cancer","kind":"journal","name":"Zhongguo fei ai za zhi","aka":["Zhongguo fei ai za zhi = Chinese journal of lung cancer","Chinese Journal of Lung Cancer","Zhongguo Fei Ai Za Zhi","Zhongguo feiai zazhi","CJLC","中国肺癌杂志"],"tldr":"The Chinese Journal of Lung Cancer is a monthly open access journal from Tianjin publishing Chinese and English research on lung cancer, from basic biology to surgery, chemotherapy, radiotherapy and nursing.","summary":"Chinese Journal of Lung Cancer (CJLC) describes itself as a monthly peer-reviewed open access journal hosted by the Chinese Anti-Cancer Association, the Chinese Antituberculosis Association and Tianjin Medical University General Hospital, established in 1998 and edited by Professor Qinghua Zhou. Its focus and scope page says it publishes editorials, perspectives, original research, review articles, short communications and case reports on clinical and basic science aspects of lung cancer, including prevention, epidemiology and aetiology, basic biology, pathology, clinical assessment, surgery, chemotherapy and radiotherapy, with sections for nursing practice, guidelines and meeting reports. Articles are chiefly in Chinese with English abstracts and some articles in English; the NLM Catalog notes print ceased in 2022. The site carries a Creative Commons Attribution licence and DOAJ lists CC BY with an article processing charge; indexed in MEDLINE, PubMed Central, DOAJ and Embase/Scopus.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"http://www.lungca.org/"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101126433"},{"label":"DOAJ record","url":"https://doaj.org/toc/1009-3419"}],"tags":[],"related":["pubmed-europepmc"],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Editorial Board of the Chinese Journal of Lung Cancer (Chinese Anti-Cancer Association and Chinese Antituberculosis Association)","url":"http://www.lungca.org/","issn":"1009-3419","scope":"lung cancer","access":"open-access","founded":1998,"matchNames":["Zhongguo Fei Ai Za Zhi","Zhongguo fei ai za zhi","Chinese Journal of Lung Cancer","Chinese journal of lung cancer"],"society":"Chinese Anti-Cancer Association and Chinese Antituberculosis Association"},{"id":"chinese-journal-of-oncology","kind":"journal","name":"Zhonghua zhong liu za zhi","aka":["Zhonghua zhong liu za zhi [Chinese journal of oncology]","Chinese Journal of Oncology","Zhonghua Zhong Liu Za Zhi","中华肿瘤杂志"],"tldr":"The Chinese Journal of Oncology is the Chinese Medical Association's oncology journal, published in Chinese from Beijing since 1979 and indexed in MEDLINE.","summary":"Zhonghua zhong liu za zhi (Chinese Journal of Oncology) is published in Beijing by the Chinese Medical Association (Zhonghua yi xue hui). The NLM Catalog records that it began with volume 1 in 1979, is issued by the Ministry of Health Cancer Prevention and Control Research Office together with the journal's editorial board, appears bimonthly, and is indexed for MEDLINE under Medical Oncology. Articles are in Chinese with tables of contents in Chinese and English and some English abstracts, and the journal is also issued online. It is not listed in DOAJ and has no Crossref journal record for its ISSN. The journal page on the Chinese Medical Association Publishing House platform is used as the homepage because the journal's own domain redirects to a login page.","asOf":"2026-09-10","links":[{"label":"Homepage","url":"https://www.yiigle.com/journal/CN112152"},{"label":"NLM Catalog","url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/7910681"}],"tags":[],"related":["pubmed-europepmc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"publisher":"Chinese Medical Association","url":"https://www.yiigle.com/journal/CN112152","issn":"0253-3766","scope":"clinical oncology","founded":1979,"matchNames":["Zhonghua Zhong Liu Za Zhi","Zhonghua zhong liu za zhi","Chinese Journal of Oncology","Chinese journal of oncology"],"society":"Chinese Medical Association"}]